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Abstract
Neuropathic pain is pain caused by dysfunction in the nervous system. Current
treatments have limited efficacy, often with intolerable side-effects. There is a need
for therapies to prevent or reduce the severity of neuropathic pain. The N-methyl D-
aspartate receptor (NMDAR) plays a key role in neuropathic sensitisation. In animal
neuropathic models spinally administered NMDAR antagonists are effective in
reducing behavioural changes associated with neuropathic pain. Clinical trials using
NMDAR antagonists have shown them to be effective adjuncts in the treatment of
acute pain and as a treatment option in established chronic pain. The clinical role of
NMDAR antagonists in the development of neuropathic sensitisation is yet to be
defined.
The aim of this thesis is to investigate the use ofNMDAR antagonists in preventing
neuropathic sensitisation.The chronic constriction injury (CCI) model of neuropathic
pain is used to study the role ofNMDARs in the development of neuropathic pain
and subsequent modulation. Behavioural effects are assessed in association with
changes in NMDAR subtypes. Memantine and ketamine (NMDAR antagonists) are
shown to attenuate typical behavioural responses (thermal hyperalgesia and cold
allodynia) to nerve injury. In addition, NMDAR antagonist pre-treatment is shown to
effect the subsequent NMDAR subunit expression, with improved susceptibility to
subsequent NMDAR antagonist treatment.
The clinical use of epidural ketamine as a preventative drug prior to lower limb
amputation is investigated in a double blind randomised placebo controlled study. No
significant effects on the incidence of post-amputation pain were found, although the
overall incidence of pain was lower than in comparable studies. Ketamine is shown
to improve peri-operative analgesia and have long lasting effects (up to one week) on
sensory processing in the remaining stump.
In summary, NMDAR antagonists seem to be effective in attenuating neuropathic
pain in animal models. The promise shown in these studies has not translated into a
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reduction in post-amputation pain in a clinical study. Ketamine remains a clinically
useful drug in peri-operative pain management but the role of ketamine and other
clinically available NMDAR antagonists in the prevention of neuropathic
sensitisation is still not clearly defined.
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1.1 Nociception and Nociceptive Pathways
1.1.1 Peripheral Nociceptors
Sensory neurones responding to stimuli capable of producing tissue damage are
termed nociceptors. Most body structures contain nociceptors. These are high
threshold polymodal receptors, meaning they respond to a variety of noxious stimuli.
Typically they respond to noxious heat, strong mechanical stimuli and chemical
stimuli, both endogenous and exogenous (1). Cutaneous nocicieptors can be divided
into two main categories, A8-mechanical nociceptors and C-polymodal nociceptors.
These are named after the afferent fibres that innervate them and the stimuli that they
respond to (2). In general terms, nociceptive processes begin with activation of the
primary afferent nociceptor, a process known as transduction. Transduction results in
the conversion of the noxious stimuli into electrochemical activity. Despite
nociceptors normally having a high threshold for activation, repeated activation may
reduce that threshold for activation, as can occur with peripheral sensitisation (3).
1.1.2 Primary afferents and cytoarchitecture of dorsal horn
Somatic primary afferent neurones are located in the dorsal root ganglia (DRG).
They are unipolar neurones which conduct sensory inputs from peripheral nerve
endings to the spinal cord. Transmission of nociceptive activity is via both small
unmyelinated c-fibres (diameter <2 pm; conduction speed -lms"1) and small
myelinated A5-fibres (diameter 2-5 pm; conduction speed 15ms"1). This contrasts
with the much larger (>10 pm) rapidly conducting (>30ms_1) Ap-fibres, which
transmit light touch (2). Primary afferent fibres synapse in the dorsal horn of the
spinal cord, where they form a highly organized somatotopic map (4). The spinal
cord is divided into 10 laminae (2;5). The dorsal horn is made of laminae I-VI.
The first synapses where nociceptive information is processed are situated in the
superficial dorsal horn. The superficial dorsal horn is made up from what is known as
the marginal zone and the substantia gelatinosa (lamina I and II). Lamina I and II are
the primary termination zone ofC- and AS-fibre primary afferents. Ascending output
is mostly from Lamina I, though only about 10% of lamina I neurones are projection
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neurones. The projection neurones are largely nocipetive responding to mechanical
and noxious thermal stimulation. The vast majority of these neurones express NK-1
receptors. Immuno-staining for the NK-1 receptor can be used to define lamina I.
Superficial dorsal horn projections are to the contralatersal spinathalamic tracts and
other areas such as the lateral periaqueductal grey matter (PAG) and the parabrachial
area.
Nociceptive information is predominantly processed in lamina I, II, V, VI and X (the
area around the canal. C-fibres and A5-fibres largely terminate in the superficial
laminae (I and II), while Ap-fibres terminate in deeper laminae (III and IV) (6). Not
only do primary afferent fibres synapse with second order neurones, but there is a
complex interaction with local intrinsic spinal neurones and descending modulatory
neurones coming from the brain.
Glutamate is the major excitatory neurotransmitter in the CNS and so,
unsurprisingly, glutamate receptors are widespread in the spinal cord. These are both
ionotropic and metabotropic. Immunohistochemical staining demonstrates ionotropic
glutamate receptors (in the laminae I - III). There is evidence for the involvement of
both a-amino-3-hydroxy-5-methyl-4-isoxasolepropionic acid (AMPA) and kanaite
receptors in sensory processing in the superficial dorsal horn (7). In addition the
subunits of the N-methyl D-Aspartate (NMDA) receptor, NR1 and NR2B, are
prodminantly found in the laminae I-III).
1.1.3 Dorsal horn neurotransmitters
A wide range of neurotransmitters are involved in nociception. Examples ofprimary
afferent and dorsal horn receptors and their ligands are shown in table 1.
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Table 1.
Examples of primary afferent dorsal horn receptors and ligands
Ionotopic receptor Subtype Ligand
TRP channels TRPVI Heat (>42°C), capsaicin, H
TRPV2 Heat (>53°C)
TRPA Noxious cold (<17°C)










































acid sensing ion channel
adensosine triphosphate
bradykinin

















Others (e.g. HI, EP1-4, TRPV2) are designated subtypes of receptors rather than
abbreviations.
Reproduced from Acute Pain Scientific Evidence, 2nd Ed 2005 with permission of
NHMRC.
Excitatory neurotransmitters
The predominant excitatory neurotransmitters are the amino acid glutamate and the
neuropeptide, substance P, a tachykinin acting on NK-1 receptors. Glutamate acts on
a variety of receptors, the slow G-protein linked metabotropic receptors and fast
ligand-gated ion channels namely AMPA receptors, kainate receptors and the
NMDA receptors (8) (see table 1). Fast excitatory synaptic transmission is mediated
by glutamate acting on AMPA and kainate receptors, while NMDA receptors are
thought to mediate the slower synaptic effects of glutamate. Co-release of substance
P and another tachykinin, neurokinin A (NK-A) facilitate both the release of
excitatory neurotransmitters and enhance glutamate mediated post-synaptic activity
(9).
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In addition to the excitatory amino acids and tachykinins described above, there are
other neurotransmitters which act as pronociceptive mediators in the dorsal horn.
These include calcitonin gene related peptide (CGRP) adensosine triphosphate
(ATP), nitric oxide (NO), phospholipid metabolites, prostaglandins and various
neurotrophins (10).
Inhibitory neurotransmitters
A6 and C fibres excite centrally projecting neurones. Dorsal hom activity can
however be modulated by inhibitory DH neurones, acting both pre- and post-
synaptically.
Many different neurochemical types have been identified including GABAergic
inhibitory neurones, cholinergic inhibitory neurones and opioidergic inhibitory
neurones. The majority of inhibitory neurones in the spinal cord use Gamma-
aminobutyric acid (GABA) and glycine as their principle fast neurotransmitters. In
the main GABA receptors are pre-synaptically situated (11). Electrophorectic
application ofGABA to the spinal cord alters the neuronal conductance to CI"
resulting in an inhibitory effect (12). GABA and glycine open ligand gated ion
channels which allow CI" and HCO3" across the cell membrane. The a2 and a3
subunits of the GABAa receptor are most prominent in lamina II of the dirsal hron
and are postulated to have a specific function in nociceptive transmission. Central
inflammatory pain may originate from a disinhibition of dorsal horn neurones
through a prostaglandin (PGE2) mediated inhibition of glycine receptors.
Cholinergic inhibitory neurones act via muscarinic receptors while opioidergic
inhitory neurones containing enkephalins and/or dynorphin act via p, 5 and K-opioid
receptors (13;14).
1.1.4 Ascending Transmission
Spinal horn neurones are organised into 3 distinct groups; noceptive specific
neurones (NS), wide dynamic range neurones (WDR) and Non Nociceptive (NON-
N). NS neurones respond exclusively to noxious stimuli and are found in laminae I,
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II (external), V and VI. Afferent input is from A5- nociceptive high threshold and
heat nociceptive fibres and C polymodal nociceptive fibres. Their receptive fields are
punctiform and show a degree of somatotropic organisation, largely lamina I. WDR
neurones respond to mechanical thermal and chemical stimuli, with input from A8, C
and Ap fibres. They are found in laminae I, II (external), IV ,V ,VI ,X and the
anterior hom. They are able to respond to a range of stimuli from innocuous to
clearly noxious. NON-N respond to low intensity mechanical and thermal stimuli
and proprioceptive inputs via both A5 and Ap fibres, though these low threshold
mechanical receptors may be involved on the mechanisms of allodynia (15).
Nociceptive information is transmitted cephalad via spinal sensory neurones. These
are either nociceptive specific neurones (NS; responding to noxious stimuli only) or
wide dynamic range neurones (WDR; responding to a range of stimuli from
innocuous to clearly noxious). Both NS and WDR neurones will travel 2 or 3
segments in the tract of Lissauer and form connections in the substantia gelatinosa
(SG) of adjacent segments (2). This may explain expansion of the receptive field
after injury.
1.1.5 Projection of dorsal horn neurones
In general terms, the spinal cord has three major projections to the brain (16). They
are
• Direct thalamic projections (Spinothalamic Tracts, STT)
• Direct projections to the reticular and homeostatic control regions of the brain
stem (Spinoreticular and Spinomesencephalic Tracts)




Cells projecting to the spinothalamic tract arise in three regions of the spinal cord
(16).
The first of these projections is from lamina I, with input being predominantly from
A8 and C-fibres. Lamina I cells are usually NS cells or polymodal nociceptive cells
The second deeper area is from laminae IV and V. Input here is predominantly from
Afl-fibres, with some smaller myelinated and unmyelinated fibre inputs. Cells here
are largely NON-N or WDR. The third region is lamina VII and VIII, an
intermediate/ ventral horn zone which receives large diameter afferents from the skin
and deep inputs from muscles and joints.
Spinothalamic tracts usually cross within one or two segments rostral to their origins.
Classically there are two distinct tracts, the lateral spinthalamic tract and the anterior
spinothalamic tract (17). Input to the lateral tract is largely from superficial laminae,
while the deeper laminae project to the anterior tract. The tracts are loosely
somatographically organised, with caudal fibres more lateral and cephalad fibres
more medial.
All nociceptive information reaching the cortex is processed and relayed by the
thalamus. The spinothalamic tract terminates in 6 distinct regions of the thalamus.
They are the ventral posterior nucleus, the ventroposterior inferior nucleus, the
posterior portion of the ventral medial nucleus, the ventral lateral nucleus, the lateral
central nucleus, the parafasciular nucleus and the ventral caudal portion of the medial
dorsal nucleus. The thalamus in turn has cortical projections. The ventral posterior
nucleus projects to SI, the venteroposterior inferior nucleus projects to SII, the
posterior portion of the ventral medial nucleus projects to the insula and the ventral
caudal portion of the medial dorsal nucleus projects to the anterior cingulate cortex
(ACC). These are areas of the brain that have been shown to be active in functional
imaging of the brain (18).
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Spinoreticular and spinomesencephalic tract
The spinoreticular tract originates mainly from laminae V, VII and VIII. It is made
up mostly from NS andWDR neurones, although there is some NON-N neuronal
involvement (19). This tract has two main projections to the brain stem. One is to the
precerebellar nucleus in the lateral reticular formation and the other to the medial
pontobulbar reticular formation (10). The spinoreticular tract neurones are involved
in the motivational-affective and neuro-vegatative responses to pain. It activates
brain stem structures involved in descending suppression.
The spinomesencephalic tract is made from NS, WDR and NON-N neurones. They
are arranged in a somatotropic way like the STT.
Spinohypothalamic tracts
The spinohypothalamic tract is composed ofNS, WDR and NON-N neurones. The
tract originates from laiminae I, V, X, the lateral nucleus, nucleus caudalis and
regions around the central medullary canal. Neurones in this tract respond to stimuli
(noxious and non-noxious) from muscles, tendons, joints, skin and viscera. It has
projections to various parts of the hypothalamus. Projections are thought to
contribute to the neuroendocrine autonomic and motivational-affective components
of pain
1.1.6 Descending modulatory systems
Descending pathways from the brainstem and other cerebral structures play an
important role in modulation and integration of afferent activity in the dorsal horn.
Modulation may be either inhibitory or facilitatory. Sources ofmodulation include
the cerebral cortex, the hypothalamus, the periaqueductal grey (PAG), the
rostroventromedial medulla (RVM), the dorsal reticular nucleus of the medulla, the
parabrachial nucleus and the nucleus tractus solitarius (NTS) (20). Modulatory
activity can be via a pre/post-synaptic action or intrinsic interneurones within the
dorsal hom.
In the main inhibitory modulation is via serotoninergic and noradrenergic systems
(14). Descending pathways generally inhibit nociceptive DH neurones either directly
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or by inhibition of excitatory interneurones or excitation of inhibitory neurones.
There are indications that there is preferential inhibition of excitation ofWDR
neurones to noxious as opposed non-noxious stimulation i.e. there is interference
with the activation of neurones by A8 and C fibres rather than Ap fibres (10). It is
worth noting that although monoamines are considered the major neurotransmitters
released by the descending inhibitory pathways, other neurotransmitters may be
important such as acetylcholine, encephalin and GABA (10).
Descending facilitation is a type of anti-analgesia and can be initiated in the RVM.
Triggers include peripheral and visceral inflammation and injury to primary afferent
nerves. Descending facilitation contributes to hyperalgesia and allodynia. CCK,
Substance P, NMDA and NO receptors have been implicated in descending
facilitation (20). There is some evidence that this pathway may predominate in
chronic pain states (21).
1.1.7 Cortical pain processing
The IASP defines pain as "An unpleasant sensory and emotional experience
associated with actual or potential tissue damage or described in terms of such
damage" (22). It follows therefore that central processing of pain must reflect both a
sensory-discriminative component and an affective-motivational component.
Sensory-discriminative aspects of pain parallel other sensory modalities like vision
or olfaction while affective-motivational aspects ofpain reflect 'suffering' with
regard to emotion, arousal and behaviour.
The cerebral cortex plays an important role in the both pain perception and the
affective-motivational aspects of pain. Cortical responses can be measured by single
neurone recordings. Important areas that have been studied by single neuron studies
are the SI, SII and the ACC (19). Modern imaging techniques such as positron
emission tomography (PET) and functional magnetic imaging (fMRI) have also been
used. These imaging modalities make indirect measures of function by measuring
increases in regional cerebral blood flow (rCBF) Cortical areas of the brain showing
31
an increase in rCBF are the primary and secondary somatosensory cortices (SI and
SII), the insula and the anterior cingulate cortex (18).
One current model is that there are two distinct nociceptive projections acting in
parallel. These are divided in to lateral and medial systems depending on whether
they project through the medial or lateral thalamic nuclei. The sensory-discriminative
aspects ofpain are processed through the lateral nociceptice system; while affective-
motivational aspects of pain are processed in the medial nociceptive system (23;24).
SI & SII
The main thalamic projections to SI and SII are from the ventral posterior lateral
nuclei, the ventral posterior medial nuclei and the ventral posterior nuclei of the
thalamus (19;25).
Both SI and SII have projections from the lateral systems. SI has the ability to
topographically code noxious stimuli of variable intensities making it an important
area in the sensory discriminative component of pain. SII neurones, in addition, code
noxious stimuli in temporal terms (26;27).The medial system also has projections to
SI and SII although these are less well defined.
Insula
The insula has multiple thalamic inputs as well as inputs from SI, SII and the parietal
association cortex (25). Its projections are to the limbic system, mainly amygdala,
and regions of the prefrontal cortex involved in both memory related to painful
experiences and the affective-motivational component ofpain.
Anterior cingulated cortex
The ACC is involved in the affective-motivational component of pain. Projections to
the ACC are from the anterior thalamic nuclei, the medial dorsal nuclei and the
central lateral and parafasicular nuclei (25). Strength of cingulated gyrus activity
correlates with unpleasantness of stimuli. ACC activation is important in affective-
motivational aspects of pain and in involved in behavioural an autonomic responses
to pain (24).
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1.1.8 Brain Imaging and Pain
The pain experience, as discussed above, is a complex integration of sensory-
discriminative, cognitive-evaluative and affective motivational components. A large
part of the body's response to pain occurs in supraspinal structures from the brain
stem to forebrain. Brain imaging techniques allow brain structure and function to be
studied. Studies can be carried out in a range of pain conditions from the
experimental scenario through to chronic pathological states. Brain imaging studies
allow evaluation not only of the brain's response to the sensory-discriminative aspect
ofpain, but the cognitive-evaluative and effective motivational components as well.
Brain imaging methodology
Brain imaging of pain uses a mixture of structural and functional imaging. Functional
CNS imaging in effect is an attempt to visualise physiological activity at the
synapses. Brain function is made up from neuronal and glial activity. It is not
possible to measure this activity directly, but factors that correlate closely to synaptic
activity such as changes in regional blood flow, blood oxygenation and energy
metabolism can be. These factors are measured in brain imaging studies and used as
markers of brain function. The relationship between neuronal and glial activity,
metabolic activity and blood flow is known as neurometabolic and neurovascular
coupling. This relationship is key to the principles behind modem brain imaging
Brain imaging modalities
There are several brain imaging modalities in common usage such a
magnetoencephalography (MEG), high density electroencephalogram (EEG), single
photon emission computerised tomography (SPECT), PET and fMRI.
There is a close relationship between glucose utilisation and synaptic activity.
Imaging techniques such as PET and SPECT make use of this relationship. These
techniques are based on the detection of the product of flurodeoxyglucose
metabolism which is accumulates at active presynaptic terminals. These modalities,
however, can be time consuming to acquire images and require the use of a
radioactive isotope flurodeoxyglucose. The isotope has a half life of 110 minutes
which again limits the ease of use.
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fMRI does not image brain activity directly but is based on changes in blood volume,
flow and oxygenation. This is usually by changes in blood oxygenation and the
signal contrast generated, known as blood oxygenation level dependent (BOLD).
BOLD fMRI studies are frequently used in brain imaging studies. Neural activity in
the brain is associated with an increase in local blood flow to the local vasculature.
There is in fact a reduction in deoxyhaemoglobin because the increase in blood flow
exceeds the rate of oxygen extraction. Deoxyhaemoglobin is paramagnetic and alters
the T2 weighted magnetic resonance image signal. Deoxyhaemoglobin acts as an
endogenous contrast enhancing agent, meaning that human cortical function can be
observed without the need for exogenous contrast.
fMRI can readily image brain activity related to a specific task or in terms of pain
activity related to a particular sensory stimulus (Both noxious or non-noxious).
Advantages include; no requirement for radioactive isotopes, relatively short scan
times of 1.5-2 minutes per run and resolutions of 1.5mm x 1.5mm (smaller resolution
is possible, down to less than 1mm).
Brain imaging studies and pain
On of the first studies of immediate brain activity and pain was a PET study. This
study showed that human perception of pain correlates with activity in S1 and S2 and
the ACC (28). Subsequent studies confirm this with activity being most consistent in
the medial mid-brain, thalamus, lentiform nucleus, cerebellum and the insular,
prefrontal, parietal (inc. SI and S2) and anterior cingulated cortices. These multiple
areas represent the entire pain experience i.e. sensory, affective and cognitive. Pain
imaging studies are able to identify functional specificity ofdifferent parts of the
brain. For example, areas of the brain correlating with heat pain unpleasantness can
be separated from those correlating to heat pain intensity (29). Pain perception can be
separated from pain anticipation (30). Pain imaging studies have been used to image
neuropathic pain states. Using intradermal capsaicin models of neuropathic pain,
researchers have demonstrated unique areas of activation of the brain in response to
tactile allodynia. fMRI can show the importance of cortical networks (comprising
areas such as SI, the parietal association cortex, S2/insula and inferior frontal cortex)
in processing of dynamic allodynia (31).
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Pain imaging studies have been also carried out in clinical chronic pain states, such
as chronic low back pain, complex regional pain syndrome (CRPS) and in phantom
pain (Discussed below, section 1.2.12). Alterations in cortical processing of
somatosensory stimuli is not unique to phantom limb pain, but can be seen in other
form of chronic pain including CRPS and chronic low back pain (32-34).
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1.2 Neuropathic pain
Neuropathic pain is defined by the International Association for the Study of Pain
(IASP) as "pain initiated or caused by a primary lesion or dysfunction in the nervous
system" (22). The lesion can vary from transection of a major nerve to a subtle nerve
lesion such as irritation of a nerve by inflammatory substances such as blood or
infection. It typically has different characteristics from nociceptive pain and sufferers
often use words such as burning, pulsing or stabbing. There is commonly pain in an
area of sensory loss. Allodynia, hyperalgesia or dysaesthesia may be found.
1.2.1 Mechanisms of neuropathic pain
The mechanisms ofneuropathic pain are complex. Understanding in this area is a
rapidly changing and advancing field. Nerve injury causes neuroma formation in the
nerve and increased excitablitity with ectopic discharge. There are changes in ion
channel expression particularly sodium channels. The nerve phenotype changes with
alteration in neuropeptide expression. Neurotrophins play a major part in these
changes. There is evidence of involvement of the sympathetic system. In addition
there are changes in central anatomy and electrophysiology leading to long term
potentiation and central sensisitation. Dorsal hom inhibitory control is diminished
and changes occur in both descending modulatory systems and the cerebral cortex.
1.2.2 Neuroma formation and ectopic discharges
Following peripheral nerve transection, damage to primary afferent fibres results in
areas of demyelination at the injury site. Attempts at nerve regeneration by axonal
sprouting results in a neuroma, a tangled axonal mass. Amputation of a limb may
result in a neuroma. Experimental neuroma in a rat sciatic nerve have been shown to
cause spontaneous discharges in the dorsal roots which could be augmented by
mechanical and chemical stimulation (35). These frequent abnormal spontaneous
discharges, termed "ectopic activity", arise, not only from the neuroma, but in other
parts of the nerve, including the dorsal root ganglion (DRG), where the cell bodies of
the primary afferent fibres are located (36). Accumulation of sodium channels at the
sites of ectopic discharges may result in altered membrane threshold leading to
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spontaneous discharge (37). Ectopic activity in the nerve following injury can be
prevented using systemic lignocaine, perhaps acting on TTX-resistant Na channels,
at doses that do not block normal nerve conduction (38). In humans ectopic activity
has been shown to correlate with pain in amputees and dysaesthesia associated with
back pain and radicular pain (39;40). Cross-talk can occur in sensory neurones. This
may result in amplification of sensory stimuli. Ephaptic (electrical) cross-talk can
occur in regenerating neurones and may reflect the lack of glial insulation in the
damaged axons (41 ;42). Ephapsis however, may not occur in the DRG following
nerve injury (43).
1.2.3 Increased expression of sodium channels
Voltage-dependent sodium channels produce the inward currents that depolarise the
cell membrane and thus are fundamental to conduction of the action potential in the
nerve. As discussed above nerve injury leads to hyperexcitability in the peripheral
nerve, therefore research has focussed on peripheral nerve sodium channels and what
happens following nerve injury. There are almost a dozen molecularly distinct
sodium channels in mammals, some ofwhich are largely limited to the DRG (For
review see Lai et al. (44)) Sodium channels are broadly classified into those that can
be blocked by tetrodotoxin (TTX-sensitive) and those that cannot (TTX-
resistant).See table 2 for classification of channels. Following injury to DRG axons
there is accumulation and increased expression of sodium channels proximal to the
site of injury (45). More recently research has been focusing on the types of sodium
channel involved and how they are regulated following nerve injury. Following
axotomy, there are changes in the sodium channel gene expression. Axotomy results
in the upregulation of the Navl.3 channel mRNA while Navl.8 and Navl.9
expression is down regulated (46-48). Nav 1.8 and Nav 1.9 encode for TTX-resistant
channels. Axonal transection can be shown to result in loss of TTX-resistant
currents. The TTX-sensitive channels switch properties, with the time constant for
recovery increasing almost fourfold (49). The TTX sensitive channel Navl .3 is
thought to be responsible for this and can also be shown to accumulate in
experimental neuromas. These changes in sodium channel expression may underlie
hyperexcitablilty and spontaneous activity ofDRG neurones (50).
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Table 2 shown overleaf
Reproduced with permission from Neurology (51).
Key
GEFS(+) Generalised epilepsy with febrile seizures plus
SMEI Severe myoclonic epilepsy of infancy
DRG Dorsal root ganglion
HyperKPP Hyperkalaemic periodic paralysis
PMC Paramyotonia congenita
PAM Potassium aggravated myotonia.
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Table2VoltagegatedNa+ ch nn ls ChanneltypLocalisation a-subunit Navl.l Nav1.2 Nav1.3 Na„1.4 Nav1.5CellbodiesofCNS neurones,cardiac monocytes CNSunmyelinatedaxo s Embryonicneuronsof CNSandDRG Skeletalmuscle Heartandmbryonic neurons
KineticsandTTXs sitivity Lowthresholdfactivation,fativationn inactivation,slowrecoveryfromctivation,TTX sensitive Lowthresholdfactivation,fativationnd inactivation,slowrecoveryfromctivation,TTX sensitive Fastctivationndfarecoveryromin ctiv tion,TTX sensitive Lowthresholdfactivation,faactivationnd inactivation,andslowrecoveryfromi tivation,TTX sensitive Lowthresholdfactivation,fativationnd inactivation,andslowrecoveryfromi tivation,TTX resistant
Function Initiationofactivationc potential,repetitivefi i g Conductionofactiopotential Persistentdepolarisationinresponset subthresholdimuli,increasing excitability,andrepetitivefi i g Muscleactionpotentialndexcitation- contractionoupling Actionpotentialinheart
Na.1.6 Nav1.7
NodesfRanvieriCNS andPNS CNS,DRGand sympatheticneuron s
Lowthresholdfactivation,fativationnd inactivation,slowrecoveryfromi i tion,TTX sensitive Lowthresholdfactivation,fativationnd inactivation,andslowrecoveryfromi i tion,TTX sensitive
Fast(salutatory)conduc i nfction potential Initialdepolaris tionfactionpotential
Nav1.8
SmallDRGneurones
Highthresholdandslowkin ticsofctivation inactivation,f srecoveryromi ctivation,TTXres st nt
Activatedaft rdepolarisationini e
byNavl.7ndsustainsrepetitivefi i g
Navl.9SmalDRGneuronesV rylowthresh ldandslowkin ticsfactivationTTXPer i te tsubthreshdepol ris ti resistant
Clincalsignificance Pointmutationsa ddelet onscauseGEFS+ andSMEI PointmutationcauseGEFS+ Up-regulatedfollowingaxotomyndspinal cordinju y,mediatingpaintheseondit ons PointmutationscausehyperKPP,MC,r PAM PointmutationscauselongQTsyndrome Pointmutationsinicecauseserebellar ataxiaormotorend-platedis se Mutationsc useprimaryfamilial erythromelalgia Upregulatedbyinflammatorymedi tors, involvedinflammatorypainnd hyperalgesia Upregulatedbyinflammatorymedi tors, involvedinflammatorypainnd hyperalgesia
1.2.4 Neuropeptide changes (table 3)
Primary sensory neurones contain a significant amount of peptides. Some like
substance P (SP) and calcitonin gene related peptide (CGRP) are present in the
normal state, while others such as vasoactive intestinal polypeptide (VIP), galanin
(GAL) and neuropeptide Y are normally expressed at low levels. Axotomy results in
a phenotypical change in the neurone. In the DRG, following axotomy, there is
down-regulation of several peptides that are normally present in the primary afferent
cell bodies. This includes SP and CGRP (52;53). In contrast, there is an increase in
VIP, GAL and NPY expression (54). Hokfelt has suggested that axotomy transfers
the role of excitatory mediator from substance P and CGRP to VIP, with GAL
having a protective effect. The sensory neurone in effect changes its phenotype with
regard to messengers, receptor expression and function.
Table 3 Changes in neuropeptides in the DRG.











CGRP Calcitonin gene related peptide
GAL Galanin
NPY Neuropeptide Y
PACAP Pituatary adenylate cyclase-activating polypepetide
SOM Somatostatin
SP Substance P
VIP Vasoactive intestinal polypeptide
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1.2.5 Neurotrophins and other signal molecules
Neurotrophic factors are molecules that play a role in the development, maintenance
or regeneration of the nervous system. An important group of neurotrophic factors
are the neurotrophins (55). Members of the neurotrophin family are nerve growth
factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3) and
neurotrophin-4/5 (NT-4/5). Adult sensory neurones have specific receptors for
neurotrophins. These receptors are a family of transmembrane tyrosine kinases, trkA
which binds NGF, trkB which binds BDNF and NT-4/5 and trkC which binds NT-3.
NGF is important in inflammatory pain states. In addition NGF regulates the
expression ofBDNF which is released from activated nociceptors and acts as a
central modulator of pain (56). NT-3 and NT-4/5 do not seem to have a major role in
pain processing
NGF
NGF acts as an inflammatory mediator. NGF exerts a lot of influence via its
regulation of gene expression in trkA containing neurones. NGF causes the
upregulation of substance P and CGRP in neurones. The expression ofBDNF is
induced in almost all trkA expressing neurones following NGF treatment. Many
ligand gated ion channels e.g TRPV1, P2X3, ASIC3 are regulated by NGF.
NGF regulates voltage gated ion channels such as calcium, potassium and in
particular sodium channels. NGF is required for maintenance ofNavl.8 expression
in normal neurones (57). NGF delivered to DRG cell bodies causes a reduction in
Nav 1.3 and an increase in Nav 1.8 expression, a reverse ofwhat happens in the
neuropathic state (58). It can be shown to partially restore TTX-R sodium currents in
DRG cells (59). NGF, infused onto the liagted nerve has been shown to alleviate the
painful neuropathy in a rat CCI model (60).
In vivo, NGF can cause sprouting of sprouting of sympathetic post-ganglionic fibres.
Many changes induced by axotomy such as down regulation of substance P, CGRP
and down regulation of galanin and VIP can be prevented by a NGF infusion. BDNF
is induced in nociceptors by NGF and may contribute to central pain processing.
NGF acts as an inflammatory mediator. In inflamed tissues NGF levels increase,
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both through increases in constitutive expression and de novo production (56). In
human subjects subcutaneous or intramuscular NGF gives rise to pain land
tenderness lasting for hours. Intravenous doses can cause pain lasting for days.
BDNF
BDNF is released in the dorsal horn by afferent fibre stimulation (61). BDNF
increase is seen in typical models of neuropathic pain such as constriction injuries to
the sciatic nerve. BDNF is found in vesicles in primary afferent terminals located in
the superficial dorsal hom (lamina I and II) of the spinal cord (62). Noxious stimuli
causes release ofBDNF into these superficial laminae. BDNF causes activation of
spinal trkB receptors which in turn causes intracellular signalling cascades and early
gene and protein synthesis. An important result ofBDNF activity is the modulation
of glutamate receptor activity. BDNF can modulate spinal neurone responsiveness by
potentiation of post-synaptic NMDA receptors and seems to potentiate glutamergic
neurotransmission at the level of the spinal cord.
1.2.6 Sympathetic system
In the normal situation there is no connection between the sympathetic post¬
ganglionic neurones and the peripheral afferent neurones. In effect, small nociceptive
fibres are physiologically and functionally distinct from efferent sympathetic tissues,
after peripheral nerve injury, catecholamine containing perivascular axons sprout
into the DRG and form basket-like structures around large-diameter axotomised
sensory neurones (63;64). This sprouting may be triggered by cytokine-induced
production of neurotrophins. Stimulation of sympathetic neurones innervating the
DRG can alter activity (either excite or depress) in the spontaneously active DRG
neurones. However the pattern of activity changes with time. At 2-44 days post nerve
lesion sympathetic activation predominantly enhances activity of spontaneously
active DRG cells, whereas by later time-points (110-171 days) depression of
spontaneous activity becomes more prominent (65). In the clinical situation there is
evidence of autonomic dysfunction that for certain types of neuropathic pain (e.g.
phantom pain or CRPS (66;67). Indeed in CRPS, evidence of autonomic dysfunction
is one of the diagnostic criteria (68). In CRPS patients, injection of adrenergic
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agonists can provoke or increases pain, while increases in sympathetic arousal can be
shown to increase pain (67;69). Sherman has shown that patients with burning type
phantom pain have reduced surface blood flow to the stump (66). Despite the
proposed link, treatment with sympathectomy has been disappointing. Systematic
review of studies using intravenous sympathetic blockade using guanethidine, has
not shown this treatment to be superior to placebo in the treatment of CRPS (70).
Likewise, in the treatment of phantom pain, sympathectomy does not give long-term
relief. Despite the association of autonomic dysfunction and certain types of pain, a
causal link in humans has not been definitely established.
1.2.7 Central anatomical changes
It has been postulated that following peripheral nerve injury, there may be
reorganisation of central terminals of myelinated primary afferents. Woolf et al have
shown that after axotomy, large myelinated Ap-fibre (and possibly A8-fibres)
terminals sprout from the deeper laminae to the more superficial laminae II (71).In
this model, using Horse Radish Peroxidase (HRP) as a neuronal marker, sprouting
was detectable by one week and persisted for over six months (72). Ap-fibre
activation of spinal neurones, normally activated by C-fibres, may contribute to
touch-evoked pain (mechanical allodynia) (15). There are now, however doubts as to
the validity of this method of labelling. Neuronal transport ofHRP following
axotomy may be altered with both large and small diameter neurones being labelled
(73). More recent papers on central changes following axotomy seem to indicate that
sprouting of central afferents is not a great as once thought (74;75).
There does however seem to be a functional reorganisation of sensory pathways in
the dorsal horn. Following nerve injury, stimutalation of Ap afferents causes
excitatory post-synaptic currents (EPSCs) in the substantia gelatinosa (76). It is
unclear whether this functional connection is predominantly due to sprouting or via
excitatory interneurones.
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1.2.8 Long term potentiation (LTP)
Following peripheral nerve injury, there are alterations of central neuronal
electrophysiology. Increased afferent input can lead to long-term potentiation, central
sensitisation and increases in receptive fields.
LTP is a long-lasting increase in synaptic efficiency as result of tetanic stimulation. It
is in effect the way the central nervous system stores information for a prolonged
period of time, i.e. in learning or memory. However, LTP can also occur in
nociceptive processing and may account for some of the features seen in chronic pain
states e.g. allodynia and hyperalgesia (77).
LTP is the use dependent long-term increase in synaptic strength. This was first
measured in hippocampal cells and forms the basis for learning and memory (78).
LTP is, however, not confined to the hippocampus. It can occur in all parts of the
brain and can occur in the spinal cord (79). Glutaminergic synapses; the most
common excitatory synapse in the CNS has been extensively studied over the years.
In essence high frequency stimulation (20-100Hz) for a few seconds can cause LTP
lasting several hours. It is calcium dependent. In glutamate receptors there is calcium
influx through glutamate-gated channels of the NMDA receptor. It also involves
voltage gated Ca2+ channels, AMPA receptors or Ca2+ release from intracellular
stores. Repetitive electrical stimulation of fine primary afferents (both A8 and C-
fibres) can produce LTP. LTP of C-fibre evoked potentials is prevented by NMDA
receptor blockade (80). Although LTP can be shown to occur in the spinal cord and
can be blocked by NMDA antagonists it remains to be seen as to whether LTP
underlies allodynia and hyperalgesia. In neuropathic rats neither electrical nor natural
conditioning can be shown to produce a long-term increase in evoked neuronal firing
(81). It may be that LTP is very rapidly induced following nerve injury and further
increases are not possible.
1.2.9 Central Sensitisation
Central sensitisation is an important factor in the development of chronic pain states.
Following sustained nociceptive input, whether from nerve damage or tissue injury
results in sustained alteration in spinal cord neurones, with a prolonged increased
output from the dorsal horn. A wide range of changes can be detected including, an
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increase in receptive field (spatial changes), increased response to afferent activity
(threshold changes), increased spontaneous neuronal activity and prolonged after
discharges in response to transient stimuli (82;83).
The release of the excitatory amino acid glutamate and the subsequent activation of
NMDA receptor are key to the development of central sensitisation. In the resting
state the NMDA receptor is blocked in a voltage-dependent manner by extracellular
magnesium such that it is not usually activated at normal resting membrane
potentials. However if there is sufficient C-fibre activity, this leads to an increase in
calcium in the C-fibre pre-synaptic terminal, resulting in increased release of
substance P and glutamate. Post-synaptic membrane depolarisation occurs via
activation of the AMPA receptor. This results in removal of the magnesium ion and
allows receptor activation by glutamate. Consequently there is post-synaptic influx of
both sodium and calcium ions. Increased cytosolic calcium levels result in activation
of protein kinase C (PKC) and subsequently other protein kinases TrkB and protein
tyrosine kinase (Src) with resultant phosphorylation of the NMDA receptor, resulting
in reduced magnesium block and prolonged depolarisation (84).In the normal
physiological state only C-fibres activation can induce central sensitisation. However
in pathological states when there is loss of inhibitory GABA neurones stimulation
via A-fibres can give rise to central sensitisation (85).
Clinical relevance of central sensitisation
The post-injury hypersensitive state leads to alterations in the sensory modality of
low-threshold mechanoreceptors. Pain may occur following a normally innocuous
stimulus (such as brushing), a condition known as allodynia. In additon the
facilitated spinal processing may give rise to an exaggerated response to a normally
painful stimulus, a condition known as hyperalgesia
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1.2.10 Loss ofGABAergic of inhibitory control
Processing of nociceptive activity in the spinal cord is a balance between excitatory
neurones and inhibitory neurones. GABA along with glycine is one of the major
inhibitory neurotransmitters in the central nervous system. The central nervous
system is normally under a state of chronic inhibition largely due to the action of
GABA containing neurones. In the spinal cord GABA is concentrated in the
superficial laminae of the spinal cord, where the most of the AS and C-fibres
terminate. They make up between 24 and 33% of neurones in laminae I-III (86) At
the time ofnerve injury, an intense neuronal discharge from primary afferent
neurones has been detected (87;88). This massive neuronal firing may cause
excitotoxic cell death. These predominantly small neurones in the superficial layers
of the dorsal horn, are more susceptible to depolarisation injury (89;90). Many of
these small neurones are inhibitory and thus there is a reduction in presynaptic
inhibition. Using animal models, partial peripheral nerve injury (but not axotomy),
has been shown to cause a selective loss ofGABAergic inhibition in the superficial
dorsal horn (91). There seems to be a decrease in both presynatic GABA release and
a reduction in the GABA synthesising enzyme (glutamic acid decarboxylase). These
alterations in GABAergic function may lead to a loss of tonic inhibition of both
primary afferent neurones and post-synaptic spinal cord neurones resulting in
increased afferent transmission.
1.2.11 Supraspinal modulation of pain
Descending input from supraspinal sites are important in modulating neuropathic
pain. In an animal model of secondary hyperalgesia, spinal cord transection abolishes
behavioural pain responses. This indicated that increased sensitivity to mechanical
stimuli is also dependent on supraspinal factors. Cord transection on the side
ipsilateral to nerve injury abolishes increased sensitivity to mechanical stimuli but
not contralateral cord transection (92). This may mean that rather than afferent input
promoting neuropathic pain being carried in the spinothalamic tracts, it may be
carried via alternative routes e.g. the dorsal columns.
Areas of the brain that are considered important in modulating control are the PAG
and the RVM. These two areas link with the spinal cord to produce a descending
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pain modulating circuit (For review see Fields and Basbaum; Ren and Dubner
(14;93). Tonic descending facilitation is an important driver in the maintenance of
both thermal hypertalgesia and tactile allodynia (94). In addition the neuropeptide
CCK may be a driver of tonic facilitation (95).
PAG
The PAG is sited in the midbrain and is important in descending inhibitory pathways.
Electrical stimulation of the PAG produces potent antinociception (96). This is
probably mediated by endogenous opioid systems as this can be mimicked by focal
application ofmorphine and blocked by systemic naloxone (97;98).
RVM
The RVM is an important site for descending modulation of nociceptive signals. Like
the spinal cord, activity-dependent plasticity takes place in the RVM. Both NMDA
and AMPA receptors are involved, with changes in excitatory amino acid (EAA)
gene/protein expression and increased phosphorylation of these receptors (99). While
other CNS sites can enhance behavioural or spinal responses to a noxious stimulus,
the final common facilitatory output seems to be the RVM (21). The RVM can,
however, function in a bidirectional manner, i.e. inhibit or facilitate afferent activity.
The RVM has three types of cells. These are 'On' cells, 'Off cells and 'Neutral'
cells (100). 'Off cells attenuate nociceptive input and p-opioid agonists increase
their activity. In acute pain states 'On' cells accelerate firing before a nociceptive
reflex and are seen to be a source of descending facilitation (100). Facilitation of
'On' cells in the RVM may account for maintenance of pain in chronic conditions.
The function of neutral cells has yet to be clearly determined, but there seems to be
evidence for phenotypic changes occurring in thee RVM following inflammation,
with cells changing their response profile with time (101; 102).
CCK
CCK is an endogenous neuropeptide which reduces the antinociceptive effect of
opioids. Anatomically there is overlap in the distribution ofCCK, endogenous
opioids and their receptors, suggesting a functional link (103). CCK, its receptors
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and the level of its release exhibit considerable plasticity in the chronic pain state.
CCK is thought to be involved in the supraspinal facilitation of neuropathic pain.
Using a spinal nerve ligation model, microinjection of the CCK-B antagonist
L365,260 into the RVM reverses tactile allodynia and thermal hyperalgesia (95). The
application ofCCK-8, an agonist, to the RVM of naive animals produces behaviour
suggestive of neuropathic pain (95). In nerve injured animals the effect of injection
ofmorphine into the PAG is attenuated but can be restored by L365,260. This adds
weight to the idea that CCK is, at least in part, responsible for the poor response of
neuropathic pain to opioid analgesia (95). Despite the promise of animal studies,
L365,260 did not potentiate the effects ofmorphine in humans with neuropathic pain
(104). This disappointing result may be due to the fact that, in primates, CCK-A and
not CCK-B seems to be the predominant receptor particularly in the DRG (105).
1.2.12 Cortical changes and Pain
Melzack has proposed the concept of the neuromatrix (106). This is made up from
central neural networks linking certain areas of the brain including the thalamus, the
somatosensory cortex, reticular formation, limbic system and posterior parietal
cortex. These linked areas create the concept of self. Melzack has proposed that the
neuromatrix is effect a neurosignature i.e a characteristic pattern of neuronal activity
caused by cyclical processing and synthesis of nerve impulses. The neuromatrix is
created genetically but it can evolve in response to the external environment. .
Particular alterations in central neuronal input may do this i.e. from an increase in
afferent activity from a damaged nerve or perhaps decreased activity from, for
example, an amputated limb. This concept is hard to prove. In certain types ofpain
e.g. CRPS or phantom pain, alterations in somatosensory processing can be
demonstrated in both animal and human studies. Phantom limb pain gives in-sight to
the concept of central neural plasticity. Much research has focussed on plasticity of
the somatosensory cortex (107). The primary somatosensory area is located in the
post central gyrus. This area is organised into a specific somatotopic map, known as
the Penfield homunculus. Following denervation it has been shown that the cortical
representation of a body part may expand into that part of the cortex supplying the
deafferented area. In the adult macaque monkey, as in humans, the sensory area for
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the hand is located adjacent to the area corresponding to the face. After upper limb
amputation, tactile stimulation to the face resulted in cortical activity in the area
which normally corresponded to the hand (108). Cortical reorganisation was found to
occur over distances up to 14mm, ten times the distance that was previously thought
possible. Similar cortical remapping has been demonstrated in human. In subjects
with previous upper limb amputation, stimulation of areas of the face ipsilateral to
the amputation results in sensation in the phantom hand, especially the digits (109).
There seems to be an over-representation of the thumb and little finger, perhaps
reflecting the greater cortical magnification of these areas. The relationship between
the area of the face stroked and the region of the phantom where the sensation was
felt was very consistent. Stimulation to contralateral areas of the body did not usually
give rise to phantom sensations. This phenomenon was also consistent in other
sensory modalities, i.e. the subject felt heat and vibration in the phantom if
stimulated on the face. With reference to the Penfield homunculus, this would be
exactly as expected, the arm and the face being topographically adjacent to the lower
limb. A study by Knecht at al supports the overall theme of cortical shift and
perceptual changes but observed that the mislocalisation ofpain or non-painful
modality specific sensation was not as exact as Ramachandran would have us believe
(110). This gives rise to the question: Is cortical reorganisation related in some way
to phantom pain? Using brain imaging techniques, cortical remapping has been
demonstrated in patients with upper limb deafferentation (111). The magnitude of
cortical remapping was correlated with the severity of phantom pain but not phantom
sensations (112). The mechanism behind cortical reorganisation may be
multifactorial, perhaps involving potentiation of synapses, unmasking latent
connections or by growth ofnew neural connections. There is evidence to suggest
that plasticity in the somatosensory cortex changes can occur very rapidly. Referred
sensations from the face have been demonstrated within 24 hours of amputation of
the upper limb and cortical remapping confirmed using fMRI at one month (113).
Plasticity is not only rapid but in patients with painful upper limb phantoms has been
shown to be rapid and reversible (114). This study ofupper limb amputees with
phantom pain found that cortical remapping was rapidly reversed with a brachial
plexus block only when the phantom pain was relieved. In patients in whom phantom
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pain persisted, despite a successful block, no reversal in cortical remapping was
found. These rapid reversible changes in central neural plasticty suggest the
mechanism, in part at least, to be due to unmasking of latent pathways rather than
neuronal sprouting. Regrowth of new neural connections would take many months
and traditionally very little new growth in the central nervous system was thought to
occur. There is now some evidence for both new cortical connections and brainstem
connections developing in monkeys following deafferentaion. Markedly expanded
cortical connections in macaque monkeys have been demonstrated many years
following loss of the upper limb (115). There was no evidence for new
thalamocortical connections. The same group went on to study the brain stem in
monkeys who had either suffered loss of their upper limb or had lesions in their
dorsal columns (116). Connections in the brain stem between the trigeminal nucleus
(the area for afferent sensory input to the chin) and the caudate nucleus (where
sensory information from the denervated area is processed) were studied. At lower
brainstem levels, the chin representation in the trigeminal nucleus lies adjacent to the
hand representation in the cuneate nucleus. They were able to demonstrate that the
face afferents from the trigeminal nucleus of the brain stem sprouted and grew into
the cuneate nucleus. It is evident therefore that although some of the changes in the
cortex may be rapid and plastic, as a result of alterations in synaptic function or
unmasking latent pathways, there may also be growth of new connections both in the
cortex and the brain stem.
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1.3 Models of neuropathic pain
There is no human experimental model that directly minics neuropathic pain in the
clinical setting, i.e a model that involves direct injury to a nerve. Human
experimental models of neuropathic pain are thus surrogate models and as such have
some limitations.
1.3.1 Human experimental models of neuropathic pain
Human models of neuropathic pain focus on sensory signs and symptoms. Human
models have the advantage that verbal communication can be used to convey the
various qualities of the pain using descriptive language and is able to describe
location and temporal qualities of the pain. Evoked signs can also be elicited.
Patients with neuropathic pain often complain of burning or paroxysmal pain
described like 'electricity'. Pain often occurs in anarea of sensory loss. Models that
have been developed try to mimic these situations. Examples include the application
of topical irritants such as mustard oil or capsaicin (both topically and intradermally).
These produce burning type pain and can model hyperalgesia. There is some overlap
with nociceptive pain. Electrical stimulation has also been used, both direct
stimulation of nerve trunks and intracutaneous electrodes. Attempts have been made
to mimic paraesthesia using direct nerve pressure to cause nerve ischaemia. These
models by definition cannot mimic the long lasting effects of denervation or nerve
injury.
1.3.2 Animal models of neuropathic pain
Animal models ofneuropathic pain have been developed with signs consistent with
the clinical syndromes. Most of our current understanding of the neurobiology of
neuropathic pain is based on study of these models. In research terms, animal
models have the advantage that they are highly reproducible in experienced hands
and consistently produce behavioural signs of allodynia and hyperalgesia to both
thermal and mechanical stimuli. However it is worth noting that the majority of
humans, despite clear evidence of nerve injury, do not go on to develop neuropathic
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pain. Common models in current use invariably use partial damage to a peripheral
nerve (usually sciatic).
The first widely used animal model used total transection of the sciatic nerve (117).
This results in a denervated limb with no sensory or motor function and was thought
to reproduce 'Anaesthesia Dolorosa' that is seen in humans. This model however has
high levels of selfmutilation (known as autotomy). Autotomy may occur as a result
of having a denervated limb rather than as a result of pain. In addition, for ethical
reasons, autotomy is considered undesirable. Current models have a low incidence of
autotomy.
Most subsequent models use partial damage to the sciatic nerve. The three most
commonly used are the chronic constriction injury (CCI), partial sciatic nerve
ligation (PSNL) and spinal nerve ligation (SNL). The CCI model was described by
Bennett and Xie (118). It involves tying 4 loose chromic ligatures around the sciatic
nerve. The resultant inflammation and swelling results in neuronal loss, largely ofA-
fibres but also some c-fibres. Within three days the animal displays behavioural signs
of spontaneous pain, allodynia and hyperalgesia. The PSNL model ligates only 33-
50% of the sciatic nerve at the mid thigh level (119). Animals develop similar
changes to the CCI model. The third commonly used model is the spinal nerve
ligation model ofKim and Chung (120). This model uses tight ligation of the spinal
nerves of L5 and L6. In contrast to the first two models described, this model only
affects only the sensory afferents and also spares the spinal nerve of L4, which
means that changes in the DRG of the undamaged afferent can be studied. A direct
comparison of the three models has been carried out (121). This shows the models
largely comparable, but that they have subtle differences. For example, mechanical
allodynia as measured by an 8.4mN Von Frey hair was greatest in the SNL model
and least in the CCI model. In ongoing pain the reverse was true. The greatest change
post sympathectomy was seen in the SNL model. The authors suggest that the choice
ofmodel may depend on which is the most important outcome measure. A more
recent development of the sciatic nerve damage models is the spared nerve injury
model (122). This produces profound and persistent behavioural changes suggesting
mechanical allodynia, cold allodynia and hyperalgesia to pinprick. This model
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involves a tight ligation of the tibial and common peroneal nerves leaving the sural
nerve intact. This model has the advantage ofpaw testing involving areas with both
nerve damage and areas with an intact nerve supply.
1.4 Glutamate and Glutamate receptors
Glutamate is the major excitatory neurotransmitter released in the central nervous
system in response to noxious stimuli. Glutamate has many target receptors including
metabotropic and ionotropic receptors. Metabotropic receptors are G-protein linked
and modulate production of intracellular messengers, while ionotropic receptors are
cation specific channels. Ionotropic glutamate receptors are divided into AMPA,
kainate and NMDA receptor channels (For review of glutamte receptors see Ozawa
et al. 1998 (8). The N-Methyl D-Aspartate (NMDA) receptor is key to the
development of synaptic plasticity and maintenance of chronic pain states. Studies
from both animal and human studies suggest that NMDA receptor antagonists may
have a useful role in the management of chronic pain states. The NMDA receptor,
however, is widely distributed throughout the CNS and, in addition to its
involvement in spinal sensory processing, has involvement in memory, motor-
function and vision (For review see Mayer & Westbrook 1987 and McBain & Mayer
1994(123; 124)). This can restrict the use ofNMDA antagonists in the clinical setting
due to unwanted side effects (125).
I
1.4.1 NMDA receptors
NMDA-sensitive ionotropic glutamate receptors are widely distributed in the CNS.
The NMDA receptor has three major properties. Firstly, the receptor controls a
cation channel permeable to monovalent ions and calcium. Secondly, for optimal
efficiency the simultaneous binding of glycine (a co-agonist) with glutamate is
required and thirdly NMDA receptors are blocked in a voltage dependent manner by
magnesium which means depolarisation of the post-synaptic membrane is required
for activation (e.g. by activation ofpost-synaptic AMPA receptors) (8).
NMDA receptor complexes are probably tetrameric structures (126). Functional
receptor complexes are made up from combinations ofNR1 subunits and NR2
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subunits. Formation of functional NMDA receptor channels requires coexpression of
NR1 and at least one of the NR2 subunits. The NR1 subunit contains the glycine
recognition site while the NR2 subunit contains the glutamate recognition site . There
are 8 isoforms of the NR1 subunit and four individual (NR2A-NR2D) subunits of the
NR2 subfamily. (127; 128). The NMDA receptor is associated with scaffolding
protein complexes such as PSD-95. PSD-95 is specifically restricted to lamina II of
the spinal cord and overlaps particularly the NR2B subunit expression in the lumbar
and thoracic cord (129). PSD-95 / NMDA receptor interaction seems essential to the
development ofNMDA associated sensitivity (130).
NMDA receptor distribution studies (using binding of radioligands) show the
receptor to be distributed throughout the brain, predominantly the forebrain, with
highest levels being found in the hippocampus (131). NR1 subunits are widely
distributed in contrast to the NR2 subunits that have regional patterns of distribution.
The NR2B subunit, for example, is largely found in the forebrain and in the dorsal
horn of the spinal cord (laminae I and II), probably presynaptically (132). The NR2B
subunit is the most commonly expressed subunit in the dorsal horn of the rat. L5
spinal nerve ligation results in a reduction in NR2A mRNA expression with a
resultant relative increase in NR2B expression (133). This may be important in
neuropathic pain. The NR2B receptor is of particular interest because not only are
there are commercially available antagonists to the subunit, such as ifenprodil and
its derivatives. NR2B antagonists have been shown to be efficacious in an animal
model of neuropathic pain with a reduced side-effect profile (132).
NMDA receptors and downstream messengers may be involved in opiate tolerance,
sensitisation and physical dependence. Exogenous opioids such as morphine, by
binding postsynaptically, activate PKC, which via NO results in the removal of the
magnesium blockade and allows activation of the NMDA receptor. Increasing levels
of Ca2+ results in activation of additional PKC which results in critical changes in
opioid-responsive neurons leading to subsequent morphine tolerance (134).
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1.4.2 Pre-emptive analgesia using NMDA antagonists in animal models
In animal models of neuropathic pain, the NMDA antagonists, memantine and
ketamine, were both effective via spinal administration in reducing mechanical
allodynia, with memantine being ofhigher efficacy (135;136). Systemic or
intrathecally administered ketamine has been shown to reduce the neuropathic
sensitisation of dorsal hom neurons (137). Several animal studies have investigated
whether administration ofNMDA antagonists, around the time of nerve injury can
prevent the establishment of a sensitised neuropathic pain state. Evaluation of the
effectiveness ofpre-emptive NMDAR antagonists in preventing sensitisation
following nerve injury has been hampered since different sensory tests were assessed
in different animal models.
In the CCI model, administration of the NMDAR antagonists (memantine, MK801 or
ketamine) for 3-8 days from the time of sciatic nerve injury resulted in reduced
development of thermal hyperalgesia (138-141). Similar observations have been
made for mechanical hyperalgesia (142; 143), but in a different model, the spinal
nerve ligation (SNL) model. Single bolus administration of intrathecal or systemic
ketamine or memantine prior to nerve injury is reported to attenuate mechanical
allodynia from 6 hours to two weeks in the SNL model (143; 144), or delay its
development for 3 days in the CCI model (145). The timing of administration is
important, with attenuation ofmechanical allodynia only being observed when MK-
801 was administered pre-, but not post-operatively (146).
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1.4.3 NMDA antagonists in clinical practice
Clinically available NMDA antagonists
As discussed NMDA receptor mediated increases in synaptic excitability are key
factors in the development of neuronal plasticity and chronic pain states. NMDA
antagonists can reverse central sensitisation and as a result clinically available






Functional inhibition ofNMDA receptors can be achieved through actions at
different recognition sites. They are the primary transmitter site (competitive), the
strychnine -insensitive glycine site (glycines), the polyamine site (NR2B selective)
and phencyclidine site located in the cationic channel. These four drugs are all non¬
competitive antagonists with moderate affinity for the NMDA receptor. This means
that they block the open channel. It is thought that this may produce a better clinical
profile and avoid some of the numerous side effects that the NMDA antagonists have
such as memory impairment, psychotomimetic effects, ataxia and motor in
coordination.
Ketamine
The first clinical report of ketamine use was in 1965 (147). It is a racemic compound
with complex pharmacology (see Hirota and Lambert; Kohrs and Durieux
(148; 149)). It is known to have effects at glutamate receptors, including NMDA,
AMPA and kainite receptors. It also acts at nicotinic and muscarinic cholinergic
receptors, monaminergic receptors and opioid receptors. In addition it interacts with
voltage gated Ca2+ and Na+ channels. Its action on Na+ channels gives it a local
anaesthetic action (150). Ketamine exists in both (R) and (S) forms. (S)-ketamine has
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a more specific (four times) affinity for the NMDA receptor and is clinically more
potent. S-ketamine has been postulated to have lower incidences of neuropsychiatric
disturbances and thus might be preferred to the racemic compound. Research in this
area seems to indicate that the compounds have equivalent psychopathological and
neuropsychological disturbances as the racemic mixture (151).
At the NMDA receptor, ketamine is a non-competetive antagonist of the NMDA
receptor Ca2+ pore. It also binds to the phencyclidine (PCP) channel of the NMDA
receptor leading to significant inhibition of the NMDA receptor (148).
Ketamine has been used clinically in both acute and chronic pain (152; 153). A
Cochrane database systematic review identified 37 studies, including studies
involving the epidural administration of ketamine (154). The authors concluded that
subanaesthestic doses of ketamine in the peri-operative period are effective in
reducing opioid requirements in the first 24 hours following surgery. There was a
reduction in post-operative nausea and vomiting with little adverse effects. Another
systematic review of ketamine peri-operative ketamine showed a reduction in pain
and morphine usage. The clinical significance as opposed to statistical significance
was questioned so its use in everyday practice is not established (155).
Hocking and Cousins produced an evidence-based review of its use in chronic pain
(153). 24 studies were identified. These covered a range of chronic pain conditions
including central pain, fibromyalgia, complex regional pain syndrome, orofacial
pains and various types of neuropathic pain including phantom pain and post herpetic
neuralgia. In the last 10 years or so, the use of ketamine in chronic pain states has




Memantine was first synthesised in 1963 by Eli Lily as a hypoglycaemic agent. It
had no activity in this regard. It was noted to have CNS activity and a patent was
applied for in Germany in 1972 for its use as a potential treatment for Parkinson's
disease and other CNS disorders. Subsequently its was determined that memantine is
an NMDA receptor antagonist. Parsons et al have extensively reviewed its
pharmacology and preclinical data (156).
In brief, memantine seems to bind at the MK-801 site of the NMDA receptor
complex. It is a well-tolerated uncompetitive NMDA antagonist with strong voltage
dependency and rapid blocking and unblocking kinetics. In current UK clinical
practice memantine is licensed for treating moderate to severe Alzheimer's disease
and the majority of clinical trials reflect this. There have to date been six clinical
trials using memantine in chronic pain patients (see table 4) (157-162). These studies
have used doses ranging from 20-5 5mg per day of memantine and looked at several
chronic pain conditions (Diabetic neuropathy, post-herpetic neuralgia, post-
amputation pain and other nerve injuries). Despite the promise ofpre-clinical studies,
none of these studies have shown any benefit ofmemantine over placebo in the
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Dextromethorphan was originally synthesised as an alternative to morphine. It is the
d-isomer of the opioid agonist levomethorphan. However, it was found to have no
action on opioid receptors and for many years it was used as an anti-tussive in cough
remedies. Pharmacologically it blocks the open NMDA channel, blocks the
dopamine reuptake site, binds to PCP and PCP2 sites and binds to the sigma receptor
(165-167).
Dextromethorphan has been used in several studies of chronic pain states (see
table 5). Doses up to 920mg/day have been used. Results are mixed. In studies of
general neuropathic pain, chronic pain, facial neuralgias and post-herpetic neuralgia
(PHN), there was no difference compared with placebo. However, in studies of
patients with diabetic neuropathy (DN) and phantom limb pain (PLP) in cancer
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Amantadine
Amantadine is another low affinity non-competitive NMDA antagonist, clinically
used in the treatment of Parkinson's disease or drug induced extra-pyramidal side
effects. It has lower psychomimetic properties compared with other non-competitive
NMDA antagonists. Amantadine binds to the PCP binding site of the NMDA
receptor, the sigma i-binding site and at higher concentrations to other receptors
including the nicotinic acetylcholine receptor (174; 175). There are a least two RCTs
using amantadine in clinical practice (176; 177). Both studies used i.v. infusions at a
dose of 200mg weekly. A positive effect from the drug was seen in both studies. This
is encouraging, but further RCTs with larger numbers and using oral preparations are
needed.
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1.5 Phantom limb pain
1.5.1 Background
"Truly it is a thing wondrous, strange, andprodigious which will be scarce be
credited, unless by such have seen with their own eyes and heard with their own
ears, the patients who many months after cutting away the leg, grievously
complained that theyfelt exceeding greatpain in the leg cut off". Ambroise Pare, a
sixteenth century French military surgeon, wrote this text. Clearly, the concept of
phantom limb and phantom limb pain has been recognised for centuries. The actual
term "phantom limb", however, was first coined by Silas Weir Mitchell in 1871
(178). Mitchell was a US army surgeon working in the stump hospital in
Philadelphia at the time of the American Civil War. His first report appeared in
Atlantic Monthly, 1866, as a work of fiction, "The Case ofGeorge Dedlow." This
anonymously penned story was of an army physician who had lost all four limbs.
There was, at that time, a widespread scepticism as to the existence of phantom
phenomena, and it wasn't until Mitchell's 1871 scientific article on post-amputation
pain that term "phantom pain" was bom. Phantom limb pain is now accepted as
occurring not only from the many causes of traumatic amputation, but following limb
amputations due other causes, such as peripheral vascular disease and malignant
disease.
1.5.2 Epidemiology
The incidence of phantom pain seems to be anything between 30 and 80%
(179; 180). It is estimated that 5-10% ofpatients will suffer from chronic severe pain,
scoring greater than 5/10 on a NRS (180). Literature on the subject prior to 1978
quotes a much lower incidence of around 5-30% (see table 7). The low incidences
reported in earlier studies are thought to be because prevalence was based on
requests for treatment rather than true prevalence (179).
The majority of studies on the incidence of phantom pain are retrospective (table7).
There is always a danger that retrospective studies may overestimate prevalence as
they often use a questionnaire format, which results in those with the condition being
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more likely to take part. Good prospective data does exist, showing similar
prevalence of 72% at 8 days and 67% at 6 months (181).
Most studies on phantom limb have looked at either traumatic amputees or
amputation due to disease (mostly vascular), with almost all looking at adult
populations. Traditionally phantom sensations were thought to be rare in children.
However, a study of 28 child and adolescent amputees found a phantom sensation
rate of 92% and an 83% incidence ofphantom pain (182). The incidences in upper
limb amputees may be lower with estimated incidences of between 41 and 51% (183-
185).Phantom pain can occur even if there is a congenital absence of a limb. In a
comparative study of children and adolescents with either congenital limb absence or
surgical limb loss, the surgical amputees had an incidence of phantom pain of 48.5%
while, despite a congenital absence of the limb, the subjects born with an absent limb
had an incidence ofphantom sensation of 7.4% and phantom pain occurred in 3.7%
(186). Phantoms can occur without limb loss, following a peripheral or central nerve
lesion (e.g. a brachial plexus avulsion) (187). Phantoms sensation and pain do not
only occur following limb loss or denervation, but have been described in other body
areas with dense innervation such as the bladder, rectum, genitalia, breast, teeth and
tongue (188).
1.5.3 Presentation and natural history
When discussing post amputation pain, it is important to be clear as to what is meant
by the terms "stump pain", "phantom sensation" and "phantom pain".
• Stump pain refers to pain that is felt in the residual region, adjacent to the
amputated area.
• Phantom sensation refers to the general sensation that the amputated part is
still present in some form, but is not painful.
• Phantom pain is defined, as pain perceived to be coming from the amputated
part.
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The cause of these post amputation phenomena is complex is brought about by the
previously discussed pathophysiological response of the neuraxis (peripheral and
central nervous system) to peripheral nerve injury.
1.5.4 Phantom sensation
The phantom limb is perceived as being very real by the patient especially in the
early weeks following amputation. The phantom may be sensed in the same way as a
normal limb. If the patient has lost an arm, the patient can be aware of the arm
swinging from side to side in the normal manner when walking. They may feel that
they are able to reach out and grasp objects with the phantom hand. If the lower limb
has been removed, the patient is aware that the limb bends normally when they are
seated and will straighten when they stand up.
It is important to stress that this perception is an illusion rather than a delusion. This
means that although the patient senses strongly that the limb is there, they know that
it is not. If it were a delusion, the patient would, in addition to strongly sensing the
limb, persist in an erroneous belief that the limb still was there. It is not necessary to
amputate the limb in order to give rise to phantom limb sensations. Following
amputation, phantom limb sensations are almost universal with an incidence of over
90%, but do tend to change with time in duration and frequency (181;189;190). The
incidence ofnon-painful phantom phenomena at eight days, six months and two
years was found to be 84%, 90% and 71% respectively (190). Around 75% of
patients had kinaesthetic sensations (feelings of length, volume or other spatial
sensations) in the first six months following amputation. This fell to less than 50%
later in the time course. Between one and two thirds of amputees have been reported
to experience shortening of the virtual limb with time, a concept known as
'telescoping' (181;191) It may be that because the foot and hand has such a large
area of cortical representation that it persists much longer than the rest of the
phantom and telescoping is a manifestation of this. There does not seem to be a
difference in rate of telescoping, when comparing painful and non-painful phantoms
(183).
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1.5.5 Post amputation pain
Post amputation pain may manifest itself as either stump pain, phantom pain or both.
Stump pain has an incidence of anything between 7 and 76% (table 6); while as
discussed phantom pain occurs in around two thirds of amputees.
Phantom pain can occur almost immediately following amputation with 75% of
amputees developing pain within a few days (181; 182; 189; 192). In 10-33% of
patients however the onset of pain may not be for at least a year and in one individual
case pain occurred after 30 years (193).
The incidence ofphantom pain is highest immediately following amputation and
tends to fall with time, at least in the first six months. Jensen at al found that the
found that the incidence at one week, six months and two years was 72, 65 and 59%
(194). Parkes also found a decrease in pain at one year from 85% to 61% (195).
Nikolajsen at al found the incidence to be constant during follow-up although
frequency and duration of attacks decreased with time (192). Houghton et al found
that the median phantom pain score tended to fall with time (1 at five years following
amputation) (196).
The pain experienced is extremely variable ranging from occasional mild pain to
continuous severe pain. In general terms phantom pain tends to be located to the
distal part of the amputated limb (192; 194). The majority of patients describe
intermittent pain (184;197). The sensation described is variable but typically they
feel burning, cramping, shooting or crushing pains. Knife-like piercing pains are
reported in the early period following amputation with squeezing burning pains
experienced as time progressed (194).
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Table 6 Incidence of phantom pain
Authors Date Study No. Phantom Phantom Stump Notes
type Sensation Pain Pain
% % %
Bailey & 1941 R 137 87 34 NR
Moersch
(198)
Hermann & 1945 P 120 NR 6 NR Incidence of PLP
Gibbs in vascular patients
(199) 20-25%
Henderson & 1948 R 300 98 4 NR Original notes lost in
Smyth war,
(200) based on memory
Carlen et al. 1978 R 73 100 67 43
(189)




1982 R 42 86 73 NR
dl.
(202)
Jensen at al. 1983 P 58 90 67 22 Measured at 6 mths
(181) post amputation
Sherman et al. 1984 R 2694 NR 78 NR
(203)
Buchanan & 1986 R 716 84 62 NR
Mandel
(204)




1994 R 338 82 78 NR
dl.
(196)
Krane and 1994 R 28 100 92 NR Child and adolescent
Heller amputees
(182)
Wartan et al. 1997 R 590 67 55 56
(197)
Montoya 1997 R 32 81 50 40 Upper limb amputees
(183)
Smith at al. 1999 R 92 80 63 76
(206)
Kooijman 2000 R 124 76 51 46 Upper limb amputees
(184)
Dijkstra et al 2002 R 632 80 72 63 Phantom pain 41% in
(185) upper limb amputees
This table shows some of the epidemiological papers on phantom limb pain
R - Retropective NR - not recoreded
P - Prospective
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1.5.6 Factors influencing pain
Occurrence of phantom pain is independent of age, level or side of amputation,
reason for amputation and prosthesis use (see table 7). It is probably independent of
gender but one study has suggested an increased incidence in females (207).
Phantom sensations, stump pain and preamputation pain, however, do have an
association with phantom pain (see table 7).
Phantom limb pain sufferers frequently complain of pains similar to that before
amputation (208). Pains reported have included cutaneous lesions, deep tissue
injuries, bone and joint pain and painful pre-amputation postures. These have been
termed 'pain memories' (208). Katz and Melzack hypothesise that pre-amputation
pain may induce persistent cortical changes resulting in a somatosensory memory,
which manifests itself as phantom pain following amputation. Katz and Melzack
found that 44 out of 68 subjects reported pain at the time of injury and 29 reported
phantom phenomena, including pain, which they had had prior to amputation (208).
These somatosensory sensations were less common if there was no pain prior to
amputation or if there was a pain-free period. Jensen at al. found that 75% of
patients, mostly suffering from peripheral vascular disease, had pain prior to
amputation lasting greater than one month (194). Six months following amputation,
phantom limb pain was significantly more frequent in patients who had pre-
amputation pain that had lasted more than one month or pain in the limb on the day
before surgery. 60% of these patients, however, had pain that differed in type and
distribution from their pre-amputation pain, suggesting that although "pain
memories" are important, they are not the only factor.
Traditionally it was thought that psychological factors played a part in patients who
experienced phantom limb pain. Rather than being a physiological phenomenon,
phantom pain might in some way be a somatisation of a grief process, say for the loss
of the limb or even being a manifestation of grief for loss of a spouse. A review of
the literature concerning psychological factors and phantom pain concluded that
there is no excess of psychiatric or psychological pathology in these patients, but in
common with other chronic pain patients, they do suffer from stress, anxiety and
68
depression (209). Depressive symptoms do seem to be associated with post-
amputation pain (210).
Table 7 Risk factors in the development of phantom pain
Risk Factor Yes No
Sex Weiss & Lindell 1996
(increased report in
females) (207)
Jensen et al 1985 (194), Buchanan & Mandcl
1986 (204), Katz & Melzack 1990 (208),
Kooijman et al 2000 (184), Hanley et al. 2007
(211)
Age Buchanan & Mandel 1986 (204), Katz &
Melzack 1990 (208), Kooijman et al 2000
(184), Hanley et al. 2007 (211)
Level of amputation Jensen et al 1985 (194), Buchanan & Mandel
1986 (204), Katz & Melzack 1990 (208),
Houghton et al. 1994 (196), Kooijman et al
2000 (184), Hanley et al. 2007 (211)
Side of amputation Buchanan & Mandel 1986 (204), Jensen et al
1985 (194), Kooijman et al 2000 (184).
Previous amputation Jensen et al 1985 (194)
Unilateral or bilateral
amputation
Katz & Melzack 1990 (208)
Prosthesis use Katz & Melzack 1990 (208), Wartan et al 1997
(197)
Aetiology Buchanan & Mandel 1986 (204), Katz &
Melzack 1990(208), Houghton et al. 1994
(196), Hanley et al. 2007 (211)
Time since
amputation
Buchanan & Mandel 1986
(204)
Katz & Melzack 1990 (208)
Pain day before
amputation
Jensen at al. 1985 (194)




Jensen at al. 1985 (194)
(only at six months)
Preoperative pain Houghton et al. 1994 (196)
Krane and Heller 1995
(182), Hanley et al. 2007
(211)
Kooijman et al 2000 (184)
Stump pain Jensen at al. 1985 (194)
(only at two years)
Kooijman et al 2000 (184)
Phantom sensations Nikolajsen et al. 1997
(192), Kooijman et al 2000
(184)
Coexisting DM Jensen et al 1985 (194)
Personality Katz & Melzack 1990 (208)
Depression Ephraim et al. 2005 (210) Katz & Melzack 1990 (208)
Anxiety Katz & Melzack 1990 (208)
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1.5.7 Treatment of phantom pain
A survey was carried out in US war veterans looking at treatments in use or
treatments that they had tried (212). The fact that in excess of 50 different treatments
were described suggests that there is no one accepted treatment and success is poor.
Phantom pain is a type of neuropathic pain, and pharmacological treatment focuses
largely on accepted treatments for neuropathic pain. Several guidelines and evidence
based practice have been produced (213-216). These are for neuropathic pain in
general. First line treatments tend to be tricyclic antidepressants (TCAs),
serotonergic noradrenergic reuptake inhibitors (SNRIs; e.g. venlafaxine, duloxetine)
or anticonvulsants such as the gabapentinoids. Topical lidocaine can be used for
discrete areas of allodynia. Opioids and tramadol are used as second line agents.
NMDA are usually 3rd line agents. League tables of efficacy have been produced
using the concept of numbers needed-to-treat (NNT)* for neuropathic pain, rather
than specifically phantom pain (217). Tricyclic antidepressants have NNTs of around
2.3-3.0, Anticonvulsants have NNTs of in the range of 2.1-3.6 and i.v.lidocaine has
an NNT of 3.0 (218;219). Although these drugs have good NNT values in
neuropathic pain, they are largely based on studies of patients with diabetic
neuropathy or post-herpetic neuralgia. Whether these NNTs can be extrapolated to
phantom limb pain is debatable, but there is no doubt that these drugs are popular
first line therapies in phantom pain. The evidence base for phantom pain treatment is
sparse. Up until relatively recently many of the treatments in use were largely based
on anecdote and case reports. There is a case report supporting the use of
carbamazepine, an open label study ofmexiletine (an oral analogue of lidocaine),
reports of opioids (oral and intrathecal) and one small study of ketamine with cases
reports (220-226). These have been superseded by several small scale randomised
controlled trials (RCTs) in the treatment of phantom pain, mostly published over the
last five years. Despite a proven track record in other types of neuropathic pain,
amitriptyline in doses up to 125mg in a RCT (n=39) did not show any benefit over
placebo (227). NMDA antagonists have also been studied. There are several studies
*
The NNT is a measure of clinical significance derived from a quantitative systematic review. It is the
number ofpatients that have to be given a drug in order for one to have a 50% reduction in pain score
compared with placebo (Cook, R. J. and Sackett, D. L. BMJ 1995; 310: 452-454)
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using memantine (20-3Omg daily), none ofwhich have shown any benefit over
placebo (158;160-162). This is in contrast to anotherNMDA antagonist
dextromethorphan which has been shown to be effective in one small study of cancer
patients who have undergone amputation (169). Gabapentin, an anticonvulsant, has
shown to be superior (doses up to 2400mg) to placebo in one small RCT (228).
In summary although TCAs have a proven track record in many types of neuropathic
pain, they have not yet been shown to work in phantom pain. NMDA antagonists,
despite many promising pre-clinical studies, have had mixed results. Memantine has
at least 4 RCTs now, none ofwhich have shown efficacy. Dextromethorphan and
ketamine have one small study to support their use. The only RCT using an
anticonvulsant is with gabapentin and it had a positive result compared to inactive
placebo. In short the evidence base is still very sparse.
1.5.8 Prevention of phantom pain
As discussed, phantom pain is very difficult to treat. This has led researchers to focus
on the prevention of phantom pain
The term "pre-emptive analgesia" is much used in the literature, often incorrectly.
Igor Kissin has clearly defined the concept of pre-emptive analgesia in clinical
practice: pre-emptive analgesia must start before the surgery; prevent central
sensitisation as caused by the surgical stimulation continue into the post-operative
period to further prevent the establishment of the central sensitisation caused by
ongoing pain and inflammation (229). Many of the studies purporting to study pre¬
emptive analgesia to not in fact meet this definition. It may be more correct to use the
term "pre-treatment" unless the above three criteria can be met.
As discussed above, there are few predictive features to suggest who will get post-
amputation pain. Consistently though pre-amputation pain is associated with post-
amputation pain. Severe acute pain is known to be a risk factor for chronic pain
(230).
Severe pre and post-operative pain may lead to a lasting somatosensory change or
'memory' resulting in post-amputation pain. The observation that patients with little
or no pain immediately prior to surgery were at a lower risk ofpost-amputation pain
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led to the hypothesis that if patients could be made pain free prior to surgery there
might be a reduction in post-amputation pain. In addition the fact that prevention of
central sensitisation, particularly by using NMDA receptor blockade, might be
important in preventing chronic neuropathic pain needs to be considered.
Researchers have therefore focused on techniques that involve continuous peripheral
nerve blockade, continuous epidural analgesia and techniques which use NMDA
receptor blockade with ketamine. On trial has investigated the use of gabapentin for
30 days following amputation with no significant result (231). Table 8 shows
summary of these studies
Continuous peripheral nerve blockade
Several studies have looked at this. Two randomised double blind studies
demonstrated the technique to provide effective post-operative analgesia but not to
prevent chronic post-amputation pain (232;233). A third study looked at the early
addition of the NMDA antagonist memantine (20-3Omg daily) in addition to a
continous continuous ropivacaine brachial plexus block in upper-limb amputees.
There was a short term effect on the incidence ofphantom pain but this was not
sustained at 12 months (234).
Epidural analgesia for prevention of post-amputation pain
Bach et al were the first to study this in 1988 (235). This study compared prolonged
epidural analgesia (using bupivacaine and morphine) for 72 hours prior to surgery
compared with a more standard opioid-based analgesic regime. All patients in the
epidural group were pain free at one year. This study was small (n=25) and
unblinded. A similar prospective randomised double-blind study was carried out by
Nikolajsen et al. This study looked at 56 patients. The study group had preoperative
epidural analgesia for 18 hours compared with a more standard intramuscular
morphine technique (236). Both groups had post-operative epidural analgesia. The
incidence ofphantom pain at 12 months was similar to previous studies at round
70% with no difference between groups.
72





























(240) Pinzuretal (232) Nikolajsenatl (236) Lmabertetl (233) Hayesetl. (241) Nikolajsenetal. (231) Schleyetal. (234)
1996Randomiseddouble-blin 1997Randomiseddouble-blin 2001Randomisedpr spective 2004Randomiseddoublblind 2006Randomiseddoublblind 2007Randomiseddoublblind Upperlimb
21 56 30 45 46 19
Treatment Epiduralbu ivacaineandmorphincom ared withconventionalanalgesia ContinuousPerineuralinfusi nofbupivacai e Perineuralinfusionofbupivacaines conventionalanalgesia Epiduralinfusionofbu vacaine,clonidi ea d diamorphinevsine andopioi GroupA-epiduralbupivacaineef reand aftersurgery GroupB-Opi idsandNSAIDbef resurgery andepiduralfter GroupCOpi idsandNSAIDbef reftert surgery Perineuralinfusionofbupivacaine0.5%s saline Epiduralbu ivacaineandmorphinso l
immorphine Epiduralbu ivacaineanddiamorphis perineuralbupivacaine Boulsket0.5mg/Kgfoll wedby3day infusionvsplacebo BothgroupsreceivedGAandmorphine Gabapentinupto2400mgfor3daysvs placebo Continuousbrachialplexuslockwith ropivacainef r7dayswitheithermem ntine (20-3Omg)orplacebof3days
Outcome
Nophantominintreatmentgroup oneyear Nophantominaeyear Nodifferencebetweeng oups Significantdecreasei phantomi thestudygroup NophantomininGroupAaeyear Publishedinab tractformonly Nodifferenceinncid fphantom painbetweethogroups Nodifferenceinncidofphantom painbetweethogroups Lowerincidencefstumpapint3d ys. NodifferenceinPLPat3ys6months and12months KethadigherSP3d ysot erwiseno differenceatupto6mo ths Nodifferenceinncid fphantom painbetweethogroups Decreasedincid nceofpha tomina6 monthsintheemantinegr up.Nlong termeffectat12months
The use of ketamine to prevent phantom pain
As discussed above, animal studies suggest that the preventative use ofNMDA
antagonists may reduce the incidence of chronic pain. Ketamine has also been shown
to be effective in the short term relief ofpost-amputation pain. A small observational
study has suggested that a bolus of ketamine followed by perioperative infusion
reduces the severity but not incidence of phantom pain. A randomised controlled trial
of a ketamine bolus (0.5mg/Kg) followed by 72 hour infusion compared with
placebo showed no significant reduction in the incidence of phantom pain (241).
Sensory testing of the stump also showed no difference between groups. This study
however did not use any form of central neuraxial blockade.
1.6 Thesis aims and synopsis
The aim of this thesis is to review the mechanisms of pain, neuropthic pain and in
particular phantom pain. The concepts of pre-emptive analgesia are explored. The
importance of glutamate and subsequently NMDA antagonists in this area are
investigated using an animal model of neuropathic pain complemented by a clinical
study of patients undergoing lower limb amputation.
This thesis begins by reviewing the basic physiology of pain. The current thinking
about the mechanisms of neuropathic pain is discussed. The key role of glutamate as
a one of the major excitatory nociceptive neurotransmitters is examined along with
the concept of pre-emptive analgesia using NMDA antagonists. Using an animal
model of neuropathic pain, the thesis aims to demonstrate the protective effect that
NMDA antagonists can have following nerve injury. The effect ofNMDA
antagonists on the development of typical pain behaviours following nerve injury has
been established but the effects of pre-treatment with NMDA receptor antagonists on
subsequent NMDA receptor subunit expression has not.
The model ofpre-treatment with an NMDA antagonist prior to nerve injury is
translated into a clinical study in chapter 4. This study examines the use of the
clinically used NMDA antagonist ketamine in patients undergoing lower limb
amputation. Limb amputation was chosen as it is one of the few clinical situations
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that subjects can be identified before nerve injury occurs. The study uses pre-
treatment with epidural ketamine and examines whether it has any effect on the
prevention ofphantom limb pain. In addition the effects on the drug on sensory
processing as studied, using quantitative sensory techniques which parallels those
used in the animal model.
The final chapter discusses the findings ofboth these studies. The difficulties of
translating promising basic science studies into clinical practice is discussed.
Chapter 2 Assessment techniques
2.1 Introduction
The present studies aim to investigate the role ofNMDAR antagonists in the
prevention of neuropathic pain. A translational approach was used linking an animal
model of neuropathic pain with a difficult clinical problem - post amputation pain.
As pain perception is subjective, comprehensive assessment of pain in both animals
and humans presents some challenges. The methodology used and the rationale
behind it is discussed.
2.2 Methods of nocicepetion assessment in animal models of pain
Several rodent models of neuropathic pain have been developed (see chapter 1 for
descriptions of the commonly used models). Animals are unable to vocalise and thus
observations of animal behaviour becomes a surrogate measure of pain in the animal.
2.2.1 Behavioural testing
Commonly models of neuropathic pain use standardised limb withdrawal measures
as a surrogate measure of sensitivity to various mechanical and thermal stimuli (Both
noxious and innocuous). Tests must be reproducible and thus testing needs to be
carried out in a situation that the animal is familiar with. Ideally the animal should be
unrestrained. This will minimise stress to the animal which can otherwise alter
withdrawal thresholds. The main advantages of these methods are that they seem to
mimic the changes seen in human pain conditions i.e. sensitivity such as allodynia
and hyperalgesia, they are relatively easy to measure and can be reliably reproduced
from day to day. On the downside, these measures do not tell us anything about
spontaneous pain, a feature often seen in human conditions. One study found that in
421 papers (published in Pain) using an animal model of pain, 90% used exclusively
tests of hypersensitivity (163). There does seem to be a trend to including measures
of spontaneously occurring pain.
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2.2.2 Responses to mechanical stimuli
Early measures ofmechanical allodynia used devices such as a Randall-Selitto
device (242). This requires restraint or handling of the animal to measure withdrawal
thresholds or elicit vocalization. This produces stress in the animal and can affect the
measurements (243). Pressures required to elicit a response are high and thus
responses to deep pressure rather than light touch (tactile allodynia) was being
measured. This is important as deep pressure is probably C/A5-fibre mediated, while
light touch is AP-fibre mediated (244). Sensitivity is typically measured using the
application of graded nylon monofilaments e.g. Von Frey filaments. Each filament is
of a standard length and diameter. The filament is applied to the skin until bending
occurs. This results in the application of a standardised reproducible force. A
standard set of filaments typically contains 20 probes with force applied (in a
logarithmic scale) ranging from 0.008g to 300g. These have the advantage ofusing
low pressures, not requiring animal restraint, being reproducible and widely used.
In the animal experiments in this thesis, mechanical allodynia was measured as the
threshold for paw withdrawal in response to a graded mechanical stimuli applied to
the mid-plantar glabrous surface of the hind paw using calibrated von Frey filaments
(Stoelting, Wood Dale, IL). The method of testing was based on standard laboratory
protocol. Animals were removed from the cage and placed on a wire cage lid. This
enabled easy application of the filaments to the paw. The filaments were applied in
ascending order ofmagnitude from a fine filament upwards. The methodology was
based on the method of limits. Threshold was defined as the pressure (force per unit
area) that caused foot withdrawal five times in every ten applications, repeated at 1-2
second intervals. The pressure applied to the hind paw by the von Frey filaments is
calibrated as force (milliNewtons) divided by the area over which it is applied
(millimetres squared).
2.2.3 Thermal hyperalgesia
Nerve injury results in lowered thresholds following the application of a thermal
stimulus. Nociceptive thermal thresholds were traditionally measured using
techniques such as the tail flick or hot-plate methods. Although widely used, both
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techniques have limitations. The tail flick test stimulates an atypical (scaly) area of
skin and there is no scope for intersubject comparison. The hot-plate has no
automated end-point detection. The Hargreaves apparatus was designed to overcome
some of these limitations(245). The animal is unrestrained and free to move about on
a frosted glass plate. Radiant heat is can be applied to a paw, with the device
automatically measuring paw withdrawal by means of a photoelectric cell. The
contralateral paw can be used to provide intersubject control measurements.
In my experiments, thermal hyperalgesia was monitored using radiant heat (30-55°C;
Hargreaves' thermal device, Linton Instruments, Diss UK) applied to the mid-plantar
glabrous surface of the hind paw. The animals were placed a specifically designed
Perspex box, which allowed three animals at once on top of the frosted glass plate of
the apparatus. Animals were allowed to settle and become accustomed to their
surroundings before testing began. Using the apparatus, radiant heat is shone onto the
paw under test. The withdrawal response latency was characterised as a brief paw
flick recorded to the nearest 0.1 sec; a standard cut-off latency of 20 seconds
prevented tissue damage.
2.2.4 Cold allodynia
Pain can be elicited by cold temperatures. In neuropathic pain states innocuous cold
temperatures may cause pain (cold allodynia).The TRPM8 (transient receptor .
potential melastatin 8) receptor seems important in this area with evidence that
expression of the receptor rises following nerve injury and that the cod allodynic
response can be attenuated by TRPM8 blockers (246;247). This receptor and other
receptors are likely targets for new treatments of neuropathic pain (248).
Simple methods of cooling an animal's skin have been used such as application of
topical acetone or ethyl chloride spray to the hind limb of an animal. Paw elevation is
used as a measure of cold allodynia. Influencing factors can be ambient temperature
and animals skin temperature which can affect the rate of evaporation and hence
cooling of the skin. The substance its self, via smell or by mechanical stimulus, can
affect paw lifting. More sophisticated models have been developed which involve
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placing the hind paw of a restrained animal in a cold water bath. This is stressful to
the animal and thus may influence the nociceptive responses. Models using an ice
cooled plate or an ice cooled water bath and unrestrained animals have been
developed. These are well tolerated but can only measure behaviour at one
temperature (4°C) (249).
The protocol followed in my experiments followed established lab protocol (250).
The model used was the shallow ice cooled water bath. Animals were placed in a
perspex box with an elevated aluminium floor covered with iced water, sufficient to
immerse both glabrous and hairy skin of the hind paw (3-4°C). Once placed in the
box, rats were allowed 10 seconds to acclimatise. The number of seconds the animal
raises its hind paw above the water over a 20 second period was recorded. This was
repeated four times at 10 minute intervals to establish a mean suspended paw
elevation time (SPET) for each rat.
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2.3 Immunoblotting and Immunohistochemistry
The thesis investigates the role ofNMDAR antagonists in the prevention of
neuropathic pain. In addition to investigating drug action, an important part of the
research was to investigate the effects of the drug on the NMDARs at the proposed
site of action of the drug i.e the lumbar spinal cord. As discussed, in chapter 1, the
NMDAR is made from a combination of subunits. Functional receptor units are made
up an NR1 subunit and at least one of the NR2 subunits. The NR2B subunit is
relatively restricted to the superficial spinal cord and thought to be important in pain
transmission and sensitisation (132). This thesis investigates the effect ofNMDAR
antagonists on the expression on the NR1 and NR2B subunit in the spinal cord. The
two techniques that were used were immunoblotting and immunohistochemistry.
Immunoblotting allows detection of specific antigen in a sample of tissue and can
provide information on molecular weight and quantity. The technique allows
quantification of the amount of a particular receptor in a given sample of tissue i.e
the specific receptor of interest can be labelled and then quantified. Immunoblotting
does not however localise a protein in a sample. To do this, proteins need to be
labelled in situ using the technique of immunhistochemistry.
I am very grateful to have had the assistance ofDr Emer Garry and Heather
Anderson (Centre for Neuroscience Research, University of Edinburgh) who helped
in this part of the research. Dr Garry performed the immunoblotting experiments and
Heather Anderson carried out the immunohistochemistry reactions and prepared the
slides for analysis.
The concepts behind immunblotting and immunohistochemistry are discussed below.
Standard established laboratory protocols in the Centre for Neuroscience Research
were used and these are described.
2.3.1 Immunoblotting
Imunnoblotting (Western blotting) is used to detect a specific protein in a sample of
tissue. The techniques typically uses gel electrophoresis to separate proteins based on
length of polypeptide. Proteins are transferred to a nitrocellulose membrane.
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Nitrocellulose is a sticky membrane used to immobilise proteins. It has a non specific
affinity for amino acids. Specific antibodies to the protein of interest are used to
'probe' the proteins and detect the protein of interest
General technique
The sample of tissue is first of all homogenised. A buffer is typically used to aid cell
lysis and to solubilise the proteins. Protease and phosphatase inhibitors are added to
prevent digestion of the sample by its own enzymes.
Gel elecrophoresis is used to separate the proteins. A membrane fraction (i.e a
fraction of cells including membranes and plasma) is loaded in the gel and an electric
current used to separate the proteins. The proteins are then transferred to on to the
nitrocellulose membrane. In order to get clearer samples the membrane is exposed to
a dilute protein solution which attaches in the places other than where the target
proteins are.
The membrane is then incubated with a dilute solution of the primary antibody. The
membrane is then rinsed to remove unbound primary antibody and exposed to
secondary antibody. The secondary antibody is typically peroxidase linked and used
in conjunction with a chemiluminescent agent which then produces luminescence in
proportion to the protein present. The membrane can then be exposed to a
photographic film and an image obtained. The image can then be analysed by
densitometry which quantifies the protein in terms of optical density.
Technique used
Western blotting was carried out to assess NMDA receptor subunit expression in the
lumbar spinal cord of rats. Spinal cord segments (L3-6) were removed from
anesthetised animals and quickly homogenised in ice-cold buffer containing 5%
glycerol with peptidase and phosphatase inhibitors. A membrane fraction was then
solubilized in 1% deoxycholate. Blots were probed with rabbit or goat polyclonal
primary antibodies to NR1 (SC-1467), NR2A (Cat No 06-313, Upstate Biotech) or
NR2B (Cat No: AB1557P, Chemicon) and detected by peroxidase-linked secondary
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antibody enhanced chemiluminescence. The ubiquitous housekeeping enzyme
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was monitored as a control,
for protein level normalisation using mouse monoclonal antibody (cat no MAB374,
1:750 from Chemicon International Ltd, Harrow, UK). Following quantitative
densitometry, arbitary grey scale values for receptor subunits were calculated as a
percentage of that for GAPDH in each case and the statistical significicance of injury
induced changes between the ipsilateral and the contralateral side, sham or naive
controls was assessed by the Wilcoxon test.
2.3.2 Immunohistochemisty
Immunohistochemistry, in contrast, is the process which can localise exactly where
an antigen is localised a tissue section. In a similar fashion to immunoblotting
antibodies bind to the antigen of interest in the tissue section. The antibody is again
conjugated to a perioxidase enzyme which catalyses a colour producing reaction
enabling visualisation of the antibody-antigen complex.
General technique
The tissue of interest is typically fixed by rapidly transcardially perfusing the animal
with paraformaldehyde. Post-fixation is carried out in paraformaldehyde with a
buffer.
Following fixation, the sample of interest is mounted in wax and then can be sliced
into thin slices using a microtome. The tissue slices are then mounted on a slide.
A two stage technique is used. The tissue is exposed firstly to a primary antibody
which attaches to the antigen of interest. A second antibody against the IgG of the
animal used (e.g goat) to create the first antibody is then used. This antibody is
labelled with an enzyme or florescent dye. Typically the enzyme is coupled with a
horse radish peroxidase which can be reacted with 3,3' diaminobenzidine (DAB) to
produce a brown colour where the antibody is attached, a process known a DAB
staining. For a detailed review of the technical aspects of immunohistochemisty see
review article by Ramos-Vara (251).
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Technique used
Under deep anaesthesia, rats were perfused transcardially with saline containing 100
units heparin/ml, followed by 4% paraformaldehyde in 0.1 M phosphate buffer, pH
7.4. Lumbar spinal segments (L3-6) were post-fixed in 4% paraformaldehyde/0.1M
phosphate buffer for 4-5 hr at 4°C, before being stored in 0.1M phosphate buffer at
4°C. 70 pm transverse sections were initially incubated in normal serum from the
species which donated the secondary antibody, to block non-specific binding. They
were then incubated overnight at 4°C with either rabbit anti-NMDARl polyclonal
antibody (Chemicon, 1:500) or rabbit anti-NMDAR2B polyclonal antibody
(Chemicon, 1:750). Control sections were processed without the addition of primary
antibody and incubated overnight at 4°C in 0.1 M phosphate buffer. Simultaneous
staining was carried out for all treatments. All sections were then incubated in
biotinylated donkey-anti-rabbit IgG (1:200, 60 min; Chemicon), followed by
incubation for a further 60 min with an avidin-biotin complex solution (ABC Elite,
Vector Laboratories, UK, 1:50). Following wash, sections were exposed to 3,3'
diaminobenzidine tetrachloride (DAB; 0.2mg/ml; Sigma, UK) in the presence of 3%
hydrogen peroxide (lpl/ml) to enable visualisation of the precipitate, washed and
mounted onto poly-L-lysine-coated microscope slides (BDH, UK), air-dried
dehydrated through ascending concentrations of alcohol, cleared in xylene (Sigma)
and mounted in DePeX (BDH, UK).
I
For relative quantification of immunoreactivity, an Improvision 1.44 Image Analysis
Package (NIH) was used at a magnification of x 40. Each image field was captured,
using a CCD video camera (Sony, Japan), mounted on a Zeiss Axioscope
microscope. The images were blank field-adjusted to compensate for any artefacts in
the camera apparatus. A standardised region of interest (ROI; 80 pm diameter circle)
cursor was aligned and consecutively centred on the mediolateral region of laminae
I-II or III. Arbitrary grey scale units (in the range of 1-200) were assigned to make
optimal use of the range for the given sample. Non-specific background levels were




In addition to the techniques described above, there are other laboratory techniques
that can be used to determine the presence and/or quantity of a specific antigen.
Enzyme Linked Immunosorbent Assay (ELISA) can be used to detect specific
antigens in a sample of tissue or serum (252). ELISA commonly used as diagnostic
tool in medicine and is used to dectect antigens such as HIV in a serum sample. The
basic principle involves fixing the sample of interest onto a surface (usually a
multiwell plate) and using antibodies to probe the sample. Antibody can be
visualised using colourimetry or chemiluminescence. Techniques such as flow
cytometry and immuno-electron microscopy can be used. These do require expensive
and specialised equipment.
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2.4 Assessment of pain in clinical practice
2.4.1 Introduction to clinical pain assessment
Pain is a subjective experience, with several different components including
cognitive and affective components. The pain experience is a personal experience
which can be influenced by the patient's beliefs, mood, personality, prognosis and
culture. Assessment tools have been developed to either give a global assessment or
to characterise the pain experience in more detail. When considering any assessment
tool it is important to consider its reliability, how it has been validated and its
applicability to the clinical situation being studied. In an ideal situation one observer
should assess all the patients in a study.
The simplest measure of pain is that of pain intensity which is typically measured
using a unilateral scale. Examples of scales used are verbal rating scales (VRS),
numerical rating scales (NRS) and visual analogue scales (VAS). These are
discussed below. Unidimensional scales are ideal in studies ofperi-operative pain.
The complete multidimensional pain experience is not however captured by these
scales and thus pain intensity alone is insufficient alone in studies of chronic pain.
Outcomes are more complex and measures must reflect the multidimensional nature
of pain focusing on other outcome variables such as quality of life, changes in
function, sleep patterns and affect.
There are many scales in used in the assessment of outcome in chronic pain studies.
In clinical practice, especially in chronic pain states, outcome measures must reflect
the whole pain experience. This means measuring not only the sensory component,
but the affective and cognitive components as well. Consensus guidelines have been
produced by the IMMPACT group (Initiative on Methods, Measurement and Pain
Assessment in Clinical Practice) which recommend 6 core outcome domains (253).
The first three of these are pain, physical functioning and emotional functioning.
There is little evidence to suggest that one scale is superior to another in any
particular domain (254). Pain intensity is generally measured on a unilateral pain
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scale, while the physical and emotional functioning usually requires some type of
multidensional scale. Changes in sensory processing can be measured and quantified,
a process known as quantitative sensory testing (QST).
2.4.2 Unilateral Pain Scales
Verbal Rating Scale (VRS)
The VRS measures pain in distinct categories, e.g. a four point scale such as no pain,
mild, moderate or severe pain. It is very easy to use in clinical practice. The main
downside of the VRS is that change between each point cannot be assumed to be the
same, so it is difficult to record reductions in pain accurately. In research terms this
may mean that small reductions in pain are not accurately detected. In the clinical
setting the VRS may be a more appropriate scale for use in elderly patients who may
have more difficulty understanding numerical rating and visual analogue scales
(255).
Numerical Rating Scale (NRS)
The NRS uses a numeric scale ranging typically from 0-100 or 0-10. Zero represents
no pain while the highest number in the maximum pain possible. A NRS unlike the
VRS possesses ratio properties, i.e. a reduction in pain from 6 to 3 would indicate a
50% reduction in pain. In clinical practice a 0-10 point scale is as good as the longer
scale. There seems to be no loss of sensitivity by reducing to the shorter scale and the
11 point scale is as reliable at detecting clinically meaningful reductions in pain
compared with a 0-100 scale (256). The NRS is easy to apply even when a patient
cannot use pencil and paper. It can be used over the telephone or using a computer
data collection system.
Visual analogue scale (VAS)
The VAS is plain ruled line usually 0-100 mm long, the left hand side being no pain
and the right the worst pain imaginable. The patient is asked to mark on the line a
point corresponding to the severity of their pain. The pain score is then the distance
in millimetres from the left hand side. It is easy to use but the paper version does
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require the ability to use a pencil. Slide rule and computerised versions can get round
this. It has been widely used in pain research since the 1960s and is reliable, valid
and internally consistent (257). Like the NRS it has ratio properties and can measure
percentage reductions in pain.
Choice of scale
In the research setting the uindimensional scale of choice should either be the NRS
or the VAS. These scales correlate very well and are easy to administer (256). The
VRS is probably the easiest to use but can underestimate severe pain and is only
recommended as a coarse screening tool (258).
2.4.3 Multidimensional scales
As discussed the IMMPACT guidelines suggest that pain in addition to pain severity
other outcome, measure ofphysical and emotional functioning should be used (259).
At its most simple The VAS or NRS scales can be used to measure 'unpleasantness'
ofpain or of a particular stimuli. In addition the IMMPACT guidelines suggest the
inclusion of a questionnaire designed to measure the affective and sensory
component of the pain e.g. the SF-Magill Pain Questionnaire or the Magill Pain
Questionnaire(260;261). Measures of physical functioning should ideally be
included. Questionnaires ofphysical functioning focus on areas such as activities of
daily living (ADL) and sleep. Patients with chronic pain often complain of
interference with ADLs and sleep. Physical function, however, does not correlate
well with pain giving rise to need for a separate assessment (262). In the absence of a
disease specific questionnaire the guidelines suggest using either the
Multidimensional Pain Inventory (MPI) or the Brief Pain Inventory (BPI) (263;264).
These are both reliable and validated measures of the effect of pain on daily life. The
recommended scales for measurement of emotional functioning are the Beck
Depression Inventory (BDI) or the Profile ofMood States (POMS)(265;266). Like
the measures of physical function, these are both reliable and validated. The impact
guidelines were produced after the clinical study was complete and I was unable to
benefit from these recommendations in the study design.
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There are increasing numbers of scales designed to assess neuropathic pain becoming
available. There are designed either to screen for the presence or absence of
neuropathic pain to assess pain severity in those suffering from neuropathic pain.
Scales designed to screen for the presence ofneuropathic pain include the Leeds
Assessment ofNeuropathic Symptoms and Signs (LANSS) pain scale and the DN4
questionnaire (267;268). The LANSS pain scale is based on analysis of sensory
description coupled with a bedside sensory function. A score of greater than 12
suggest that the patient is likely to have neuropathic pain. The initial validation
study shows that it correctly identified 85% of the patients with neuropathic pain in a
study population. The DN4 used 7 questions relating to sensory symptoms and 3
bedside examinations of signs. A score of 4 or greater out of 10 suggests that the
patient may have neuropathic pain. The development study showed the DN4 to have
83% sensitivity and 90% specificity compared with clinical diagnosis (268). In
addition to the LANSS and the DN4 there are other screening questionnaires in
clinical use such as the Neuropathic Pain Questionnaire, PainDETECT and ID-pain
(For a review of these scales and the use of screening questionnaires in neuropathic
pain see Bennett et al. (269)). In addition to screening questionnaires there are scales
designed and validated to measure neuropathic pain severity. Examples of these are
the Neuropathic Pain Scale (NPS) or the Neuropathic Pain Symptom Inventory
(NPSI) (270;271). I used the NPS and this is discussed below.
Assessment Questionnaires used
This thesis used a specifically designed data collection questionnaire which was a
modification of that used by Shermann et al (Appendix 1). In addition the Magill
Pain Questionnaire was used along with Hospital Anxiety and Depression Scale and
the Neuropathic Pain Scale. These are discussed in detail below.
McGill Pain Questionnaire (MPQ)
The MPQ was first described in 1975 (261). It is a multidimensional assessment tool
designed to separate and quantify the three distinct components of pain, sensory-
discriminative, motivational-affective and cognitive evaluative. It consists of 78
words grouped into groups, which are further arranged into 4 categories, a sensory,
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affective, evaluative and a miscellaneous category. There is also a 6-point verbal
rating scale (Present Pain Index; PPI). The Questionnaire is self administered by the
patient. A word from each category is selected that best describes the pain. Not all
categories need be marked. The total score (known as the Pain Rating Index; PRI) is
made up from adding the rank in the category of each word selected. The PPI score
can be used as a response to treatment. The initial idea was that the three different
components ofpain making up the PRI could be assessed separately. The problem is
that the sensory, affective and evaluative factors are highly interlinked rather than
independent variables, therefore it has been suggested that the total PRI should be
used when assessing pain with this tool (272). The MPQ has been extensively
validated over the years and has good predictive validity, construct validity and test
retest reliability (257).
The Hospital Anxiety and Depression Scale (HADS)
The HADS was devised by Zigmond and Snaith in 1983 (273). The purpose of the
scale is to identify the probable and possible cases of anxiety and depression in
patients in the non-psychiatric clinical setting. It specifically avoids symptoms such
as dizziness, fatigue, insomnia or headache that may be associated with somatic
disorders. It has been used in hundreds of studies since its introduction (274). In
addition it has been used in studies of chronic pain such as musculoskeletal pain, low
back pain and importantly post-amputation pain (275-277). <
The questionnaire consists of 14 questions, seven concerning anxiety symptoms
(HADS-A) and seven concerning depression symptoms (HADS-D). Each question
has 4 possible answers, marked 0-3, thus making the maximum score for each
subscale of 21.
A recent detailed review of 747 papers using the HAD scale suggests that the optimal
balance between sensitivity and specificity is achieved with a cut off of 8 or greater
for both HADS-A and HADS-D (274). In addition the authors conclude that the scale
performs well in the assessment of symptom severity and helps to identify cases of
anxiety and depression in hospital, primary care and the general population. However
the scale can only act as a case finder and thus more detailed assessment is required
to a make a specific psychiatric diagnosis.
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The Neuropathic Pain Scale (NPS)
The NPS was described in 1996 (270). This was designed to complement existing
pain questionnaires such as those described above. The NPS has been designed to
assess the distinct pain qualities associated with neuropathic pain. The scale uses 10
descriptors of pain such as sharp, hot, cold etc. and the subject rates each descriptors
on a scale of 0-10. Preliminary validation suggest that the descriptors are for the most
part statistically distinct may have some value in distinguishing one type of
neuropathic pain from another (270). The NPS main strength is as a severity measure
of neuropathic pain, rather than as a screening tool. At the time of study design and
recruitment it was the one of the few scales available to assess neuropathic pain. That
said, the NPS has however been shown to discriminate between neuropathic pain and
non-neuropathic pain (278).
2.4.4 Quantitative Sensory Testing (QST)
Introduction
As discussed above, pain research has traditionally focussed outcome measures on
qualitative responses to pain, such as VAS or NRS. Pain classification is now
moving towards a mechanism-based approach (279). This may mean more accurate
understanding and subsequent targeting of pain treatment therapies. QST can be used
to detect modality specific disturbances in sensory processing. In essence it measures
the intensity of stimuli needed to produce specific sensory perceptions and thus
measures the function of the somatosensory system.
QST techniques use psychophysical techniques, with different stimulus modalities to
assess functional changes in primary afferent fibres, central spinal connections and
subsequent sensory projections. In effect using different sensory modalities to
determine at what intensity they produce specific sensory perceptions. Detailed QST
is time consuming and does require a cooperative, fully alert patient who can
understand the, sometimes, complex tasks required.
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Sensory information is carried in the large myelinated A[3-fibres, the smaller
myelinated A5-fibres and the unmyelinated C-fibres. In normal physiological states
the A(3-fibres carry mechanosensitive modalities such as light touch, vibration and
pressure while A5-fibres and C-fibres can respond to both noxious and non-noxious
stimuli. QST must then use targeted sensory tests to detect dysfunction in these
pathways. On a practical level simple bed side teats may be used, such as an artist's
paintbrush (measures dynamic allodynia; Ap-fibre mediated), hot and cold rollers
(temperature related pain; A5 and C-fibres) and a pin (painful pinprick; A5-fibres)
(280).
In a lab based research setting more detailed testing methods may be employed
These include the use ofVon Frey hairs to measure tactile and pain thresholds,
vibration and pressure thresholds and the use of a thermode to measure warm/ cold
thresholds and heat/cold thresholds.
A comprehensive protocol now exists which was agreed after the completion of our
study. The German Research Network on Neuropathic Pain have published a
suggested battery of tests comprising seven tests covering 13 parameters (244). The
group has also published reference values using the suggested protocol (281). The
protocol suggests the following tests.
• Thermal detection thresholds for the perception of cold, warm and
paradoxical heat sensations
• Thermal pain thresholds for cold and hot stimuli
• Mechanical detection thresholds for touch and vibration
• Mechanical pain sensitivity including thresholds for pinprick and blunt
presuure, stimulus/response-functions for pinprick sensitivity, and dynamic
mechanical allodynia, and pain summation to repetitive pinprick stimuli
(wind-up type pain)
This battery of tests can be done mostly using simple bed side devices, although no
easily potable device exists to measure thermal thresholds. Unlike standard
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neurophysiology this battery ofQST testing enables assessment ofboth small and
large fibre dysfunction. Although the tests are comprehensive in nature they are still
not the stage ofproducing a complete mechanistic approach to pain.
QST in clinical trials of neuropathic pain
There are increasing numbers of trials in patients with neuropathic pain showing the
usefulness of the measure in these patients. In the same why sensory testing is used
in animal models of pain, QST can be used in human models of central sensitisation
(282). In clinical studies designed to prevent central sensitisation, QST has been
shown to a valuable outcome measure. A study of a patients undergoing abdominal
surgery was able to use Von Frey filaments to map out punctuate hyperalgesia
around an abdominal wound to show a long term effect of ketamine on long term
sensitisation (283). QST has also been used in patient with peripheral vascular
disease showing sensory dysfunction is already established in these patients and
dysfunction can be detected in the affected leg (284). QST has been also been used
in groups of patients undergoing limb amputation (285;286). Although QST is
becoming a vital tool in assessment and outcome in patients with neuropathic pain it
has not yet really been able to predict likely responders to available therapeutic
options (287;288).
QST protocol used
In designing the QST protocol for this study, a translational approach was used. The
design of the QST protocol tries to reflect, at least in part, the testing modalities used
in the animal studies, especially as some of the hypotheses generated come from the
laboratory experiments. In this thesis the sensory testing modalities chosen were
sensitivity to stroking light touch (Ap-fibres), tactile threshold using Von Frey
filaments (Ap-fibres), mechanical sensitivity to painful pinprick (A5-fibres),
vibration (Ap-fibres) and sensitivity to cold using drops of topical acetone (Ad-
fibres). The tests chosen needed to be easy to apply, easy for elderly patients to
understand and be portable as some follow-up assessments took place outside the
hospital setting.
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The protocol designed attempted to delineate any areas of abnormal sensation using a
soft artist's paint brush. This was applied to the stump to try and identify any areas of
abnormal sensitivity. Further sensory testing was then carried out on the stump using
the contralateral limb as a control. Rolke et al. demonstrated that although QST
parameters are age and site specific, there is a high side to side correlations of all
QST parameters, suggesting that the opposite side of the body is an ideal control
(244).
Tactile threshold was measured using von Frey filaments (North Coast Medical, Inc.,
San Jose, California), described above. The methodology used in this thesis was to
apply them in ascending and descending force magnitude until the subject was able
to perceive four out of six stimuli. This is known as the method of limits, which is
the commonly used method of testing. The method of limits involves a step wise
increase (or decrease) in stimulus intensity. The stimulus is started at a level below
which the subject is not able to perceive the stimulus. As the stimulus increases the
subject will be able to perceive the stimulus and the threshold is measured when the
subject perceives greater than 50% of the applied (six) stimuli, i.e. 4/6 applications.
The main disadvantages to this method are that the subject may start to anticipate the
detection or disappearance of the threshold (error of expectation). The alternative to
the method of limits is to use a fixed choice method which asks the subject to choose
between two different stimuli. This method is relatively slower (289).
Mechanical sensitivity to painful pinprick was used by the application of
standardised blunt neurology pain (Neurotips ™; Owen Mumford). These were
applied to the stump and control areas, with the subject recording the pain induced on
a visual analogue scale.
A standard battery powered electrical tooth brush was applied to the stump to see if
vibration elicited any painful sensations. The brush was switched on and then applied
to the area under test. The patient was then asked to record a VAS scale for both
unpleasantness and pain.
Finally the response to topical cold was assessed using acetones dripped form a
dropper onto the area under test. Any pain elicited was recorded using a VAS score.
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Chapter 3
Investigation of the effects of pre-treatment with NMDAR antagonists using an
animal model of neuropathic pain
3.1 Introduction
NMDA receptors (NMDAR) are widely distributed in the CNS and involved in
excitatory neurotransmission(290). They have an important role in cognitive
functions (eg learning and memory) (291). They also play a key role in the central
sensitisation that occurs in the spinal cord in many chronic pain states, such as
neuropathic pain (292-294). NMDAR antagonists have a potential therapeutic role in
pain as well as many CNS disorders such as brain ischaemia, neurodegenerative
disease, epilepsy and psychiatric disease (295-302).
3.1.1 NMDA receptors
As outlined in more detail in Chapter 1, NMDARs are heteromeric complexes made
up from combinations of three subunits, NR1, NR2 and NR3. Functional receptors
are made up from expression of at least one NR1 subunit and an NR2 subunit (A,B,C
or D). In the functional receptor, the NR1 subunit binds the co-agonist glycine, while
the NR2 subunit binds glutamate. Activation of the NMDAR requires simultaneous
binding of these two co-agonists (303;304). NR1 subunits are widely distributed in
the CNS. In the spinal cord, NR2A receptors are found in lamina III and IV while
NR2B receptors are found lamina I and II (132;305). In addition NR2B receptors are
found in the forebrain, cortex, hippocampus, striatum, thalamus and olfactory bulb
(306;307). They are also found in DRG cells (308;309).Within the spinal cord,
NR2B receptors are relatively restricted to the superficial laminae, known to be
important in nociceptive transmission. This makes them a potentially important
therapeutic target in chronic pain states where NMDA receptors are activated, such
as occurs in neuropathic pain.
Other subunits may also be important, with evidence for the role ofNR2A in
inflammatory pain and NR2D in neuropathic pain (310) The role of the NR2A
subunit in central sensitisation is not clearly determined but it does seem to be
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involved in the development of analgesic tolerance (311). It has also been suggested
that NR2A receptors are critically important in LTP induction (312).
The two principle NMDA receptor subunits, NR1 and NR2, show differential
expression in sensory pathways in spinal dorsal horn (7;132;313-315). Single dorsal
horn neurones may express multiple NMDA receptor subunit combinations (133).
There is evidence that NR2B receptors are situated both pre and post-synaptically
and (in rats) expressed on astrocytes (316). The contribution made by specific
subunits to neuropathic sensitisation remains, however unclear.
3.1.2 Pharmacology ofNMDARs
The NR2 subunits (A-D) determine the pharmacology and function of the receptor.
NR2A and NR2B are pharmacologically distinct (317).
Most sub-type receptor specific antagonists are for the NR1/NR2B subunit. These
are based on ifenprodil and its derivatives. Ifenprodil binds to the NR2B subunit and
acts as a non-competitive antagonist in a use-dependent voltage-independent manner.
Ro 25-6981 and CP-101,606 (traxoprodil) are derivatives of ifenprodil and also act
as antagonists at NR1/NR2B receptors, both with a higher preference than ifenprodil.
Specific NR2A receptor antagonists are less common although zinc and NVP-
AAM077 (Novartis) do have specificity for the channel (318;319).
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3.1.3 NMDAR antagonists (Table 9)
Non specific NMDAR antagonists can be divided into competitive or non¬
competitive antagonists. Competitive antagonists bind to the glutamate-binding site
on the NR2 subunit. Examples of competitive antagonists include (R)-2-amino-5-
phosphonopentanoate ((R)-AP5) and (R)-4-(3-phosphonopropyl) piperazine-2-
carboxylic acid ((R)-CPP). Available compounds do show some NR2 subunit
selectivity but currently there are no truly selective compounds that are competitive
antagonists. Non-competitive antagonists act by occluding the pore of the ion
channel. These compounds require prior receptor activation (pore opening). All are
positively charged and act in a voltage dependent manner. Examples include
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dizolcipine (MK-801) and clinically used compounds such as ketamine, memantine
and amantidine (see Paoletti and Neyton 2007 for review (320)).
3.1.4 NR2 subunit selective compounds (Table 9)
Ifenprodil (NR2B) and its derivatives have NMDAR subtype selectivity. They are
voltage dependent and non-competitive. Traxoprodil (CP 101,606) has been used in
clinical trials of ischaemic brain injury but there are no published studies of its use in
chronic pain states (321-323). The clinically available drug haloperidol is an NR2B
selective antagonist but there is very little research in terms of an analgesic adjunct,
with no trials in the treatment or prevention of neuropathic pain (324).
Selective NR2B antagonists have been shown to reverse neuropathic pain behaviour
(132).
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Table 9 Examples of NMDAR and NMDAR subtype specific antagonists
Compound Action Reference
(R) - AP5 Competitive NMDAR antagonist
Poor subunit selectivity
Olverman et al 1984 (325)
(R) - CPP Competitive NMDAR antagonist
Poor subunit selectivity
Davies et al 1986 (326)
MK-801 Non-competitive ion channel
blocker
Wong et al. 1986 (327)
Ketamine Non-competitive ion channel
blocker
Hirota and Lambert 1996
(148)
Memantine Non-competitive ion channel
blocker
Parsons et al. 1999 (156)
Ifenprodil NR2B selective antagonist
(non-competitive)
Williams et al. 1993 (328)
Ro 25-6891 NR2B selective antagonist
(non-competitive)
Grimwood et al. 2000 (329)
CP 101,606 NR2B selective antagonist
(non-competitive)
Brimecombe et al. 1997 (330)




NR2A selective antagonist Wu et al. 2007 (319)
3.1.5 NMDAR antagonist in animal models of pain
In rodent neuropathic pain models, spinally administered NMDAR antagonists are
effective in reducing mechanical allodynia (135; 136) and reducing spinal neuronal
sensitisation (137). Evaluation of the effectiveness of the pre-emptive NMDA
receptor antagonists in preventing sensitisation following nerve injury has been
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hampered since different sensory tests were assessed in different animal models. As
discussed in chapter 1, administration ofNMDA receptors antagonists (memantine,
MK-801 or ketamine) for 3-8 days from chronic constriction injury (CCI), reduced
development of thermal hyperalgesia (138-141). Similar observations have been
made for mechanical hyperalgesia in the spinal nerve ligation (SNL) model
(142;143). Single bolus administration of intrathecal or systemic ketamine prior to
nerve injury attenuates mechanical allodynia from 6 h to 2 weeks (143; 144), or
delays its development for 3 days in the CCI model (145). The timing of the
administration might also be important, attenuation ofmechanical allodynia only
being observed with pre-, not post-operative MK-801 (146).
The primary aim of this study was to clearly define the effects ofpre-treatment with
NMDAR antagonists on the development ofbehavioural signs of neuropathic pain
following nerve injury (mechanical allodynia, cold allodynia and thermal
hyperalgesia)., Secondly, the effect of nerve injury and nerve injury, modified by
NMDAR antagonist pre-treatment, on spinal NMDA subunit expression was
investigated. Finally the pharmacological properties of residual mechanical and cold
allodynia that remained after pre-emptive treatment with NMDAR antagonists were
investigated.
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3.2 Materials and Methods
3.2.1 Partial chronic constriction injury to the sciatic nerve
Experiments were carried out in accordance with the U.K. Animals (Scientific
Procedures) Act 1986 and followed IASP guidelines. Adult male Wistar rats (200-
350g, Charles River, U.K.) were anaesthetised with intraperitoneal (i.p.) sodium
pentobarbital (0.06ml/100g, Rhone Merieux, U.K.), supplemented with halothane/02
(Astra-Zeneca, U.K.). Under aseptic conditions, the right sciatic nerve was exposed
proximal to the bifurcation and four 4/0 chromic gut ligatures (Ethicon, Edinburgh,
UK) were tied to loosely constrict the tibial and peroneal nerves, but leaving the
smallest, sural nerve intact (modification of the chronic constriction injury model
(CCI))(118).
3.2.2 Testing of behavioural reflex responses to mechanical, thermal and cold
stimuli
In order to ensure an accurate baseline, animals were exposed to the behavioural tests
for several days prior to surgery. This ensured that the animals were habituated to the
testing. Pre-surgical testing continued until there was no day to day variation in the
values measured. Testing recommenced on day 5 following surgery and continued
every two or three days until evidence of recovery was seen. In the experiments
involving intrathecal injections, only nerve-injured animals that showed clear signs
of thermal hyperalgesia, mechanical and cold allodynia were used for further study.
Behavioural tests were carried out using quantified, sensory stimuli delivered to the
mid-plantar glabrous surface of the hind paw. Reflex behavioural tests were
performed to measure mechanical allodynia, thermal hyperalgesia and cold
allodynia. The tests are described in detail below.
Mechanical allodynia was measured as the threshold for paw withdrawal in
response to a graded mechanical stimuli applied to the mid-plantar glabrous surface
of the hind paw using calibrated von Frey filaments (Stoelting, Wood Dale, IL).
Threshold was defined as the pressure (force per unit area) that caused foot
withdrawal five times in every ten applications, repeated at 1 -2 second intervals. The
99
pressure applied to the hind paw by the von Frey fdaments is calibrated as force
(milliNewtons) divided by the area over which it is applied (millimetres squared).
Thermal hyperalgesia was monitored using noxious radiant heat (30-55°C;
Hargreaves' thermal device, Linton Instruments, Diss UK) applied to the mid-plantar
glabrous surface of the hind paw. The withdrawal response latency was characterised
as a brief paw flick recorded to the nearest 0.1 sec; a standard cut-off latency of 20
seconds prevented tissue damage.
Cold allodynia was measured by placing the rats in a perspex box with an elevated
aluminium floor covered with iced water, sufficient to immerse both glabrous and
hairy skin of the hind paw (3-4°C). Once placed in the box, rats were allowed 10
seconds to acclimatise. The number of seconds the animal raises its hind paw above
the water over a 20 second period was recorded. This was repeated four times at 10
minute intervals to establish a mean suspended paw elevation time (SPET) for each
rat.
3.2.3 Statistical analysis
Mean behavioural data were analysed by SigmaStat software (version 2.03). In tests
of thermal hyperalgesia and cold allodynia, the ipsilateral value was compared to the
contralateral value at each time point using a paired Student's t-test then each
compared to pre-surgery or pre-drug baseline using a one-way repeated measures
ANOVA, with post-hoc analysis using Dunnett's test. The ANOVA test assumes
normal distribution and identical variances but possible different means. It can be
used to compare means of different groups. Dunnett's test is used in situations were
the all groups are referred to a reference group and is used to identify which groups
differ from the reference group (in this case baseline data). In tests ofmechanical
allodynia, the ipsilateral value was compared to the contralateral value at each time
point using a Wilcoxon signed rank test and each compared to baseline using a
repeated measures ANOVA on ranks, with post-hoc analysis using Dunn's test.
These were used for the reasons above but assume non-parametric distribution.
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3.2.4 Dose estimation for memantine and ketamine.
Memantine and ketamine are both clinically available uncompetitive antagonists
which act by occluding the channel of the pore. Three studies using a rat model of
pain and using pre-treatment with memantine were identified (136; 141; 143). The
studies varied in design and technique of drug administration. Animals showed side-
effects at doses >20mg/Kg (i.p.). Eisenberg et al used 15mg/Kg i.p. without side-
effects, while Carlton and Hargett noted increased motor activity at 20mg/Kg (i.p.)
(141 ;143). 15mg/Kg was chosen as the maximum dose that would be unlikely to
produce side-effects in the animals. Side-effects (by behavioural observation) were
not seen in animals at this dose. Two studies used a single dose of preemptive
ketamine at lmg/Kg in a neuropathic model of pain (144; 145). One study used a
continuous intrathecal infusion in a rat model of visceral and somatic pain, although
not a nerve injury model (331). The dose used was 250pg/Kg/hour. No study
discussed side-effects. A dose of 150pg/Kg/hour was chosen, giving a dose of
3.6mg/Kg over 24 hours. No side-effects (by behavioural observation) were seen at
these doses.
3.2.5 Pretreatment protocol for NMDAR antagonists
Memantine (15mg/kg, 0.5 ml, n=10; Sigma-RBI, Poole, Dorset, UK), Ro 25-6891
(lOmg/Kg in 0.5ml saline with 45% hydroxypropyl-beta-cyclodextrin, n=8*; Sigma-
RBI and Tocris, Bristol, UK) or vehicle (0.9% saline, 0.5 ml, n=10) was
administered by intraperitoneal (i.p.) injection immediately prior to surgery and
repeated at the end of the first day and then twice a day for two days following
surgery. Previous experiments showed no discernible effect of the vehicle used with
Ro 25-6891 on nociceptive reflex responses.
Continuous lumbar intrathecal infusion of ketamine (Sigma-RBI, Poole, Dorset,
UK), was provided by an implanted osmotic minipump (Alzet, 0.25 pi per hour, total
capacity 28 days, Alza Corporation, Palo Alto, CA, USA). Ketamine was dissolved
in sterile 0.9% saline, pH 7.4, to give an infusion rate of 150 pg/kg/hour over 3 days.
*
Pre-treatment experiments using Ro 25-6891 were performed by Dr Garry. Included with
permission.
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The day 3 volume of ketamine solution in the cannula was separated by a small
volume of paraffin from saline filling the remainder of the cannula connected to the
minipump. In this way, the infusion was switched from ketamine to saline after 3
days. The minipump was inserted under sterile conditions. Anaesthesia was provided
by i.p. sodium pentobarbital (0.06ml/100g, Rhone Merieux, U.K.), supplemented
with halothane in oxygen (Astra-Zeneca, U.K.). The minipump was placed
intramuscularly at an interscapular site. The catheter was threaded through muscle
close to the exposed region of the spinal column and directed caudally. A small area
of the muscle and vertebral bone was cleared from two dorsal thoracic segments
(T10-T12), and the tip of the cannula was placed through a small incision, under the
dura, and eased down the dorsal spinal cord by a premeasured distance to lie in the
region of the lumbar segments L3-L6. Only data from animals with L3-6 cannula
placement (ascertained at the end of the experiment) and showing normal gait were
used in analysis.
3.2.6 Intrathecal injection NMDAR antagonists
All intrathecal injection experiments were carried out on CCI animals, 16 days
following surgery at peak behavioural change. These animals had received pre-
treatments with either vehicle (n=8), memantine (n=10) or the NMDA NR2B subunit
selective antagonist, Ro 25-6981 (n=8) just prior to nerve injury and for 3 days after.
Baseline measurements for thermal hyperalgesia, mechanical and cold allodynia
were recorded both ipsilateral and contralateral to nerve injury over 2 hours prior to
injection and mean values calculated. The effects of intrathecal administration of the
highly selective NMDA R antagonist, 3-(2-carboxypiperazin-4-yl) propyl-1-
phosphonic acid, ((R)-CPP), memantine, and the NMDA NR2B subunit selective
antagonists, Ro 25-6981 and ifenprodil, or vehicle (saline) were examined on
behavioural reflex responses.
Rats were briefly anaesthetised with halothane/C>2 and injected intrathecally at the
L4-5 spinal segments with either (R)-CPP (1, 3 or lOnmol, where lOnmol was used
as the standard dose in all figures; Tocris), memantine (150 nmol; Sigma RBI), Ro
25-6981, (50 nmol; Tocris) or ifenprodil (25nmol; Sigma RBI), all in 50pl saline,
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using a 25 guage needle microsyringe. The vehicle for ifenprodil was 0.3%
dimethylformamide in saline (previous experiments have shown that this has no
effect on ipsilateral and contralteral nociceptive reflexes, following nerve injury
(250)). Behavioural reflex testing began 20 minutes post-injection (following
recovery from anaesthetic) and was carried out until recovery to pre-injection values
was observed.
In the extensive tests comparing the acute sensitivity of mechanical allodynia to
NMDA R antagonists in control or pre-treated rats, the percentage reversal of the
pre-drug ipsilateral: contralateral difference in responses was calculated for each
time point following drug injection. Statistical significance of differences in these
values between control and pre-treated rats was assessed by Wilcoxon test.
3.2.7 Assessment ofNMDA receptor subunit expression levels by Western
immunoblotting
Western blotting was carried out to assess NMDA receptor subunit expression in the
lumbar spinal cord of sham operated or naive animlas (n=6 in each case). At peak
behavioural change (day 16) and while under deep anaesthesia (halothane/O2),
lumbar spinal cord segments (L3-6) were removed and quickly homogenised in ice-
cold buffer containing 5% glycerol with peptidase and phosphatase inhibitors and a
membrane fraction was solubilized in 1% deoxycholate.
The blot experiments were all carried by Dr Emer Garry. The methodology for these
is described in chapter 2.1 am very grateful to Dr Garry for her assistance.
3.2.8 Immunohistochemical studies on NMDA receptor subunit expression
Immunohistochemistry was carried out to assess the expression and localisation of
NR1 and NR2B NMDA R subunits in the lumbar spinal cord following memantine
pre-treatment
Rats with either vehicle (n=3) or memantine (n=3) pretreatment (at the time of
surgery for the partial CCI injury) were studied at peak behavioural change (16 days
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later). Under deep anaesthesia (Pentobarbital (Sagatal) 60mg/kg, i.p.), rats were
perfused transcardially with saline containing 100 units heparin/ml, followed by 4%
paraformaldehyde in 0.1 M phosphate buffer, pH 7.4. Lumbar spinal segments (L3-
6) were post-fixed in 4% paraformaldehyde/0.1M phosphate buffer for 4-5 hr at 4°C,
before being stored in 0.1M phosphate buffer at 4°C. The fixed specimens were then
mounted in liquid wax, which was allowed to harden. The sections of spinal cord
were then sliced using a microtome. Slices of 70 pm were made and placed in 0.1M
phosphate buffer prior to preparation.
The methodology used in the immunohistochemical studies is described in chapter 2.
I am very grateful to Heather Anderson (Centre for Neuroscience Research,
University of Edinburgh) who prepared the slides for analysis.
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3.3 Results
3.3.1 Neuropathic behavioural hyperalgesia and allodynia
Neuropathic sensitisation of behavioural reflexes, characteristic of the CCI model,
began to appear at 7-9 days following surgery, with maximal changes in thermal
hyperalgesia, cold allodynia and mechanical allodynia being observed at around 16
days (followed by plateau) in vehicle-treated animals (Figs la & c; 2a & c; 3a &c).
No consistent changes were detected contralateral to nerve injury. In each case the
changes recovered to baseline levels by 43 days post treatment. Rats that had
undergone sham surgery, showed no change from baseline.
3.3.2 Effect of NMDAR pre-treatment on behavioural responses following
CCI
Pre-treatment with non-competitive NMDA receptor ion channel blockers,
memantine or ketamine completely prevented the reduction in paw withdrawal
latency to noxious heat that occurs ipsilateral to nerve injury in saline-treated CCI
rats (Figure 1).
Cold allodynia responses which are observed only in neuropathic animals, ipsilateral
to nerve injury, were significantly reduced after both memantine and ketamine
treatment to approximately half the magnitude of those in vehicle-treated animals
through the first 30 days following CCI (Figure 2).
In contrast, memantine or ketamine pretreatment caused little alteration in the
reduced paw withdrawal threshold to von Frey filaments that occurs ipsilateral to
nerve injury (Figure 3).
Interestingly, pre-treatment with the selective NR2B-selective antagonist, Ro 25-
6891, given systemically over 3 days, beginning immediately prior to exposure of the
sciatic nerve, also showed similar effects to memantine and ketamine, with the main
residual sensitisation being mechanical allodynia.
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Figure 1. The effect of memantine and ketamine pre-treatment on the
development of thermal hyperalgesia
Data shows the mean ± SEM responses before (time zero) and following the induction ofCCI for
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Figure 1 shows the effect of pre-treatment with both intraperitoneal memantine
(a & b) and intrathecal ketamine (c & d) on the paw withdrawal latency (PWL)
to a thermal stimulus.
la and c show the development of thermal hyperalgesia following CCI in the
vehicle treated animals
lb and d shows the attentuation of the development of thermal hyperalgesia
caused by pre-treatment with a NMDA antagonist (Memantine (b) or ketamine
(d)).
Figure 2. The effect ofmemantine and ketamine pre-treatment on the
suspended paw elevation time (SPET) in seconds (response to cold (4°C))
Data shows the mean ± SEM responses before (time zero) and following the induction ofCCI for
both ipsilateral and contralateral hindlimbs (n=10).
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Figure 2 the suspended paw elevation time (SPET, number of lifts)
in response to a cold (4°C) stimulus
2 a & c shows the SPET to cold following CCI in the vehicle
treated animals
2b & d shows the effects on the SPET caused by pre-treatment
with a NMDA antagonist (Memantine (b) or ketamine (d)).
Figure 3 The effect of memantine and ketamine pre-treatment on paw
withdrawal thresholds to Von Frey filaments (PWT, mN/mm3).
Data shows the mean ± SEM responses before (time zero) and following the induction of CCI for
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(Repeated measures ANOVA on ranks, Friedmanns test with Dunn's post hoc analysis)
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(Wilcoxon test)
Figure 3 shows the development ofmechanical allodynia as measured by
PWT (mN/mm3) following CCI
3 a & c shows PWT following CCI in the vehicle treated animals
3b & d shows PWT following pre-treatment with a NMDA antagonist
(Memantine (b) or ketamine (d)).
It can be seen that there is no discemable difference between groups.
3.3.3 Effects of subsequent intrathecal NMDAR and NMDA NR2B selective
antagonists in pre-treated animals
Although pre-treatment with the NMDAR antagonists blocks the development of
thermal hyperalgesia, it is unknown whether any residual sensitisation, such as cold
allodynia, displays altered susceptibility to pharmacological interventions using acute
spinally administered NMDAR antagonists.
Here we assessed whether there were any alterations in the subsequent sensitivity to
NMDAR antagonists with particular interest in the NR2B subunit, since selective
antagonists exert marked analgesic effects on sensitised behaviours following CCI.
The effects of memantine pre-treatment on subsequent sensitivity ofmechanical
allodynia to acute challenge with different types ofNMDAR antagonist (either the
general NMDAR antagonists, (R)-CPP, memantine, or the NR2B sub-unit-selective
antagonists, Ro 25-6891 or ifenprodil) can be seen on Figs. 4a, b and 5a, b.
Although the degree ofmechanical allodynia was essentially unaffected by
memantine pre-treatment, there was a significantly greater extent and/or duration of
reversal ofmechanical allodynia by acute intrathecal administration of (R)-CPP,
memantine, ifenprodil or Ro 25-6891. In vehicle pre-treated rats acutely
administered (R)-CPP, memantine and ifenprodil caused significant attenuation of
ipsilateral allodynia and the extent of this reversal was significantly greater in
memantine pre-treated rats (Fig. 4a, b). Facilitation of the acute reversal of allodynia
following memantine pre-treatment was seen with (R)-CPP doses of 10 nmol (Fig. 4)
and also 3 nmol, but not 1 nmol (data not shown). Ro 25-6891 did not cause
significant attenuation of ipsilateral allodynia in vehicle pre-treated rats, but did in
memantine pre-treated animals. This reversal was sustained for up to 65 min
following injection (Fig. 5a) such that the Ro 25-6891 -induced reversal of allodynia
in the 35-50 min period ofmemantine pre-treated rats was significantly greater than
controls. None of the acutely administered drugs had any significant effect on
contralateral responses. Acute intrathecal injection of saline vehicle, in both groups
of rats, had no discernible effect on behavioural reflexes. It was not possible to test
thermal hyperalgesia as this was effectively absent following memantine pre-treatent.
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Ro 25-6891 also inhibited cold allodynia with the partially reduced responses (SPET
scores) after memantine pre-treatment being significantly inhibited for 80 min by
acute Ro 25-6891 injection, whereas in vehicle pre-treated controls there was no
significant effect ofRo 25-6891 beyond 50 min (Fig 5b). Contralateral SPET scores
were zero in every case. It is notable that the 2B-selective agent can substitute
effectively for memantine in the pre-treatment paradigm with subsequent reversal of
CCI-induced mechanical allodynia by acute (R)-CPP or ifenprodil, both being
significantly facilitated following the pre-emptive treatment (Fig. 5c).
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Figure 4.
The effect of memantine pre-treatment on subsequent
sensitivity of allodynia to different types of NMDA receptor
antagonist.
Data is all shown as mean ± SEM
(Legend overleaf)
Figure 4. (previous page)
The effect ofmemantine pre-treatment on subsequent sensitivity of allodynia to
different types of NMDA receptor antagonist.
Data in (a) and (b) reveal differences in the acute, spinally administered drug-
induced reversal ofmechanical allodynia (expressed as mean percentage reversal of
the ipsilateral/contralateral difference in paw withdrawal threshold; PWT±SEM,
n=8) in vehicle or memantine pre-treated animals, (a) shows enhanced reversal by
(R)-CPP ofmechanical allodynia ipsilateral to injury following following memantine
pre-treatment compared to vehicle pre-treatment in nerve injured animals, ^indicates
statistically significant differences between control and memantine pre-treated
animals in the extent of allodynia reversed by (R)-CPP, p<0.05 by Wilcoxon test.
There were no detectable effects of (R)-CPP on the contralateral hindlimb
mechanical PWT. (b) Compares the effect ofNMDA R antagonists, (R)-CPP,
memantine and NR2B subunit-selective antagonists, Ro 25-6891 or infenprodil on
residual mechanical allodynia (either 15-30 min (stripped bars) or 35-50 minutes
(white bars) following intrathecal injection of drug), following either vehicle (veh) or
memantine (mem) pre-treatment. The residual mechanical allodynia was more
sensitive to acute injection ofNMDA R antagonists in memantine pre-treated
animals. Following memantine pre-treatment all drugs showed significantly
enhanced extent or duration of reversal ofmechanical allodynia (expressed as mean
percentage reversal of the control ipsilateral/contralateral difference in paw
withdrawal threshold (PWT)±SEM) compared to vehicle pre-treatment (n=8 in each
case), ^represents a significant ipsilateral to contralateral difference at each time
point, p<0.05 by Wilcoxon test.
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Figure 5.
A highly selective NR2B antagonist elicits inhibition of both mechanical
and cold allodynia after memantine pre-treatment and can effectively
substitute for memantine in the pre-treatment paradigm.
Data is all shown as mean ± SEM
a
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Figure 5. (previous page)
A highly selective NR2B antagonist elicits inhibition of both mechanical and
cold allodynia after memantine pre-treatment and can effectively substitute for
memantine in the pre-treatment paradigm.
Data in (a) are presented as mean paw withdrawal threshold (PWT) responses to
graded mechanical (von Frey filaments). In (a), memantine pre-treated animals
showed a marked prolongation of the Ro 25-6891-induced reversal of ipsilateral
mechanical allodynia (•) compared to vehicle treated animals (o). Statistically
significant differences between memantine pre-treatment and vehicle pre-treated of
reversal of allodynia are shown as *p<0.05 (by Wilcoxon test). In (b), memantine
pre-treated animals (•) showed a clear prolongation (up to 30min longer) of the Ro
25-6891-induced reversal of cold allodynia, compared to vehicle-treated animals (o;
n=8). Statistically significant differences between ipsilateral pre-drug and post-drug
values are shown, |p<0.05), repeated measures ANOVA with Dunnett's post
analysis, (c) When Ro 25-6891 (Ro) was substituted as a pre-treatment instead of
memantine , acute intrathecal administration of (R)-CPP of infenprodil caused
enhanced reversal ofmechanical allodynia, ipsilateral to nerve injury (expressed as
mean percentage reversal of the control ipsilateral/contralateral difference in paw
withdrawal threshold ((PWT±SEM, n=8) compared to vehicle (veh) pre-treated
animals. The striped and white bars show mean data from 15-30 min and 35-50.min
periods following drug injection respectively. *represents a significant ipsilateral to
contralateral difference at each time point, p<0.05 by Wilcoxon test.
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3.3.4 Effects of NMDAR antagonist pre-treatment on NMDAR receptor
subunit expression in the spinal dorsal horn.
In animals 16 days after nerve injury, at peak behavioural sensitisation, or in sham
operated or naive animals, the levels ofNR1 and NR2 subunit expression were
examined by Western immunoblotting (Fig. 6) and their localisation was examined
by immunohistochemistry (Fig.7). In Fig. 6 the levels ofNR1, NR2A and NR2B
immunoreactivity in L3-6 spinal cord were compared between animals
ipsilateral/contralateral to partial CCI, sham surgery or naive controls. Expression
levels were compared (on the same blots) with those of the ubiquitous housekeeping
enzyme GAPDH, which undergoes no discernable change in expression following a
wide range of afferent manipulations. Figure 6 shows examples of immunoblots
showing a reduction in NR1 subunit expression ipsilateral to CCI, no change in
NR2A, and an increase in NR2B subunit expression. These results were typical of at
least six separate experiments. Quantitative densitometry and image analysis relative
to GAPDH expression were used to calculate values for the relative changes in NR1
and NR2B expression levels (Figure 6). Immunohistochemistry and subsequent
image analysis of grey scale densities confirmed that NR1 expression was decreased
in spinal dorsal horn and further that this change took place selectively in ipsilateral
laminae I-II (but not laminae III or ventral horn) in CCI animals pretreated with only
vehicle (Figure 7a, c, d, e). This reduction in NR1 expression represented a change of
-7.3 ± 0.96 grey scale units ipsilateral to CCI compared to the contralateral side,
which had a grey scale score of 28.2 ± 1.54; mean ± SEM; one ROI per side; n=45
sections (Figures 7 a, c). In laminae I-II of nai've animals, the mean
ipsilateral:contralateral difference was 0.0 ± 0.52 grey scale units. In contrast, in
memantine pretreated animals there was a relative increase in laminae I-II NR1
immunoreactivity ipsilateral to CCI (+7.1 + 2.2 grey scale units ipsilateral to CCI
compared to the contralateral side of 23.6 ± 1.61; mean ± SEM). Both of these
ipsilateral/contralateral differences in NR1 immunoreactivity in dorsal horn laminae
I/II were statistically significant (p<0.05; Student's t-test). There was no change in
laminae III or ventral horn NR1 immunoreactivity (Figure 7d, e). Equivalent analysis
ofNR2B immunoreactivity (Figure 7b-e) showed a relative increase in NR2B
immunoreactivity on the ipsilateral side relative to the contralateral side in vehicle-
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pretreated CCI rats. In laminae I-II the increment in NR2B immunoreactivity
represented +9.6 ±1.3 grey scale units ipsilateral to CCI compared to the
contralateral side, which had a grey scale score of 16.5 ± 1.25; mean ± SEM; Figures
7b, c, p<0.05, Student's t-test. Corresponding values for ipsilateral/contralateral
differences from naive rats were 0.61 ± 0.85 (not significant). In CCI animals that
had been pre-treated with memantine, NR2B expression appeared similar in laminae
I-II of both dorsal horns (with an excess grey scale score of only 0.6 +/- 1.2 units
ipsilaterally compared to a contralateral score of 17.1 ± 1.45; mean ± SEM; Figures
7c).
NR2B immunoreactivity was also increased in laminae III ipsilateral compared to the
contralateral side in vehicle-pre-treated CCI rats (Figure 7d). The increment was +
8.3 ± 1.4 grey scale units above the contralateral side, which had a grey scale score
of 19.4 ± 1.3, mean ± SEM, (p<0.05, Student's t-test). However, in contrast to the
results in more superficial laminae, memantine-pretreatment appeared to have little
effect (Figure 7d). Ipsilateral NR2B expression in lamina III ofmemantine pretreated
CCI rats was 24.1 ± 2.1 grey scale units greater than that on the contralateral side,
which had a score of 17.9 ±1.9 units, mean ± SEM, (p>0.05, Student's t-test).
Ventral horn values for NR2B immunoreactivity were not discernably different




Assessment of injury induced changes in spinal cord expression of
NMDA receptor subunits by immunoblotting.
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NR1 30.7 ± 1.9 * 41.8 ± 1.5 44.3 ±2.0 40.9 ±4.0
NR2A 48.6 ±2.7 51.3 ±3.1 47.2 ± 1.6 50.0 ±2.6
NR2B 72.8 ± 5.3 * 47.3 ±4.2 48.5 ±3.9 53.8 ±6.0
Immunoblots for the levels ofNR1, NR2A and NR2B NMDA receptor
subunit expression in L3-6 spinal cord from the ipsilateral and contralateral
pCCI, as well as sham-operated or naive rats showed that NR1 subunit
expression was reduced and NR2B subunit expression was increased
ipsilateral to pCCI. NR2A expression appeared to be unchanged. The table
shows mean ± SEM values (n=6-8) derived from quantitative densitometry of
co-processed immunoblots from NR1, NR2A and NR2B in the spinal cord
following pCCI. Differences in the levels of protein expression (arbitrary grey
scale values) given as a percentage ofGADPH levels, were assessed between
ipsilateral and contralteral pCCI, sham operated or naive spinal cord (as
shown in blots above the table) and statistically significant changes are shown
as *p<0.05 by Wilcoxon test.
Figure 7.
Immunohistochemical localisation and image analysis of NR1 and NR2B NMDA
receptor subunit expression in the superficial dorsal horn, following nerve
injury and the effects of pre-treatment with memantine.
Typical examples are shown. Of the expression ofNR1 (a) or NR2B (b) subunits of
the NMDA receptor in the ipsilateral and contralateral dorsal hom ofpCCl animals
pre-treated with either vehicle (upper panels; n=3) or memantine (lower panels; n=3).
In vehicle pre-treated animals (a) shows relatively lower levels of ofNR1 subunit,
ipsilateral to CCI compared to the contralateral side. Memantine pre-treatment
however, results in relatively higher levels ofNR1 expression ipsilateral to CCI
compared to the contralateral side, (b) shows that in contrast to NR1, higher levels of
the NR2B subunit are expressed ipsilateral to CCI compared to the contralateral side
(white bar) side. Following memantine pre-treatment, this ipsilateral; contralateral
difference in the NR2B subunit are no longer apparent. Scale bar represents 100 pm
in each panel. In (c-e) data from the immunohistochemistry experiments were
analysed by quantitative densitometry and expressed as arbitrary grey scale values
(mean ± SEM) in vehicle- (veh; n=3) and memantine- pre-treated animals (mem;
n=3). Relative expression ofNR1 subunit (on the left hand side) or NR2B subunit
(on the right hand side) is shown for ipsilateral (black bar) or contralateral (white
bar). Statistically significant differences between ipsilateral (black bar) and
contralateral (white bar) within a treatment group are represented by *p<0.05,
Students's matched pair t-test, fp<0.05 represents statistically significant differnecs
between vehicle and memantine pre-treated animals (One-Way ANOVA with
Dunnett's post hoc analysis).
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Figure 7.
Immunohistochemical localisation and image analysis of NR1 and NR2B NMDA
receptor subunit expression in the superficial dorsal horn, following nerve injury and
the effects of pre-treatment with memantine.
Contra b: NR2B Ipsi Contra















































Peripheral nerve injury leads to central sensitisation, where increased excitability of
the neurones in the spinal cord is thought to underlie chronic hyperalgesia and
allodynia (82;332-334). Pre-emptive analgesia attempts to reduce or prevent the
spinal plasticity associated with the development of chronic pain and would be of
clear clinical value. The spinal NMDAR plays a crucial role in sensitisation, however
previous studies investigating the potential ofpre-emptive NMDAR antagonist
treatment show little direct comparison of relative effectiveness on different sensory
modalities ofneuropathic pain.
Using a comprehensive range of sensory tests, it was found that pre-emptive
NMDAR antagonist treatment over 3 days from nerve injury caused differential
effects on the development of neuropathic pain behaviours to different sensory
stimuli. There was a virtual abolition of thermal hyperalgesia and marked attenuation
of cold related pain behaviours, contrasting with minimal effects on mechanical
allodynia in the same animals. Similar results were obtained with pre-emptive use of
several different NMDAR antagonists including memantine, ketamine and the
NR2B- selective antagonist, Ro 25-6891, and several routes of administration
(systemic memantine, Ro 25-6891 or intrathecal ketamine). The marked preventative
effect on thermal hyperalgesia is consistent with previous pre-emptive NMDAR
antagonists studies in rodents, using chronic administration, where only noxious
thermal heat responses were measured following CCI, using either memantine (i.p.
for 7 days (141)) or MK801 (i.p. 7-15 days (138; 139)). Shorter duration NMDAR
antagonist administration (MK801, HA 966, ketamine or dextrorphan, either i.p. or
i.t for 4 days), yielded only partial attenuation of thermal hyperalgesia
(139; 140;335).
The effects ofpre-emptive NMDAR antagonists on the degree and duration of
mechanical allodynia in previous studies have been more variable. Single dose
intrathecal ketamine pre-treatment at CCI surgery delayed mechanical allodynia until
post-surgery day 3 (145), although prolonged intrathecal ketamine (144) or
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intravenous MK-801 (146) administration gave attenuation up to 14 days after
surgery in the SNL model. MK-801 administration for 8 days (subcutaneously)
following CCI was reported to attenuate mechanical allodynia at 27 days (142),
although 8 days ofmemantine treatment (i.p.) following SNL attenuated mechanical
allodynia for only 3 days (143). Our results establish that the sensitisation of
different sensory modalities is differentially affected by early administration of
NMDAR antagonists following nerve injury.
This study showed that pre-emptive systemic or intrathecal administration of
NMDAR antagonists attenuated the development of thermal hyperalgesia to a greater
extent thanthat ofmechanical allodynia. A similar profile ofmechanical allodynia
resistant to pre-treatment with NMDA receptor antagonists has been reported in a
neuropathic pain model involving transient cryoneurolysis injury to the peripheral
nerve (336). It has also been found that acutely administered NMDA antagonists
reversed thermal hyperalgesia, but not mechanical allodynia following CCI (337) or
nerve root ligation (338). There is contradictory evidence with some rodent studies
describing robust reversal of thermal hyperalgesia and mechanical allodynia by
NMDAR antagonists (129; 135; 136).
The reason for this differential between thermal and mechanical stimuli is not clear,
but may reflect the fibres and the pathways involved in these sensitivities and
perhaps the model used. CCI results in extensive demyelination of the nerve with a
preferential loss of large myelinated axons which is associated with heat hyperalgesia
(118;339). Spontaneous activity, with lower response threshold has been shown to
occur in both C-fibres and A6-fibres following nerve injury (340). The afferent fibres
responsive to heat stimulus were all C-fibres, which may be relatively spared (340).
In addition, there is evidence that mechanical allodynia may in fact be mediated by
ascending spinal dorsal column projection and not in the dorsal horn, the proposed
site action on the NMDAR antagonists (92). The specific channels involved in
noxious heat might also be relevant.
TRPV1 is a sensory neuron specific channel sensitive to noxious heat (341). TRPV1
primary afferents use glutamate as a neurotransmitter and target post synaptic
NMDA/NK-1 receptors (342). In nerve injury models of neuropathic pain TRPV1
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expression rises in fibres with undamaged sensory connections, while decreasing in
damaged axons (343). Using a partial nerve injury model will result in intact fibres
and an increase in TRPV1 which may account for an increased sensitivity to noxious
heat.
Capsaicin sensitive primary afferents (CSPAs) express TRPV 1 and are involved in
central sensitisation. Spinal NR1 is up regulated in response to nerve injury such as
CCI. Depletion ofCSPAs prevents NR1 upregulation and importantly prevents
thermal hyperalgesia but not mechanical allodynia (344)
This study showed for the first time that the expression ofNR1 and NR2 R subtypes
in the spinal dorsal horn changed radically and differentially over the time of
development of neuropathic pain behaviours following CCI and that this was
prevented by NMDAR antagonist pre-treatment. Novel evidence is presented
showing that the sensitivity of CCI-induced mechanical allodynia to acute,
intrathecal ofNMDAR antagonists was greater or longer lasting in animals that had
been pre-treated with an NMDAR antagonist at the time of nerve injury. The
substantial time after injury (16 days) ensures there is no significant concentration of
the original drug still present, suggesting the pre-treatment regime may enable more
effective analgesic treatment for any residual pain development in human pain
patients. In clinical trials, the NMDAR antagonists, ketamine and dextromethorphan
have been shown to have a preventative effect, with effects seen more than 5 half
lives after the administration of the drug (345). While this long term effect has been
demonstrated, there is no research on human subjects investigating the hypothesis
that pre-treatment with a NMDAR antagonist will result in an improved
susceptibility to subsequent treatment with a NMDAR antagonist.
The NMDA R subunits, NR1 and NR2 are important candidates in the cellular
mechanisms underlying neuropathic sensation after nerve injury. Immunoblotting
and immunohistochemical studies found an alteration in expression levels ofNR1
and NR2B, but not NR2A in animals with established CCI sensitisation. NR1
expression appeared to be reduced ipsilateral to CCI consistent with previous reports
(129;346). Although we found no change in NR2A expression in dorsal horn tissue
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following CCI, a single cell RT-PCR study on acutely dissociated dorsal horn
neurones reported a relative decrease following L5 spinal nerve transaction (133).
The neuronal population from dissociated dorsal horn neurones and that assayed here
by immunoblot and immunohistochemistry are unlikely to be equivalent. Moreover,
no overt changes in pain- related behaviours were observed in NR2A subunit knock¬
out mice (347). Nevertheless, our data do not address directly a role for NR2A,
which may still be functionally important, either alone in complexes with NR1 or in
mixed complexes with NR1 and other NR2 subunits such as NR2B.
In contrast, the expression ofNR2B was elevated ipsilateral to CCI. It might be
expected that nerve-injury-induced pain states would show a relatively greater
sensitivity to selective NR2B antagonists than other forms of pain. Although some
previous reports have described only scarce expression ofNR2B in dorsal horn
(313;314;348) , single cell RT-PCR found NR2B to be the most commonly
expressed variant in dissociated dorsal horn neurones (133). Recent
immunohistochemical evidence suggests that NR2B protein shows a distribution
associated with small diameter fibres in laminae I and II, which are postulated to be
ofprimary afferent origin (132;349) and post-synaptically on dorsal horn neurones
(7;350). Several NR2B-selective antagonists show good efficacy and a particularly
low incidence of side-effects upon acute administration in animal models of
inflammatory and neuropathic hyperalgesia (132;351). In these studies mechanical
allodynia and hyperalgesia were both shown to be sensitive to NR2B-selective
antagonists.
Following NMDA R antagonist pre-treatment, we found that CCI-induced thermal
hyperalgesia was essentially was essentially prevented, while cold allodynia was
reduced and mechanical allodynia was apparently unaffected. This would be
consistent with the idea that NMDA R complexes are involved to different degrees in
these different types of sensitised sensory reflexes. In view of these findings, we
further assessed the analgesic effectiveness ofNMDA R antagonists (including
NR2B-selective agents) on the CCI-induced mechanical allodynia that remained
following pre-treatment with NMDA R antagonist around the time of injury.
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Sensitivity to all acutely administered antagonists (including agents selective to a
greater or lesser degree for NR2B subunit-containing complexes) was increased in
nerve-injured animals following NMDA R antagonist pre-treatment. This suggests an
important role ofNMDARs, especially the NR2B subunit, not only in the untreated
neuropathic pain state but notably in the case of residual pain following pre-emptive
NMDAR antagonist treatment. When injury-induced changes in NMDAR subunit
expression were investigated, the increased expression ofNR2B in lamina II was
prevented following memantine pre-treatment, whereas the similar increment in
lamina III was unaffected.
In summary these studies provide further evidence for a role for the NMDAR in the
development ofneuropathic pain and suggest that the NMDAR may normally play a
greater role in the development and expression of thermal hyperalgesia rather than
mechanical allodynia. Correspondingly, the lasting attenuation of neuropathic
behavioural sensitisation caused by NMDAR antagonist pre-treatment is more
marked for thermal hyperalgesia than mechanical allodynia. The reasons for this are
discussed above and amongst other things may reflect the importance of other
receptors such as TRPV1 which use glutamate as a neurotransmitter. This study did
not look at other receptor sub-types but future studies might further investigate the
links between NMDA receptors, TRPV1 and thermal hyperalgesia.
The timing ofpre-emptive drug administration may also be relevant, with prolonged
delivery being more effective. The increased expression ofNR2B relative to NR1
that we observed in spinal dorsal horn laminae II and III may contribute to the
sensitisation of behavioural reflexes following CCI. Since pre-treatment with the
NMDAR antagonist memantine blocks both NR2B expression in laminae II and
thermal hyperalgesia, these may be linked events. In contrast, CCI-induced NR2B
expression in lamina III was undiminished by memantine pre-treatment, although the
residual CCI-induced mechanical allodynia showed increased sensitivity to NMDAR
or NR2B-selective antagonists. These findings suggest that NMDAR antagonist pre-
treatment is an effective analgesic therapy for thermal aspects of neuropathic pain
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and that it increases the subsequent sensitivity of residual mechanical allodynia to
treatment with NMDAR and NR2B-selctive antagonists.
There is however great difficulty in translating these findings to clinical research. In
terms of clinically available NMDAR antagonists, ketamine is the most commonly
used in the peri-operative period. The effects on long term clinical sensistisation have
been researched (283), but no research has yet looked re-challenging these patients
with an NMDAR receptor antagonist at a later date. There may be opportunities to
treat patients suffering from herpes zoster infection with NMDA antagonists and
hope that in those unfortunate to develop pain there may at least an increased
susceptibility to treatment with NMDAR antagonists. In terms of clinically available
NR2B antagonist, Traxoprodil and haloperidol can be used. Little or no clinical
research has been conducted with these drugs in the prevention of treatment of
neuropathic pain. Infusions of traxoprodil have, however been used in patients with
serious head injury and seem to be well tolerated (321 ;323). Haloperidol is an
extensively researched drug in terms of its anti-emetic and anti-psychotic properties
but not in the area of chronic pain. This may well reflect its high risk of adverse
events, in particular movement disorders (352). Future research in the treatment and
prevention of neuropathic pain, may address the use of these drugs. Increasing
numbers of clinical studies are using quantitative sensory testing and this study
reinforces the relevance of these to outcomes and in particular to address both ,
thermal and tactile hyperalgesia.
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Chapter 4
Investigation into the effects of peri-operative epidural ketamine on the
development of post-amputation pain following lower limb amputation
4.1 Introduction
Up to 80% of patients may experience persistent pain after lower limb amputation
(179;210).
Post amputation pain may either be stump pain (pain at the site of amputation that
may have neuropathic elements) or phantom pain, which is a form ofneuropathic
pain, perceived where the limb was previously. Post-amputation pain is an important
clinical problem as strong evidence for its prevention and treatment is lacking (353).
The mechanisms ofpain following amputation are not fully understood however the
neuronal plasticity that is seen following the inevitable nerve transaction is
important.
It is difficult to determine the true incidence of post amputation pain, with
considerable differences from study to study, as summarised in Nikolajsen and
Jensen's paper and in chapter 1 (table 7) (179). Kehlet et al estimate the figure to be
lower at up to 50% with chronic severe disabling pain occurring in 5-10% of patients
(180). The figure quoted in Kehlet et al.'s paper is derived from the review of
Nikolajsen and Jensen and it is not clear how these lower figures are arrived at..
Nikolajsen and Jensen reviewed the original papers and demonstrate an incidence in
the region of 50-80%. Pain severity is not commented on.
Following amputation major changes occur in the peripheral and central nervous
system in response to peripheral nerve injury and subsequent alterations in peripheral
sensory input (187;354). Central sensitisation, occurring at the level of the spinal
cord, is likely to play a key role in ongoing pain (355). Melzack et al hypothesise that
if central sensitisation is to be reduced or avoided then blockade of the neuronal
barrage at the time if surgery using either a regional anaesthetic technique and/or pre¬
emptive opioids is required (356). Spinal anaesthesia, in contract to epidural
anaesthesia, can block somatosensory evoked potentials (SSEPs) completely and
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thus will (at least for a time) completely suppress afferent inputs to the spinal cord
(357;358). As shown and discussed in chapter 3, animal models of peripheral nerve
injury have shown that activation of the ionotropic glutamate receptor, the N-methyl
D-aspartate (NMDA) receptor is integral to the process of central sensitisation (83).
In animals, NMDA antagonists given before nerve injury can reduce behavioural
signs of neuropathic pain and associated neurochemical changes (144;359).
There is a need for early intervention as the onset ofpost-amputation pain can be
rapid, with approximately 30% of patients experiencing phantom pain within the first
24 hours (189).In keeping with this cortical remapping, which is associated with
phantom pain is equally rapid and can also occur within the first 24 hours (113). As
discussed the mechanism of pain is complex but nerve injury results in an excitotoxic
discharge with glutamate release leading to sensitisation (87-90).
The aim of this study was to determine the role of the NMDA receptor in the
development of the different components ofpost-amputation pain. An NMDAR
antagonist, ketamine, was administered close to the proposed site of action. Spinal
anaesthesia at the time of nerve transaction ensured that maximal suppression of
afferent sensitising neuronal barrages occurred. A post-operative epidural infusion
was given to try and suppress central sensitisation using both local anaesthetic and an
NMDAR antagonist.
4.1.1 The use of ketamine and epidural ketamine in the peri-operative period
Ketamine is in widespread use in the peri-operative period, with numerous studies
and reports of its use in both children and adults with no adverse events. It can be
given pre-, intra- or post-operatively, usually in combination with an opioid. The
main side-effects seen are hallucinations, dreams, dizziness, blurred vision and
nausea and vomiting. A Cochrane Database systematic review found it to have a
morphine sparing effect, a decrease in nausea and vomiting and with minimal
adverse events (154). The authors tried to identify an optimal morphine sparing
effect. All trials used a subanaesthetic dose. Ketamine dose ranged from about 1 Omg
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up to around 260mg (with twenty-four different doses). Although no conclusion on
optimal dose was made, a dose of grater than 30mg/24hours seemed to have a greater
morphine sparing effect. In a systematic review, Subramaniam et al identified thirty-
seven RCTs in ofketamine as an adjuvant analgesic to opioids (360). Eight of these
used epidural ketamine. Five studies had a beneficial effect. Importantly, although
one study demonstrated increased sedation in the ketamine group, no major short or
long term adverse events were described.
In the vascular surgical unit in the Royal Infirmary of Edinburgh, epidural ketamine
is routinely used in adults in clinical practice. Previous experience has shown that a
bolus of epidural ketamine larger than 500 meg/kg was likely to be associated with
increased sedation after surgery in some patients. A dose of 500 mcg/kg was
therefore chosen as being the highest dose that was not likely to be associated with
increased sedation in an elderly patient group. Experience of continuous infusions of
subcutaneous ketamine in elderly patients found that doses above 5 mg/h were likely
to be associated with sedation or psychological side-effects. We presumed that the
same side effects would be likely with epidural infusion doses above 5 mg/h. Our
previous experience of continuous local anaesthetic epidural infusions with ketamine
between 2 mg/h and 4 mg/h found that analgesia appeared to be improved but
sedation or psychological side effects were rare in this dose range. Therefore we
chose a starting epidural infusion dose corresponding to 3mg/h in a 60 kg patient or 5
mg/h in a 100 kg patient as being doses likely to demonstrate an analgesic effect
without being associated with significant sedation or psychological side effects
4.1.2 Ketamine and phantom pain
Two case reports suggest that the NMDA antagonist ketamine might be a useful drug
in the treatment of established phantom pain (223;224). A small (n=l 1) double blind
trial of an IV ketamine infusion found a reduction in stump and phantom pain as
assessed by VAS and MPQ (361). In addition sensory testing found an increase in
pressure threshold, a reduction in 'wind-up' type pain but no effect on pain evoked
by repeated thermal stimuli. Side-effects were seen in 9 of the 11 patients. These
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case reports and one small study were in established phantom pain. As discussed in
pre-clinical models NMDAR receptors antagonists can not only reverse established
sensitisation, but prevent or delay the onset of sensitisation when given in the peri¬
operative period.
4.1.3 Epidural analgesia and NMDAR antagonists in the prevention of
phantom pain
Clinical studies ofpre-emptive treatment interfering with spinal sensory input are
inconsistent. One non-blinded, non-randomised study of 25 patients found a
reduction in long-term phantom limb pain by using epidural analgesia with
bupivacaine and morphine started prior to surgery and continued afterwards (235). A
larger randomised controlled trial of 56 patients found an incidence of-70% for
phantom pain at one year regardless of whether epidural bupivacaine and morphine
were commenced 18 hours before surgery or immediately after surgery (236).
A study of intravenous ketamine used around the time of amputation in combination
with general anaesthetic and morphine, had no significant effect on the incidence of
phantom limb pain (241). Administration of the oral NMDA antagonist memantine
resulted in a reduction in phantom pain at 6 months which was not sustained at 12
months (234).The route of administration ofNMDA receptor antagonists may
therefore be clinically relevant in terms of efficacy. As discussed, the hypothesis
behind our study is that it is specifically spinal NMDAR activation that is one of the
crucial factors leading to post-amputation pain and sensitisation. The receptor
ideally needs to be targeted before nerve injury. NMDAR antagonists do have
significant side-effects so targeting the drug at the site of the spinal receptors thought
to be crucial may result in an improved efficacy with a lower dose and a resultant
reduction in side-effects. These two previous studies using NMDAR antagonists at
the time of amputation have used parenteral ketamine and oral memantine
respectively. Neither has specifically targeted the spinal NMDA receptor.
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No previous study has tried to modulate spinal NMDA receptors at the time of
amputation. While there may be some NMDA receptor activation as a result of pre¬
operative pain, the aim of this study was to focus on NMDA receptor blockade at the
time of nerve injury. At this time a massive excitotoxic injury discharge may occur
resulting in excessive glutamate release with subsequent central neuronal plasticity
(87-90).
This study assesses the effect ofpre-emptive treatment with an epidurally
administered NMDA receptor antagonist, ketamine, in combination with local
anaesthetic, on reducing spinal sensory transmission, acute central sensitisation and
the development of persistent post amputation pain. Patients undergoing lower limb
amputation for vascular reasons are usually elderly, often smokers and have a high
risk of cardiovascular and cerebrovascular disease. Their life expectancy at surgery
may be short with an expected around 30% one year mortality (362). There is a high
risk ofperi-operative morbidity particularly cardiac (10.2%), wound infection (5.5%)
and pneumonia (4.5%) (362). Their pre-morbid condition coupled with pain and
opioid exposure increases the need to use as 'clean' an anaesthetic technique as
possible. The study was carefully designed to avoid any confounding variables on the
peri-operative period. In particular the subjects did not have a general anaesthetic or
opioid exposure in the peri-operative period. It was of course impossible to avoid
opioids in the period leading up to surgery as the vast majority of patients
undergoing limb amputation for vascular reasons do so because of severe pain.
Nevertheless it was important to try and avoid peri-operative opioid exposure as
repeated exposure to opioids can itself result in spinal cord neural plasticity in a
mechanism which involves the NMDA receptor (363).
130
4.2 Methods
Approval was granted by the local research ethics committee and was in accordance
with the Helsinki Declaration of 1975(revised 1983). International Standard
Randomised Controlled Trial Number (ISRCTN) 48374927 was assigned to this
trial.
4.2.1 Subjects
Patients scheduled to undergo lower limb amputation in the Vascular Surgery Unit,
Royal Infirmary of Edinburgh, Scotland were approached regarding participation in
the trial. After written informed consent was obtained they were then entered into the
trial. Trial recruitment took place over a twenty month period (March 2000 -
October 2001). Patients had to be able to participate in the questionnaire-based pain
assessment and lower limb examination before they were invited to take part in the
study. Exclusion criteria included: contraindication to spinal or epidural blockade;
contraindication to the use of ketamine or bupivacaine; previous lower limb
amputation. Patients who underwent further amputation during the follow-up period
were excluded from further analysis and follow-up.
4.2.2 Study design
Patients who met entry criteria were randomly assigned to one of two treatment
groups: Group K to receive epidural bupivacaine and racemic ketamine and Group S
(control group) to receive epidural bupivacaine and saline around the time of
amputation. The infusion was made up in theatre by a staff member unconnected to
the study. Sufficient infusate was made up to cover the whole study period. Both
patients and staffwere blinded as to treatment group, but for safety reasons, one of
the researchers held sealed records as to the group allocation. The researchers
involved in assessments were blind to patient allocation until all subjects had
completed their one-year assessment. Recruiting and post-operative analgesic
adjustments were carried out by a single researcher (JW).
Randomisation was by GraphPad StatMate version 1.0 (GraphPad software Inc. San
Diego) which allocated subjects to either group using computer generated pseudo-
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random numbers. All patients underwent a detailed pain assessment, including
bedside quantitative sensory testing (QST) ofboth lower limbs before surgery, and at
eight days, six weeks, three months, six months and twelve months after surgery. If
the stump was infected or not healed, no QST was performed at that visit.
4.2.3 Sample size and power calculation
The primary outcome measure was the incidence and severity of both phantom limb
and stump pain. The incidence of phantom pain was chosen to calculate sample size.
Secondary outcome measures were the effectiveness of post-operative analgesia and
changes in sensory processing as measured by QST.
The incidence of phantom pain in most comparable studies is around 80% (179;210).
We considered that a decrease to 40% would be clinically significant. For a power
of 80%, an estimated sample size of 23 per group was needed (SigmaStat 2.03;
Power = 0.8; a = 0.05). A 30% one-year death rate would increase the sample size to
30 per group. This drop-out rate is comparable to that found in other studies in this
patient population (362). Interim analysis (see below) by an observer not connected
with the study was carried out at the midpoint of the study period, using Fisher's
Exact Test, with the primary endpoint being rate of phantom pain occurrence. This
was done to further refine the sample size and ensure that recruiting did not continue
inappropriately.
4.2.4 Patient assessment and outcomes measures
The rationale and background to the assessments used have been discussed in chapter
2. In this study the primary end-points of the presence or absence of both phantom
and stump pains were used. Pain severity was measured using a standard (0-100mm)
visual analogue scale (VAS). In addition the characteristics of any phantom and
stump pain were recorded, including frequency and severity of attacks. This was
recorded using a data collection form, a modification of Sherman et al's phantom
limb questionnaire (203) (Appendix 1). Current analgesic medications were also
recorded, and classified in terms of the WHO analgesic ladder, i.e. simple analgesics,
weak opioids, strong opioids and adjuvant drugs for neuropathic pain.
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In addition other outcome measures were used namely the Magill Pain Questionnaire
(MPQ), the Neuropathic Pain Scale (NPS) and Hospital Anxiety and Depression
Score (HADS) (261;270;273). Quantitative sensory testing (QST) was also
performed to see if subtle changes in sensory processing could be found. MPQ
results were expressed as total Pain Rating Index (PRI) scores (272). Post-
amputation pain is likely to have a neuropathic component therefore the NPS was
used as another measure of pain severity and to characterize the neuropathic
component in more detail. Results were expressed as a total NPS score out of 100.
The HADS was chosen as a measure ofpsychological distress. It is widely used in
the hospital setting and is both easy to administer and for the patient to understand.
HAD scores were divided into HADS-anxiety (HADS-A) and HADS-depression
(HADS-D).
4.2.5 QST
The background, methodology and rationale for QST are discussed in detail in
chapter 2 (section 2.4.4). Only a few studies on post-amputation pain have used QST
(285;364). In this study the patient acts as his or her control using the contralateral
limb as a control. A study protocol was designed that frail, elderly patients would be
likely to be able to complete, and that was also portable. This allowed assessments to
be carried out in a community setting, if there were transport issues, thus maximising
recruitment. The assessment was as follows:
• Soft brush
• Standard pinprick (Neurotips ™; Owen Mumford)
• Von Frey filaments (North Coast Medical, Inc., San Jose, California)
• Vibration - using a standard electrical tooth brush
• Cold temperature - topical acetone was dripped a few drops at a time using a
standard laboratory pipette
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Bedside QST was carried out on the base of the stump, or where it was anticipated to
be (for pre-operative testing), using the ventral aspect of the contralateral limb as a
control. Testing on each limb was carried out equidistant from the corresponding
iliac crest. Initially any area of altered mechanical sensation was mapped out using a
soft artist's paintbrush. The brush was drawn over the skin from an area of normal
sensation towards the stump and the patient asked to note any change (increase or
decrease) in the stimulus perception. Further assessment was carried out in any area
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of altered sensation or, if none detected, on the base of the stump. Tactile and pain
thresholds were assessed using von Frey (VF) filaments (North Coast Medical, Inc.,
San Jose, California). These were applied in ascending and descending force
magnitude until the subject was able to perceive four out of six stimuli. VAS scores
to pain and to unpleasantness were recorded following brush stimuli, vibration (using
a standard electric toothbrush), pinprick, using neurological examination pins
(Neurotips ™; Owen Mumford) and cold (acetone drops).
4.2.6 Peri-operative management
The peri-operative period was from the time of consent for surgery up until 72 hours
afterwards. No premedication was given. This was to keep the anaesthetic as clean as
possible, avoiding benzodiazepines which act on GABAergic receptors. Any
prescribed analgesics were continued up until the time of surgery. No patient
received general anaesthesia or supplementary opioids over the period of epidural
use. Both groups received combined spinal and epidural anaesthesia and intravenous
sedation. Epidural catheters (16G Portex) were placed just before surgery (JW or Dr
Alastair Nimmo (a co-researcher)). These were inserted through either the L2-L3 or
L3-L4 interspace. A test-dose of 4mls of 2% lidocaine was given to exclude
intravascular or intrathecal placement. Immediately after the epidural test dose, a
spinal (intrathecal) anaesthetic was administered at an interspace below the epidural
catheter (24G Sprotte needle; 2-5-3-0ml of bupivacaine 0.5%; AstraZeneca). Before
starting surgery, an epidural bolus dose of bupivacaine 0.5% (lmg/kg) with either
0.5mg/kg preservative free racemic ketamine (Curamed Pharma, Germany) (Gp K)
or an equivalent volume ofNaCl 0-9% (Gp S) was given. The epidural infusion
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mixture was prepared in theatre by an anaesthetist not involved in the study and
labelled "study medication". Additional study medication was prepared at this time
to be available if required during the infusion period in order to maintain blinding.
Neither ward staff nor the researcher carrying out the assessments was aware of the
contents of the mixture.
Sedation was given as required using a target-controlled infusion of propofol.
Benzodiazepine sedation with drugs such as midazolam was avoided.
Intraoperatively all patients had standard monitoring, supplemental oxygen and
intravenous fluids. During surgery the epidural infusion was commenced at
15ml/hour. Group K received an infusion ofbupivacaine 0.125% with ketamine 3.3
mg/kg/1. Group S had bupivacaine 0.125% with an equivalent volume ofNaCl 0.9%.
Following surgery the epidural infusion was adjusted by a blinded observer within
the range of 10-20ml /hour to ensure adequate pain relief (VAS<30). If analgesia was
inadequate, top-up boluses (10-15mls) were given from the infusion mixture.
Post-operative analgesia was supplemented with paracetamol 1 g 6 hourly orally. No
other analgesic medication was permitted during the period of epidural use. All
epidurals ran for between 48 and 72 hours. Failure of the epidural to provide
adequate analgesia required the removal of the patient from the study.
During the period of epidural analgesia, block height (blunt pin prick) and motor
block using a modified Bromage scale (365), number of epidural bolus doses,
average pain VAS scores, sedation score, respiratory rate and presence of nausea or
vomiting (self report) were recorded twice-daily.
4.2.7 Statistics
Statistics were carried out using SigmaStat for Window version 2.03. The primary
end point was the incidence ofphantom pain. The statistical analysis is therefore
asking the question; are two variables related? Data is laid out in a contingency table
and the frequencies of the variables compared. Proportions were compared using
Chi-squared analysis or Fisher's exact test if the expected numbers in each group
were small <5. Other measures were compared using One Way Analysis of Variance
(ANOVA) or Kruskal-Wallis ANOVA on Ranks if non parametric data. The
rationale behind these tests have been discussed in chapter 3.
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Patients undergoing Lower Limb Amputation
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Figure 8
Consort diagram showing patient flow though the study
Results
4.3.1 Recruitment and baseline characteristics
Of 186 patients undergoing lower limb amputation over the 20-month period studied,
53 patients were suitable and consented to participate in the study. They were
randomised such that 24 subjects were allocated to group K and 29 to group S. Six
were withdrawn post randomisation. 47 patients were included in the analysis, with
21 subjects in group K and 26 subjects in group S. 4 subjects subsequently had a
below knee amputation revised to an above knee and were removed from further
analysis (Fig 8).





Mean age years (n; SD) Male 73 (16; 5 3) 69(19; 9 4)
Mean age years (n; SD) Female 78 (10; 5-5) 73 (2; 0-7)
Mean weight in Kg (SD) Male 68-3 (131) 74-8 (20-0)
Mean weight in Kg (SD) Female 516(100) 67 0(1-4)
(
Mean height in cm (SD) Male 172-3 (6-1) 173-5 (9-0)
Mean height in cm (SD) Female 163-9 (9-1) 161-5(2-1)
Diabetes (n) 6 7
Median pre-op VAS score (IQ range) 70 (50-83) 50 (40-50)
Above knee amputation 11 5
Below knee amputation 15 16
137
Patient characteristics (table 10)
The subjects were comparable in age, weight, height, incidence of diabetes mellitus
and type of amputation. The characteristics of each group are shown in Table 10. Of
particular note, there was no difference in median (quartiles) pre-operative VAS pain
scores (group K 50 (40-50), group S 70 (50-83)). The incidence of diabetes in group
K and group S was 7 and 6 respectively. Similar numbers in both groups used pre¬
operative opioids (K11/21 :S21/26; ns; chi squared p=0.078). No problems with
opioid withdrawal were seen when opioids were stopped from the time of surgery
onwards.
4.3.2 Interim analysis
The power of the study is an area that causes some difficulty in this type of study.
Patients undergoing lower limb amputation for peripheral vascular disease are
usually elderly, with many meeting the exclusion criteria, resulting in slower than
expected . recruitment. After taking independent statistical advice, a blinded interim
analysis was recommended.
After the first 35 patients had been assessed at three-months, interim analysis (using
Fishers exact test) was carried out for the primary end-point (presence or absence of
phantom pain) by an independent assessor not involved in the study, with the results
of this not being available to the researchers. The rate ofphantom pain at 8 days, 6
weeks and 3 months in Group K was 3/11 (27%), 7/11 (64%) and 4/10 (40%)
respectively compared with Group S where 9/18 (50%), 8/17 (47%) and 6/15 (40%)
patients had phantom limb pain. There was no significant difference between groups
at 8 days, 6 weeks and 3 months (with p-values of 0.273, 0.460 and 1.000
respectively). The study authors were blinded to the result details, but were advised
that recruitment should cease, at which time 53 patients had entered the study.
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4.3.3 Assessment during epidural infusion period (table 11)
There was no difference in median epidural infusion rates between the groups. Both
groups had good postoperative analgesia with median total VAS scores of less than
30 mm. Group K had significantly lower pain scores than group S. Group K required
a significantly lower number of epidural top-ups. Following establishment of
epidural blockade, no subject was withdrawn due to inadequate analgesia. Mean
epidural infusion rate and duration was the same for both groups.
Table 11 Peri-operative infusion data
Group K Group S p-value
Median mean VAS (Quartiles) 0 (0-17) 17 (0-35) 0 031*t
Median Infusion rate; ml/hour (Quartiles) 15 (15-18) 15(14-16) 0-397
Mean number of top-ups (SD) 1-8(2-2) 3-5 (3-2) 0 044*J
* = Significant difference f = Mann-Whitney rank sum test J = t-test
There was no significant difference in motor block between the groups during the
duration of epidural infusion. Median (IQ range) Bromage scores on day one were 1
(0-2) for group K and 0 (0-1) for group S. On day two median (IQ range) Bromage
scores were 0 (0-1) in both groups. The incidence of nausea and vomiting (Group K:
4/21; Group S: 3/26; p=0.684), sedation (Group K: 2/21; Group S: 1/26; p=0.579)
and confusion (Group K: 2/21; Group S: 0/26; p=0.194) were low and did not differ
between groups (Fishers exact test). No patients suffered from hallucinations. There
were no complications that required revealing the composition of the infusion.
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4.3.4 Post-amputation pain
The rates of phantom and stump pain did not differ between the two groups at any of
the assessments up to and including one year, when the rate ofphantom pain was no
more than 50% and stump pain was no more than 33% in either group (Table 12a &
12b). Neither stump pain nor phantom pain intensity, as measured using VAS,
differed between groups at any time point (Figures 9 and 10). Frequency and
duration of attacks are presented in graphical form at each assessment point (Figs 11-
15). Numbers in each group were small. There was no visual trends identified and
further analysis was not carried out as multiple analysis of this data would result in a
significant chance of a type 1 error i.e a false positive.
Table 12a Stump Pain
Group K Group S P
Time n (%) n (%)
8 days 11/17 (65) 15/26 (58) 0-888
6 weeks 9/17 (53) 9/20 (45) 0 879
3 months 5/15 (33) 9/19 (43) 0-635
6 months 7/15 (47) 5/16(32) 0 609
12 months 3/14(21) 5/15 (33) 0-682f
Proportions compared using chi-squared analysis except as indicated by f-
t=Fisher's exact test.
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Table 12b Phantom Pain
Group K Group S P
Time n (%) n(%)
8 days 6/17 (35) 13/26 (50) 0-525
6 weeks 10/17(59) 9/20 (45) 0 611
3 months 6/15 (40) 7/19(37) 0-867
6 months 6/15 (40) 3/16(19) 0-252f
12 months 7/14 (50) 6/15(40) 0-867
Proportions compared using chi-squared analysis except as indicated by f.
|=Fisher's exact test.
Figures 9-15 are shown on the next four pages
The intensity of stump pain (fig 9) and phantom pain (fig 10) at each time point
following amputation.
Data is shown as box plots with medians represented by horizontal lines with the 75th
percentile at the top and the 25th percentile at the bottom. The 10th and 90lh
percentiles are shown as whiskers.
Figures 11-15 show the frequency of phantom pain attacks (LEFT) and the length of
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Total MPQ scores were highest before surgery, Group K: 23 (15-33), Group S: 28.5
(15.25-35.75); median (IQ range). These fell to 3 (0-8) in Group K and 3 (1-11) in
Group S at 12 months. Scores in both groups were significantly less than pre¬
operative values by 6 weeks (Kruskal-Wallis ANOVA on Ranks with Dunn's post-
hoc analysis, p<0.001), but groups did not differ from each other at any time point
(see Figure 16)
Median NPS scores started high (Figure 17) and dropped with time, pre-operatively
scores were: Group K; 49 (40-59) vs Group S; 50 (37-66); median (IQ range). This
fell to a median score of 4 (1-22) in Group K and 5 (0-16) in Group S at 12 months.
There was a significant reduction from pre-operative values in both groups at all time
points post-operatively, but with no difference between groups (Kruskal-Wallis
ANOVA on Ranks with Dunn's post-hoc analysis, p<0.001).
Levels of anxiety, as assessed by HADS scoring (expressed as mean (SD)) were:
Group K: 8.4 (4.5) pre-operatively, decreasing to 5.4 (2.8) at 6 weeks post
amputation, and remained significantly lower at all time points up to and including
one year (4.3(2.9)) (one way ANOVA with Dunnett's post-hoc analysis; p<0.001)
and Group S: 8.2 (3.7) pre-operatively with no significant reduction any time point
up to and including one year (4.7 (4.0))(one way ANOVA with Dunnett's post-hoc
analysis; p=0.071). Levels of depression for Group K were 8.1 (4.3) pre-operatively,
reducing significantly at 3 months to 5.4 (3.8) and remaining significantly reduced
up to and including one year (one way ANOVA with Dunnett's post-hoc analysis;
p=0.003). Pre-operative scores for depression in Group S were 6.0 (3.4), with no
significant reduction at any time point up to and including one year (4.5(4.6)) (one
way ANOVA p=0.829). Figure 18 shows the mean HADS score at each time point
divided into anxiety and depression scores. The comparison between groups and the
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4.3.6 Sensory processing as measured by QST
Preoperatively there was a slightly higher tactile threshold in the ischaemic limb (206
mNmm"2 (191)) than the contralateral limb: (139 mNmm'2 (82)), t-test p=0.036.
Ketamine did modify some aspects of sensory transmission, with an alteration in the
tactile threshold of the stump on day 8 after surgery. In Group K, the tactile
threshold was found to be significantly higher on the stump (589 mNmm"2 (782);
mean (SD)) compared to the contralateral limb (180 mNmm2 (160); mean (SD)) and
to both limbs in Group S (stump; 250 mNmm"2 (97); mean (SD)), contralateral, 208
mNmm"2 (140); mean (SD)); (One way ANOVA with Tukey test.; p=0.005). This
difference was not found at 6 weeks (see Table 13). There was no significant
difference between sides at any other time point. There was no difference between
the groups in the evoked response to pin prick at any time point (Table 14). Data for
both tactile threshold and VAS score to painful pin prick has been displayed as a
scatter plot for both groups at 12 months (Figures 19 and 20). The similarity between
the two groups is clearly displayed. Data comparing those with phantom pain and
those without has been plotted using a scatter graph showing tactile threshold for the
stump and contralateral limb for both Group K and Group S (Figures 21 and 22) on
Day 8. VAS scores for cold and vibration were 0 in the majority ofpatients (88-
100%) at all time points. Further detailed analysis was not carried out.
4.3.7 Analgesic medications i
The overall number of analgesic drugs prescribed did not vary between groups. The
number of analgesic drugs prescribed pre-operatively was Group K; 2 (2-3) vs Group
S 3 (2-3); median IQ range. The number of analgesic drugs prescribed was less in
both groups after surgery. At 12 months the number prescribed was the same in both
groups: 1 (1-2); median (IQ range). There was no difference between the two groups
in the median numbers of drugs at any time point after surgery (Kruskal-Wallis
ANOVA on ranks)
149

























































































































o o o o
o o o








































































This study has found that modulation of sensory input at the time of amputation may
have both short and longer term effects on pain perception.
The anaesthetic/ analgesic technique used in our study has resulted in a lower
incidence ofpersistent pain than other randomised controlled trials of lower limb
amputation where around 70% ofpatients have persistent pain (236;241). A wide
range of incidences for post-amputation pain has been found (179;210)), with lower
incidences in particular types of study (retrospective or postal survey) and patient
groups (paediatric or upper limb amputation) compared to lower limb amputation
(183-185;197;366). Prospective data does not identify age, gender, level of
amputation or reason for amputation as a risk factor for post-amputation pain (211).
A key difference in our study is the anaesthetic technique used compared to previous
studies. This combined spinal/ epidural technique, without use of general anaesthesia
or opioids produces a very dense block of sensory input that may provide a novel
strategy for reducing persistent pain after amputation. No other published clinical
trial has used either a spinal anaesthetic or a combined spinal epidural technique. The
study was carefully designed to ensure that it was appropriately randomised and
double blind. The sample size of the study is extremely important. Interim analysis
was carried out to refine initial sample size. This was to see if the original sample
was adequate or whether a small increase would be appropriate. It was important to
not to miss a positive result due to an under powered study while at the same time it
was going to be difficult to continue recruitment for much longer than two years
using one researcher. In addition to primary outcomes the study design allowed for
secondary outcome measures such as mood. The trial was designed and completed
before the IMMPACT consensus guidelines in chronic pain study design were
published (259). Of the six recommended outcome measure three were well
addressed namely pain and pain severity, adverse incidents and patient deposition.
The HADS score gives a useful measure of emotional distress. Despite this, in the
categories ofphysical function and emotional function more information might have
been collected to improve the quality of the study design. Questionnaires such as
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Brief Pain Inventory (BPI; measuring physical functioning) or Beck Depression
Inventory (BDI; emotional functioning), with retrospect, should have been used. The
category of 'global impression of change' was not relevant to this study type and
therefore appropriately not addressed. That said the study outcomes were well
designed in keeping with similar studies at that time.
The initial hypothesis was that specific blockade of the NMDA receptor would be
required to reduce persistent pain. This was based on evidence from basic science
studies of the key role that the NMDA receptor, plays in central sensitisation and
subsequent spinal events in pathological pain states (367;368). Failure of previous
studies to reduce persistent pain may have been related to inadequate block of the
effects of massive glutamate release and excitotoxic discharge at the time ofnerve
injury (91;369). No previous study has used a spinal anaesthetic which could be
expected to completely block (at least at the time of nerve transaction) afferent
neuronal input from the lower limb(357). Clinically, there is also some evidence for
involvement of the NMDA receptor in central processing in patients with established
phantom pain (161 ;370). Intravenous ketamine has been used peri-operatively at the
time of lower limb amputation, but no acute effect on central processing was found,
nor a statistically significant reduction in phantom limb pain at 6 months, although
phantom pain was 47% in the ketamine group and 71% in the control group (241).
The potential neurotoxicty of spinal ketamine (either epidural or intrathecal) must be
considered. Firstly, there is concern that preservatives in commercially available
compound may be neurotoxic, as has been demonstrated in sub-human primates and
rabbits (371-373). Secondly, although preservative free ketamine widely used in
some European countries, there have been concerns both about a direct toxic effect
specifically related to the action ofNMDA antagonists and an increased rate of
apoptosis during neuronal development. The direct toxic effect has only been found
selectively certain cortical neurons in rodents (cingulate and retrosplenial cortices),
with both toxicity and apoptosis only seen with high doses, unlikely to be used in
clinical practice (374-376). Additionally, repeated intrathecal injections of up to 1%
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ofpreservative-free ketamine (377) or repeat epidural boluses of ketamine in dogs
(378) had no neurotoxic effect.
Recent systematic reviews of ketamine have found no clinical evidence of
neurotoxicity from epidural use, with some benefits in analgesia (360).
One reason for our study not detecting an additional effect of ketamine, over and
above local anaesthetic alone, may be that, due to the much lower overall incidence
of persistent pain, the power of the study to answer the original hypothesis was
reduced. It may be however, that the key element to reducing persistent pain is the
blockade of spinal sensory transmission (either NMDA receptor-specific or non¬
specific blockade). Previous studies have found that neither general anaesthesia,
acute opioid use, nor prolonged sensory block, with epidural analgesia before or after
surgery, were sufficient to reduce persistent pain (236;241). In order to adequately
reduce the massively increased peripheral input at the time of nerve injury, it would
be necessary to reduce sensory input to such an extent that spinal responses were
prevented. It has been shown previously that local anaesthetic administered via the
epidural route does not completely suppress neuronal input to the spinal cord (358).
There is also recent evidence from animal models that electrical stimuli well below
that required to elicit spinal cord activity, may evoke neuronal activity within the
brainstem, as assessed by fMRI (379). While electrophysiological recordings of
spinal input were not made during our study, the combined spinal/ epidural technique
did provide a significant block of sensory input such that amputation was performed
without general anaesthesia or other analgesia such as strong opioids. This blockade
of sensory input was associated with an incidence ofpersistent pain of 50% or less in
both groups in our study.
The timing ofNMDA receptor blockade may be important in its effect on the
neurobiological response, as some studies have found that NMDA receptor
antagonists did not affect phantom or stump pain, or responses to mechanical and
thermal stimuli, and cortical changes, in established post amputation pain
(158; 162)), with one small study of traumatic upper limb amputates finding that
acute administration ofmemantine (in addition to brachial plexus blockade) reduced
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prevalence and severity of phantom limb pain up to 6 months but not one year
afterwards (234). Other studies in animal models have also found an anti-allodynic
effect ofNMDA receptor antagonists that outlast their expected pharmacological
duration of action (380), with selective effects on different aspects ofpain behaviours
(144;359)
There were limitations to the QST used in this study. The need for easy to use
bedside tests limited what could be achieved. In addition QST methodology has
advanced significantly since the study was designed. The developments in QST have
been discussed in detail in chapter 2 (section 2.4.4). Few previous studies have
attempted to use sensory testing to assess the alterations in sensory processing that
might be seen following amputation. An attempt has been made to classify phantom
phenomena according to changes in peripheral sensory function (286). Sensory
abnormalities varied and no clear pattern of abnormalities in sensory processing
emerged. This study measured tactile threshold using very similar methodology to
our study. Tactile threshold did not differ, as in our control group, between the stump
and the contralateral limb. Increased sensitivity was, however, found on the scar. A
previous preventative study comparing epidural bupivacaine and morphine with
conventional analgesia assessed post-operative sensory processing (285). This
included pressure pain, VF hairs to detect touch and pressure thresholds, thermal
pain, allodynia and wind up. No differences in sensory processing were detected
between the groups. Our hypothesis was that, due to importance of the NMDA
receptor in sensitisation, an NMDAR antagonist would be needed have an effect on
sensory processing. Despite no additional reduction in persistent pain in the
ketamine group, there were alterations in pain processing, with significant
improvements in acute post-operative analgesia. Specific effects on sensory
processing were also detected, with a selective decrease in mechanical sensitivity on
the stump that outlasted the expected pharmacological action of ketamine (381),
similar to that seen in phantom and stump pain (361). Ketamine can also alter
sensory processing in chronic phantom pain (382). Ketamine treatment alters
pressure pain thresholds but not affect electrical or thermal pain. As discussed above
(chapter 3) we have found that treatment with NMDA antagonists prior to nerve
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injury in a rodent model, resulted in an enhancement of subsequent responses to
NMDA antagonists, particularly responses to mechanical stimuli (383). There is also
evidence of inhibitory pathways mediated by metabotropic glutamate receptors type
II/ III in neuropathy models, with a complex relationship between the ionotropic
NMDA receptors and metabotropic (246;384). This may partly explain the reduced
mechanical sensitivity, although the precise mechanism requires further study. These
results would support a role for the NMDA receptor in acute central sensitisation as
well as providing clinical evidence supporting the role of epidural ketamine in
modifying pain processing acutely.
There is still debate as to the role of ketamine as part ofmultimodal post-operative
analgesia. Systematic reviews of ketamine found that ketamine could reduce pain
scores and opioid consumption, with minimal adverse effects (154; 155). A
systematic review of another clinically available NMDA antagonist,
dextromethorphan, also found a reduction in opioid consumption, but no effect on
post-operative pain scores (385). The route of administration may be important, with
epidural being superior to systemic ketamine after thoracotomy, while another study
found no effect of intravenous ketamine acutely or at 6 months post lower limb
amputation (241;386). By giving ketamine, close to its putative site of action on
nociceptive pathways in the spinal cord, an adequate dose may be given without
significant adverse effects. Our study provides evidence of the efficacy of epidural
ketamine as part of an acute analgesic strategy with some detectable effects on acute
sensory responses. An additional benefit, particularly in an elderly population, is the
lack of sedation or respiratory depression produced by using a technique without a
requirement for opioid in the peri-operative analgesic regimen.
The questionnaire data did not reveal any useful differences between groups and
score in all outcome measures fell with time. A study investigating coping strategies
of amuputees with phantom pain found mean (SD) total MPQ scores in two study
groups of 31.2 (14.6) and 35.6 (15.1) (387). Similar mean values of about 30 were
found in a study of back pain patients (388). This was similar in value to our
preoperative values, though we have expressed them as median values. Nikolajsen et
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al. found a pre-amputation median score of 18 with median values of 11.0, 11.5 and
13.6 at one week, three months and six months respectively following amputation (in
patients who experienced phantom pain) (192). Our study found very low levels at
12 months in both groups. The neuropathic pain scale has mostly been used for
monitoring responses to treatment to neuropathic pain rather than distinguishing
between neuropathic and non-neuropathic pain. It has been recently shown to be
effective in distinguishing between neuropathic and non-neuropathic pain (278). This
study found total mean scores of 43.2 and 63.49 in non-neuropathic and neuropathic
pain respectively. Median pain scores in both groups in our study were very low at
all post-operative time points suggesting that neuropathic pain did not predominate.
The scale might have been better used in a study that was monitoring the response to
pain rather than as a global measure ofpost-operative pain. The HADS score is a
useful screening tool in looking for emotional distress in a population of patients.
The cut off score for both anxiety and depression is 8 (274). The mean scores in both
groups in the post-operative period was below 8 at all time points for both groups
suggesting that a low incidence of emotional distress occurring despite the loss of a
limb.
Further study of the unexpected finding of ketamine in reducing anxiety and
depression is warranted. The acute, and often dose-limiting, effects of ketamine on
mood, such as dysphoria and increased anxiety, were not found in our study, which
may relate to the route of administration. Improvement in mood has been found with
ketamine after peri-operative use in depressed patients (389), and acutely in the
treatment ofmajor depression (390-392). No previous study has found a positive
long-term effect of short-term ketamine administration on levels of anxiety and
depression (393; 394).
Future research in this area needs to focus further on the use of spinal anaesthesia at
the time of amputation. The role of the NMDAR antagonists is not clear but
memantine given for a pronged period does seem to produce a short term reduction
in the incidence of post amputation pain (234). The length of time that the NMDAR
antagonist is administered may be very important. In order to prevent or reduce
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central sensitisation, any intervention must continue into the post-operative period
(229). 48-72 hours of epidural ketamine may not be sufficient, but realistically this is
as long as is practically possible in a clinical situation. Ketamine can be given by
alternative routes e.g. using the oral or nasal route (395). It seems well tolerated and
this might give an option to carry out continue the drug administration well into the
post-operative period (4-6 weeks). Alternatively NMDARs such as dextromethorphin
or amantidine, which exist as oral preparations could be tried as a long term
suppressor of central sensitisation. Newer NR2B specific antagonists targeted at the
spinal NMDAR receptors may have a role to play. Traxoprodil has NR2B subunit
selectivity. It has been used in clinical trials of brain injury but no trials yet exist in
pain treatment or prevention (323).
In conclusion, it has been suggested that a combination of general and regional
techniques is needed to reduce central sensitisation (356). However, this may not be
the case, with the key element being modulation of sensory transmission around the
time of nerve injury. A combination of specific (ketamine) and non-specific agents
(local anaesthetic) administered close to the spinal cord can alter acute and chronic
pain processing. It may be that pronged (several weeks) administration of the
NMDAR antagonist is needed. The NMDA receptor has a defined role in the
development of pain, but further study is needed to clarify the role of the NMDA




This thesis demonstrates the importance of the NMDA receptor in neuropathic pain
syndromes and explores its potential therapeutic uses.
Animal experiments, using a CCI model of neuropathic pain, have demonstrated the
effectiveness of the NMDA antagonists, memantine and ketamine, in attenuating
typical behavioural responses to nerve injury. In addition the NR2B selective
compound Ro 25-6891 similarly attenuates these effects. Furthermore I have shown
that in animals that have had pre-treatment with an NMDA antagonist, there is a
subsequent increased susceptibility to treatment with NMDA antagonists. The
expression of the NR1 and NR2B subunits alters following pre-treatment with
NMDAR antagonists, with no change in NR2A expression. The expression ofNR2B
seems to be elevated ipsilateral to the CCI. Pre-treatment with NMDAR antagonists
blocks this elevation and might account for the increased subsequent susceptibility to
treatment seen with various NMDAR antagonists.
A clinical study was designed to mirror the animal experiments and investigated
whether the promise shown by NMDA antagonists can be translated into clinical
practice. Patients scheduled for lower limb amputation are a patient group that can be
identified before nerve injury occurs making them an ideal group to study. Ketamine
was given epidurally, close to its proposed site of action on spinal NMDARs, before
the nerves were cut in surgery. Ketamine was shown to be an effective adjunct to
plain local anaesthetic and to have a long lasting (up to one week) effect on sensory
processing in the remaining stump. Disappointingly in clinical practice 48-72 hours
of peri-operative ketamine made no difference to the primary end point of the
incidence and severity of post-amputation pain.
One other RCT has used peri-operative ketamine in an attempt to reduce the
incidence and/or severity of post-amputation pain. Hayes at al used an intravenous
infusion of ketamine, preceded by a pre-induction bolus of ketamine (241). The
infusion ran for 72 hours. No statistical difference was found in either incidence or
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severity of post-amputation pain. The incidence of phantom pain was lower in the
treatment group at 6 months which might indicate that the study was either
insufficiently powered or perhaps the ketamine might need to be given for a longer
period. Interim analysis on our own data indicated that it would not produce a
positive result even if the sample size was substantially increased. In clinical practice
it would be unrealistic to have parenteral drug administration for more than a few
days and thus if the length of time is important then an alternative NMDAR
antagonist designed for oral use might be better. Schley et a.l treated traumatic upper
limb amputees for four weeks with the orally available NMDAR antagonist
memantine (20-3Omg per day, in addition to 7 days of a continuous ropivacaine
brachial plexus block). No long term effect on the prevalence and severity of
phantom pain was found, although short term (up to 6 months) effects were
demonstrated (234).
Our own study attempts to translate promising animal data into clinical practice. Our
own basic science experiments demonstrate the potential usefulness ofNMDAR
antagonists on preventing neuropathic sensitisation and how important spinal
NMDARs are. Ketamine was given epidurally, in the clinical study, based on the
hypothesis that administration in the proximity of spinal NMDARs would optimise
efficacy and translate into a clinically useful effect with minimal side-effects. No
major side-effects were seen showing the technique to be well tolerated. Secondary
outcome measures based on QST were chosen. These allowed demonstration of the
prolonged effect (longer than pharmacological effect) that ketamine may have on
sensory processing.
The failure to translate the promise shown in the basic science experiments was very
disappointing. This is a problem often seen in pre-clinical experiments. There are a
number of reasons why this may be, both in general terms and in our own particular
studies. In the human pain is felt as a consequence of nociceptive activity in the
nervous system, which is communicated as an emotional and sensory experience.
Human brains differ considerably from rats' brains in the volume devoted to higher
function. The human forebrain makes up 85% of the volume of the human CNS, with
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the spinal cord making only 2%. In rats the percentages are 44 and 35% respectively
(396). Human forebrains play a large part in the perception and in descending
modulation of pain. This may not be mirrored in the rat model. Although nerve
injury models are well validated and accepted they do differ from clinical practice in
a number of regards. In the first incidence they are all based on damage to the nerve
rather than total nerve transaction as occurs in the clinical situation. The animal
models are very reliable and reproducible. In effect this means that most, if not all,
animals subjected to the injury will develop the associated pain behaviours. If left
long enough (several weeks) these changes resolve. In contrast not all human
develop neuropathic pain. This is regardless of the cause, i.e. amputation, post herpes
infection, diabetic neuropathy etc. Importantly, although some cases do
spontaneously resolve with time, the majority do not. Testing in animal models of
neuropathic pain depends in large part on tests of sensitivity (allodynia/hyperalgesia)
to a mechanical or thermal stimuli (163). Work is being done to try to focus on other
measures of pain such as observed behaviours which may better reflect actual pain.
Measurements of activity, such as vocalisation grooming, spontaneous paw lifting,
analgesic administration etc. have been suggested (163). This may imply that
although the models are very reliable, they are probably not exactly mirroring the
clinical situation seen in humans. In the clinical situation, neuropathic pain
symptoms such as spontaneously occurring burning pain are much more frequent and
intense than evoked thermal pains suggesting that although the models are valuable
they do not yet fully mimic human pain (397). Work is continuing to develop
improve pain models and make them more like human conditions (164).
A major strength of this thesis is the combination of a preclinical model of pain and a
clinical research project. The research investigates the use ofNMDAR antagonists in
the animal model and then tries to replicate this as far as possible in a clinical trial.
Great care was taken to try and ensure that the two studies mirrored each other as far
as possible. This type of translational research is becoming the more common but at
the time of this research was rare.
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The recruitment, study throughput and primary outcome of the presence and severity
ofpost-amputation pain were well conducted. Even in big centres, recruitment of
patients to this type of study is difficult. Patients are often elderly and have
significant medical and cognitive problems that prevent inclusion. The rate of
recruitment was good and overall compare very favourably with other larger trials in
this area. The weaknesses in the thesis mostly stem from some of the secondary
outcomes in the clinical trial. IMMPACT guidelines have focused clearly on the core
outcome variables needed in trails of chronic pain. Every attempt was made to
include outcomes other than pain, but with the benefit of hindsight, perhaps some
refinement of the questionnaires chosen should have been done. The QST
methodology was chosen to be easily and cheaply accomplished at the bedside or
even the patients home. QST guidelines are constantly developing in my own centre
and others. Further refinement of the protocol would be done if the study was to be
repeated or a similar trial contemplated. The deficiencies identified here do not
detract from the primary outcome, which was the incidence and severity ofpost-
amputation pain.
In conclusion this thesis demonstrates not only the significant role that ionotropic
NMDA receptor antagonist has in the establishment of neuropathic pain states but
the potential therapeutic roles that they might deliver. The pre-emptive effect of
NMDAR antagonists in a preclinical model is clearly demonstrated. The promise
shown in these studies fails to translate into clinical practice. Although there was a
failure to prevent post-amputation pain, there was a prolonged effect on sensory
processing which warrants further research.
Future research needs to focus on development and improvement of animal models.
There is likely to be a move away from using evoked responses as the sole outcome.
Efforts will (and are) being made to measure spontaneous pain using behavioural
observations in addition to evoked responses. There is opportunity to develop less
observer dependent outcomes such as electroencephalogram (EEG) or functional
MR1 in animal models (164). Clinical studies often use analgesic consumption as a
surrogate measure ofpain and this can be used in the preclinical setting (398).
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Analgesic drug can be given in 'on demand' fashion using a lever and give a similar
outcome measure to the clinical situation. Emotional functioning is a key outcome
measure in clinical trials of chronic pain (259). Emotional outcome can in fact be
measured in animal models and this may be become a relevant area of development
(399).
QST as an outcome measure will become more refined. The German neuropathic
pain network as made great strides in this direction, suggesting detailed protocols and
reference values (244;281). There been a long identified need to push forward on a
more mechanistic approach to pain (279). QST has the potential to deliver in this
area, but at present QST protocols are time consuming (often one hour or more) and
there is a still a way to go before detailed QST becomes a relevant 'bedside' test in
the pain clinic (400).
Future research projects, using clinically available NMDAR antagonists, might
include the long term (up to 6 weeks) use of these drugs at the time of nerve damage
in conditions such as herpes zoster. This may lead to a reduced incidence of
persistent pain but also may make those with established pain more susceptible to
subsequent treatment with NMDAR antagonists. There is a need to investigate the
use of clinically available NR2B subunit receptor antagonists. Traxoprodil has been
used in clinical studies of brain injury but no data has been yet published in pain
conditions. This is despite it being apparently well tolerated and could be taken
orally (321 ;323;401). Haloperidol, a clinically available NR2B antagonist, is more
likely to have significant side-effects and this may, as in the case of ketamine, limit
its potential therapeutic use.
Finally there is a need for greater collaboration between basic science researchers
and clinicians. Large translational research networks need to be set up that can
rapidly move promising new compounds into clinical trails, while at the same time
using clinical experience to refine laboratory methodology so that compounds more
likely to deliver in the clinical setting are identified. Governments, nationally and
internationally need to promote these collaborations and ensure a coordinated
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approach to research, ensuring good clinical outcomes, patient safety and cost-
effectiveness (402).
Reference List
(1) Cesare P, McNaughton P. Peripheral pain mechanisms. Curr Opin
Neurobiol 1997;7:493-9.
(2) Willis WD, Coggeshall RE. Sensory mechanisms of the spinal cord. 2nd ed.
New York: Plenum Press; 1991.
(3) D'Mello R, Dickenson AH. Spinal cord mechanisms of pain. Br J Anaesth
2008;101:8-16.
(4) Swett JE, WoolfCJ. The somatotopic organization ofprimary afferent
terminals in the superficial laminae of the dorsal horn of the rat spinal cord.
J Comp Neurol 1985;231:66-77.
(5) Rexed B. The cytoarchitectonic organization of the spinal cord in the cat. J
Comp Neurol 1952;96:414-95.
(6) Todd AJ. Anatomy of primary afferents and projection neurones in the rat
spinal dorsal horn with particular emphasis on substance P and the
neurokinin 1 receptor. Exp Physiol 2002;87:245-9.
(7) Yung KK. Localization of glutamate receptors in dorsal horn of rat spinal
cord. Neuroreport 1998;9:1639-44.
(8) Ozawa S, Kamiya H, Tsuzuki K. Glutamate receptors in the mammalian
central nervous system. Prog Neurobiol 1998;54:581-618.
(9) Hokfelt T, Pemow B, Wahren J. Substance P: a pioneer amongst
neuropeptides. J Intern Med 2001;249:27-40.
(10) Millan MJ. The induction ofpain: an integrative review. Prog Neurobiol
1999;57:1-164.
(11) Malcangio M, Bowery NG. GABA and its receptors in the spinal cord.
Trends Pharmacol Sci 1996;17:457-62.
(12) Roberts E. Gamma-aminobutyric acid and nervous system function—a
perspective. Biochem Pharmacol 1974;23:2637-49.
(13) Coggeshall RE, Carlton SM. Receptor localization in the mammalian dorsal
horn and primary afferent neurons. Brain Res Brain Res Rev 1997;24:28-
66.
(14) Fields HL, Basbaum AI. Central nervous system mechanisms ofpain
modulation. In: Wall PD, Melzack R, editors. Textbook of Pain. 4th ed.
Edinburgh: Churchill Livingston; 1999. p. 309-29.
168
(15) Cervero F, Laird JM. Mechanisms of touch-evoked allodynia: a new model.
Pain 1996;68:13-23.
(16) Craig AD, Dostrovsky JO. Medulla to thalamus. In: Wall PD, Melzack R,
editors. Textbook of pain. 4th ed. Edinburgh: Churchill Livingstone; 1999.
p. 183-214.
(17) Craig AD. Spinal distribution of ascending lamina I axons anterogradely
labeled with Phaseolus vulgaris leucoagglutinin (PHA-L) in the cat. J Comp
Neurol 1991;313:377-93.
(18) Peyron R, Laurent B, Garcia-Larrea L. Functional imaging of brain
responses to pain. A review and meta-analysis (2000). Neurophysiol Clin
2000;30:263-88.
(19) Almeida TF, Roizenblatt S, Tufik S. Afferent pain pathways: a
neuroanatomical review. Brain Res 2004;1000:40-56.
(20) Millan MJ. Descending control of pain. Prog Neurobiol 2002;66:355-474.
(21) Porreca F, Ossipov MH, Gebhart GF. Chronic pain and medullary
descending facilitation. Trends Neurosci 2002 ;25:319-25.
(22) Merskey H, Bogduk N. Classification of chronic pain: Descriptions of
chronic pain syndromes and definitions of pain terms. 2nd ed. Seattle: IASP
Press; 1994.
(23) Cesaro P, Ollat H. Pain and its treatments. Eur Neurol 1997;38:209-15.
(24) Sewards TV, Sewards MA. The medial pain system: neural representations
of the motivational aspect of pain. Brain Res Bull 2002;59:163-80.
(25) Willis WD. Spinothalamocortical Processing ofPain. In: Villanueva L,
Dickenson AH, Ollat H, editors. The Pain System in Normal and
Pathological States: A Primer for Clinicians.Seattle: IASP Press; 2004. p.
155-78.
(26) Treede RD, Kenshalo DR, Gracely RH, Jones AK. The cortical
representation of pain. Pain 1999;79:105-11.
(27) Timmermann L, Ploner M, Haucke K, Schmitz F, Baltissen R, Schnitzler
A. Differential coding ofpain intensity in the human primary and secondary
somatosensory cortex. J Neurophysiol 2001 ;86:1499-503.
(28) Talbot JD, Marrett S, Evans AC, Meyer E, Bushnell MC, Duncan GH.
Multiple representations of pain in human cerebral cortex. Science
1991;251:1355-8.
169
(29) Rainville P, Duncan GH, Price DD, Carrier B, Bushnell MC. Pain affect
encoded in human anterior cingulate but not somatosensory cortex. Science
1997;277:968-71.
(30) Ploghaus A, Tracey I, Gati JS, Clare S, Menon RS, Matthews PM, et al.
Dissociating pain from its anticipation in the human brain. Science
1999;284:1979-81.
(31) Maihofner C, Schmelz M, Forster C, Neundorfer B, Handwerker HO.
Neural activation during experimental allodynia: a functional magnetic
resonance imaging study. Eur J Neurosci 2004; 19:3211-8.
(32) Juottonen K, Gockel M, Silen T, Hurri H, Hari R, Forss N. Altered central
sensorimotor processing in patients with complex regional pain syndrome.
Pain 2002;98:315-23.
(33) Maihofner C, Handwerker HO, Neundorfer B, Birklein F. Patterns of
cortical reorganization in complex regional pain syndrome. Neurology
2003;61:1707-15.
(34) Flor H. Cortical reorganisation and chronic pain: implications for
rehabilitation. J Rehabil Med2003;(41 Suppl):66-72.
(35) Wall PD, Gutnick M. Ongoing activity in peripheral nerves: the physiology
and pharmacology of impulses originating from a neuroma. Exp Neurol
1974;43:580-93.
(36) Wall PD, Devor M. Sensory afferent impulses originate from dorsal root
ganglia as well as from the periphery in normal and nerve injured rats. Pain
1983;17:321-39.
(37) Matzner O, Devor M. Hyperexcitability at sites ofnerve injury depends on
voltage-sensitive Na+ channels. J Neurophysiol 1994;72:349-59.
(38) Devor M, Wall PD, Catalan N. Systemic lidocaine silences ectopic
neuroma and DRG discharge without blocking nerve conduction. Pain
1992;48:261-8.
(39) Nystrom B, Hagbarth KE. Microelectrode recordings from transected
nerves in amputees with phantom limb pain. Neurosci Lett 1981 ;27:211-6.
(40) Nordin M, Nystrom B, Wallin U, Hagbarth KE. Ectopic sensory discharges
and paresthesiae in patients with disorders of peripheral nerves, dorsal roots
and dorsal columns. Pain 1984;20:231-45.
(41) Seltzer Z, Devor M. Ephaptic transmission in chronically damaged
peripheral nerves. Neurology 1979 ;29:1061-4.
(42) Fried K, Govrin-Lippmann R, Devor M. Close apposition among
neighbouring axonal endings in a neuroma. J Neurocytol 1993 ;22:663-81.
170
(43) Devor M, Wall PD. Cross-excitation in dorsal root ganglia of nerve-injured
and intact rats. J Neurophysiol 1990;64:1733-46.
(44) Lai J, Hunter JC, Porreca F. The role of voltage-gated sodium channels in
neuropathic pain. Curr Opin Neurobiol 2003;13:291-7.
(45) Devor M, Seltzer Z. Pathophysiology of damaged nerves in relation to
chronic pain. In: Wall PD, Melzack R, editors. Textbook of Pain. Fourth ed.
Churchill Livingstone; 1999. p. 129-64.
(46) Waxman SG, Kocsis JD, Black JA. Type III sodium channel mRNA is
expressed in embryonic but not adult spinal sensory neurons, and is
reexpressed following axotomy. J Neurophysiol 1994;72:466-70.
(47) Dib-Hajj S, Black JA, Felts P, Waxman SG. Down-regulation of transcripts
for Na channel alpha-SNS in spinal sensory neurons following axotomy.
Proc Natl Acad Sci U S A 1996;93:14950-4.
(48) Dib-Hajj SD, Tyrrell L, Black JA, Waxman SG. NaN, a novel voltage-
gated Na channel, is expressed preferentially in peripheral sensory neurons
and down-regulated after axotomy. Proc Natl Acad Sci USA
1998;95:8963-8.
(49) Cummins TR, Waxman SG. Downregulation of tetrodotoxin-resistant
sodium currents and upregulation of a rapidly repriming tetrodotoxin-
sensitive sodium current in small spinal sensory neurons after nerve injury.
J Neurosci 1997;17:3503-14.
(50) Black JA, Dib-Hajj S, Cummins TR, Okuse K, Baker MD, Wood JN, et al.
Sodium channels and neuropathic pain. In: Hansson PT, Fields HL, Hill
RG, Marchettini P, editors. Neuropathic Pain:Pathophysiology and
Treatment.Seattle: IASP Press; 2001. p. 19-36.
(51) Benarroch EE. Sodium channels and pain. Neurology 2007 J;68:233-6.
(52) Nielsch U, Bisby MA, Keen P. Effect of cutting or crushing the rat sciatic
nerve on synthesis of substance P by isolated L5 dorsal root ganglia.
Neuropeptides 1987;10:137-45.
(53) Noguchi K, Senba E, Morita Y, Sato M, Tohyama M. Alpha-CGRP and
beta-CGRP mRNAs are differentially regulated in the rat spinal cord and
dorsal root ganglion. Brain Res Mol Brain Res 1990;7:299-304.
(54) Hokfelt T, Zhang X, Wiesenfeld-Hallin Z. Messenger plasticity in primary
sensory neurons following axotomy and its functional implications. Trends
Neurosci 1994;17:22-30.
(55) SniderWD, Wright DE. Neurotrophins cause a new sensation. Neuron
1996;16:229-32.
171
(56) Pezet S, McMahon SB. Neurotrophins: mediators and modulators of pain.
Annu Rev Neurosci 2006;29:507-38..
(57) Fjell J, Cummins TR, Fried K, Black JA, Waxman SG. In vivo NGF
deprivation reduces SNS expression and TTX-R sodium currents in IB4-
negative DRG neurons. J Neurophysiol 1999;81:803-10.
(58) Black JA, Langworthy K, Hinson AW, Dib-Hajj SD, Waxman SG. NGF
has opposing effects on Na+ channel III and SNS gene expression in spinal
sensory neurons. NeuroReport 1997 ;8:2331-5.
(59) Dib-Hajj SD, Black JA, Cummins TR, Kenney AM, Kocsis JD, Waxman
SG. Rescue of alpha-SNS sodium channel expression in small dorsal root
ganglion neurons after axotomy by nerve growth factor in vivo. J
Neurophysiol 1998;79:2668-76.
(60) Ren K, Thomas DA, Dubner R. Nerve growth factor alleviates a painful
peripheral neuropathy in rats. Brain Res 1995;699:286-92.
(61) Lever IJ, Bradbury EJ, Cunningham JR, Adelson DW, Jones MG,
McMahon SB, et al. Brain-derived neurotrophic factor is released in the
dorsal horn by distinctive patterns of afferent fiber stimulation. J Neurosci
2001;21:4469-77.
(62) Luo XG, Rush RA, Zhou XF. Ultrastructural localization of brain-derived
neurotrophic factor in rat primary sensory neurons. Neurosci Res
2001;39:377-84.
(63) McLachlan EM, Janig W, Devor M, Michaelis M. Peripheral nerve injury
triggers noradrenergic sprouting within dorsal root ganglia. Nature
1993;363:543-6.
(64) Chung K, Lee BH, Yoon YW, Chung JM. Sympathetic sprouting in the
dorsal root ganglia of the injured peripheral nerve in a rat neuropathic pain
model. J Comp Neurol 1996;376:241-52.
(65) Michaelis M, Devor M, Janig W. Sympathetic modulation of activity in rat
dorsal root ganglion neurons changes over time following peripheral nerve
injury. J Neurophysiol 1996;76:753-63.
(66) Sherman RA. What do we really know about phantom limb pain. Pain
Reviews 1994;1:261-74.
(67) Drummond PD, Finch PM. Persistence of pain induced by startle and
forehead cooling after sympathetic blockade in patients with complex
regional pain syndrome. J Neurol Neurosurg Psychiatry 2004;75:98-102.
(68) Stanton-Hicks M, Janig W, Hassenbusch S, Haddox JD, Boas R, Wilson P.
Reflex sympathetic dystrophy: changing concepts and taxonomy. Pain
1995;63:127-35.
172
(69) Ali Z, Raja SN, Wesselmann U, Fuchs PN, Meyer RA, Campbell JN.
Intradermal injection ofnorepinephrine evokes pain in patients with
sympathetically maintained pain. Pain 2000;88:161-8.
(70) Jadad AR, Carroll D, Glynn CJ, McQuay HJ. Intravenous regional
sympathetic blockade for pain relief in reflex sympathetic dystrophy: a
systematic review and a randomized, double-blind crossover study. J Pain
Symptom Manage 1995 ;10:13-20.
(71) WoolfCJ, Shortland P, Coggeshall RE. Peripheral nerve injury triggers
central sprouting ofmyelinated afferents. Nature 1992;355:75-8.
(72) Woolf CJ, Shortland P, Reynolds M, Ridings J, Doubell T, Coggeshall RE.
Reorganisation of central terminals ofmyelinated primary afferents in the
rat dorsal horn following peripheral axtomy. The Journal of Comparative
Neurology 1995;360:121-34.
(73) Tong Y-G, Wang HF, Gong J, Grant G, Hokfelt T, Zhang X. Increased
uptake and transport of choerla toxin subunit in dorsal root gangion
neurones after peripheral axotomy: Possible implications for sensory
sprouting. J Comp Neurol 1999;404:143-58.
(74) Bao L, Wang HF, Cai HJ, Tong YG, Jin SX, Lu YJ, et al. Peripheral
axotomy induces only very limited sprouting of coarse myelinated afferents
into inner lamina II of rat spinal cord. Eur J Neurosci 2002;16:175-85.
(75) Hughes DI, Scott DT, Todd AJ, Riddell JS. Lack of evidence for sprouting
ofAbeta afferents into the superficial laminas of the spinal cord dorsal horn
after nerve section. J Neurosci 2003;23:9491-9.
(76) Okamoto M, Baba H, Goldstein PA, Higashi H, Shimoji K, Yoshimura M.
Functional reorganization of sensory pathways in the rat spinal dorsal horn
following peripheral nerve injury. J Physiol 2001;532:241-50.
(77) Ji RR, Kohno T, Moore KA, Woolf CJ. Central sensitization and LTP: do
pain and memory share similar mechanisms? Trends Neurosci
2003;26:696-705.
(78) Bliss TV, Lomo T. Long-lasting potentiation of synaptic transmission in the
dentate area of the anaesthetized rabbit following stimulation of the
perforant path. J Physiol 1973;232:331-56.
(79) Randic M, Jiang MC, Ceme R. Long-term potentiation and long-term
depression of primary afferent neurotransmission in the rat spinal cord. J
Neurosci 1993;13:5228-41.
(80) Liu XG, Sandkuhler J. Long-term potentiation ofC-fiber-evoked potentials
in the rat spinal dorsal horn is prevented by spinal N-methyl-D-aspartic acid
receptor blockage. Neurosci Lett 1995;191:43-6.
173
(81) Rygh LJ, Kontinen VK, Suzuki R, Dickenson AH. Different increase in C-
fibre evoked responses after nociceptive conditioning stimulation in sham-
operated and neuropathic rats. Neurosci Lett 2000;288:99-102.
(82) Woolf CJ. Evidence for a central component ofpost-injury pain
hypersensitivity. Nature 1983;306:686-8.
(83) WoolfCJ, Thompson SWN. The induction and maintenance of central
sensitisation is dependent on N-methyl-D-aspartic acid receptor activation;
implications for the treatment of post-injury pain hypersensitivity states.
Pain 1991;44:293-9.
(84) Chen L, Huang LY. Protein kinase C reduces Mg2+ block ofNMDA-
receptor channels as a mechanism ofmodulation. Nature 1992;356:521-3.
(85) Baba H, Ji RR, Kohno T, Moore KA, Ataka T, Wakai A, et al. Removal of
GABAergic inhibition facilitates polysynaptic A fiber-mediated excitatory
transmission to the superficial spinal dorsal horn. Mol Cell Neurosci
2003;24:818-30.
(86) Todd AJ, McKenzie J. GABA-immunoreactive neurons in the dorsal hom
of the rat spinal cord. Neuroscience 1989;31: 799-806.
(87) Seltzer Z, Beilin BZ, Ginzburg R, Paran Y, Shimko T. The role of injury
discharge in the induction of neuropathic pain behavior in rats. Pain
1991;46:327-36.
(88) Yamamoto T, Shimoyama N, Mizuguchi T. Role of the injury discharge in
the development of thermal hyperesthesia after sciatic nerve constriction
injury in the rat. Anesthesiology 1993;79:993-1002.
(89) Sugimoto T, Bennett GJ, Kajander KC. Strychnine-enhanced transsynaptic
degeneration of dorsal hom neurons in rats with an experimental painful
peripheral neuropathy. Neurosci Lett 1989;98:139-43.
(90) Sugimoto T, Bennett GJ, Kajander KC. Transsynaptic degeneration in the
superficial dorsal hom after sciatic nerve injury: effects of a chronic
constriction injury, transection, and strychnine. Pain 1990;42:205-13.
(91) Moore KA, Kohno T, Karchewski LA, Scholz J, Baba H, Woolf CJ. Partial
peripheral nerve injury promotes a selective loss of GABAergic inhibition
in the superficial dorsal hom of the spinal cord. J Neurosci 2002;22:6724-
31.
(92) Sun H, Ren K, Zhong CM, Ossipov MH, Malan TP, Lai J, et al. Nerve
injury-induced tactile allodynia is mediated via ascending spinal dorsal
column projections. Pain 2001;90:105-11.
(93) Ren K, Dubner R. Descending modulation in persistent pain: an update.
Pain 2002;100:1-6.
174
(94) Ossipov MH, Lai J, Malan TP, Jr., Porreca F. Spinal and supraspinal
mechanisms of neuropathic pain. Ann N Y Acad Sci 2000;909:12-24.
(95) Kovelowski CJ, Ossipov MH, Sun H, Lai J, Malan TP, Porreca F.
Supraspinal cholecystokinin may drive tonic descending facilitation
mechanisms to maintain neuropathic pain in the rat. Pain 2000;87:265-73.
(96) Mayer DJ, Wolfle TL, Akil H, Carder B, Liebeskind JC. Analgesia from
electrical stimulation in the brainstem of the rat. Science 1971;174:1351-4.
(97) Akil H, Mayer DJ, Liebeskind JC. Antagonism of stimulation-produced
analgesia by naloxone, a narcotic antagonist. Science 1976;191:961-2.
(98) Lewis VA, Gebhart GF. Evaluation of the periaqueductal central gray
(PAG) as a morphine-specific locus of action and examination ofmorphine-
induced and stimulation-produced analgesia at coincident PAG loci. Brain
Res 1977;124:283-303.
(99) Dubner R, Ren K. Brainstem modulation of pain. In: Villanueva L,
Dickenson AH, Ollat H, editors. The Pain System in Normal and
Pathological States.Seattle: IASP Press; 2004. p. 107-20.
(100) Ossipov MH, Lai J, Malan TP, Vanderah TW, Porreca F. Tonic descending
facilitation. In: Hansson PT, Fields HL, Hill RG, Marchettini P, editors.
Neuropathic Pain: Pathophysiology and Treatment.Seattle: IASP Press;
2001. p. 107-24.
(101) Terayama R, Guan Y, Dubner R, Ren K. Activity-induced plasticity in
brain stem pain modulatory circuitry after inflammation. NeuroReport
2000;11:1915-9.
(102) Miki K, Zhou QQ, Guo W, Guan Y, Terayama R, Dubner R, et al. Changes
in gene expression and neuronal phenotype in brain stem pain modulatory
circuitry after inflammation. J Neurophysiol 2002;87:750-60.
(103) Wiesenfeld-Hallin Z, Xu XJ, Hokfelt T. The role of spinal cholecystokinin
in chronic pain states. Pharmacol Toxicol 2002 ;91:398-403.
(104) McCleane GJ. A randomised, double blind, placebo controlled crossover
study of the cholecystokinin 2 antagonist L-365,260 as an adjunct to strong
opioids in chronic human neuropathic pain. Neurosci Lett 2003;338:151-4.
(105) Ghilardi JR, Allen CJ, Vigna SR, McVey DC, Mantyh PW. Trigeminal and
dorsal root ganglion neurons express CCK receptor binding sites in the rat,
rabbit, and monkey: possible site of opiate-CCK analgesic interactions. J
Neurosci 1992;12:4854-66.
(106) Melzack R. Phantom limbs and the concept of a neuromatrix. Trends in
Neurosciences 1990;13:88-92.
175
(107) Flor H, Nikolajsen L, Staehelin JT. Phantom limb pain: a case of
maladaptive CNS plasticity? Nat Rev Neurosci 2006;7:873-81.
(108) Pons TP, Garraghty PE, Ommaya AK, Kaas JH, Taub T, Mishkin M.
Massive reorganisation after sensory deafferentation in adult macaques.
Science 1991;25:1857-60.
(109) Ramachandran VS. Behavioural and magnetoencephalographic correlates
ofplasticity in the adult human brain. Proceedings of the National Acadamy
of Science, USA 1993;90:10413-23.
(110) Knecht S, Henningsen H, Elbert T, Flor H, Hohling C, Pantev C, et al.
Reorganisational and perceptional changes after amputation. Brain
1996;119:1213-9.
(111) Elbert T, Flor H, Birbaumer N, Knecht S, Hampson S, Larbig W, et al.
Extensive reorganization of the somatosensory cortex in adult humans after
nervous system injury. NeuroReport 1994;5:2593-7.
(112) Flor FT, Elbert T, Knecht S, Wienbruch C, Pantev C, Birbaumer N, et al.
Phantom-limb pain as a perceptual correlate of cortical reorganization
following arm amputation. Nature 1995;375:482-4.
(113) Borsook D, Becerra L, Fishman S, Edwards A, Jennings CL, Stojanovic M,
et al. Acute plasticity in the human somatosensory cortex following
amputation. NeuroReport 1998;9:1013-1017.
(114) Birbaumer N, LutzenbergerW, Montoya P, Larbig W, Unertl K, Topfner S,
et al. Effects of regional anesthesia on phantom limb pain are mirrored in
changes in cortical reorganization. Journal of Neuroscience 1997; 17:5503-
8.
(115) Florence SL, Taub HB, Kaas JH. Large-scale sprouting of cortical
connections after peripheral injury in adult macaque monkeys. Science
1998;282:1117-21.
(116) Jain N, Florence SL, Qi HX, Kaas JH. Growth of new brainstem
connections in adult monkeys with massive sensory loss. Proc Natl Acad
Sci U S A 2000;97:5546-50.
(117) Wall PD, Devor M, Inbal R, Scadding JW, Schonfeld D, Seltzer Z, et al.
Autotomy following peripheral nerve lesions: experimental anaesthesia
dolorosa. Pain 1979;7:103-11.
(118) Bennett GJ, Xie YK. A peripheral mononeuropathy in rat that produces
disorders ofpain sensations like those seen in man. Pain 1988;33:297-301.
(119) Seltzer Z, Dubner R, Shir Y. A novel behavioral model of neuropathic pain
disorders produced in rats by partial sciatic nerve injury. Pain 1990;43:205-
18.
176
(120) Kim SH, Chung JM. An experimental model for peripheral neuropahty
produced by segmental spinal nerve ligation in the rat. Pain 1992;50:355-
63.
(121) Kim KJ, Yoon YW, Chung JM. Comparison of three rodent neuropathic
pain models. Exp Brain Res 1997; 113:200-6.
(122) Decosterd I, Woolf CJ. Spared nerve injury: an animal model of persistent
peripheral neuropathic pain. Pain 2000; 87:149-158.
(123) Mayer ML, Westbrook GL. The physiology of excitatory amino acids in the
vertebrate central nervous system. Prog Neurobiol 1987;28:197-276.
(124) McBain CJ, Mayer ML. N-methyl-D-aspartic acid receptor structure and
function. Physiol Rev 1994;74:723-60.
(125) Kingery WS. A critical review of controlled clinical trials for peripheral
neuropathic pain and complex regional pain syndromes. Pain 1997;73:123-
39.
(126) Laube B, Kuhse J, Betz H. Evidence for a tetrameric structure of
recombinant NMDA receptors. JNeurosci 1998 ; 18:2954-61.
(127) Hirai H, Kirsch J, Laube B, Betz H, Kuhse J. The glycine binding site of the
N-methyl-D-aspartate receptor subunit NR1: identification of novel
determinants of co-agonist potentiation in the extracellular M3-M4 loop
region. Proc Natl Acad Sci USA 1996;93:6031-6.
(128) Laube B, Hirai H, Sturgess M, Betz H, Kuhse J. Molecular determinants of
agonist discrimination by NMDA receptor subunits: analysis of the
glutamate binding site on the NR2B subunit. Neuron 1997;18:493-503.
(129) Garry EM, Moss A, Delaney A, O'Neill F, Blakemore J, Bowen J, et al.
Neuropathic sensitization of behavioral reflexes and spinal NMDA
receptor/CaM kinase II interactions are disrupted in PSD-95 mutant mice.
Curr Biol 2003;13:321-8.
(130) Tao YX, Huang YZ, Mei L, Johns RA. Expression of PSD-95/SAP90 is
critical for N-methyl-D-aspartate receptor-mediated thermal hyperalgesia in
the spinal cord. Neuroscience 2000;98:201-6.
(131) Monaghan DT, Holets VR, Toy DW, Cotman CW. Anatomical
distributions of four pharmacologically distinct 3H-L-glutamate binding
sites. Nature 1983;306:176-9.
(132) Boyce S, Wyatt A, Webb R, O'Donnell G, Mason G, Rigby M, et al.
Selective NMDA NR2B antagonists induce antinocioception without motor
dysfunction: correlation with restricted localisation ofNR2B subunit in
dorsal horn. Neuropharmacology 1999;38:611-23.
177
(133) Karlsson U, Sjodin J, Angeby MK, Johansson S, Wikstrom L, Nasstrom J.
Glutamate-induced currents reveal three functionally distinct NMDA
receptor populations in rat dorsal horn - effects ofperipheral nerve lesion
and inflammation. Neuroscience 2002;112:861-8.
(134) Trujillo KA. The neurobiology of opiate tolerance, dependence and
sensitization: mechanisms ofNMDA receptor-dependent synaptic
plasticity. Neurotox Res 2002;4:373-91.
(135) Yamamoto T, Yaksh TL. Spinal pharmacology of thermal hyperesthesia
induced by constriction injury of sciatic nerve. Excitatory amino acid
antagonists. Pain 1992;49:121-8.
(136) Chaplan SR, Malmberg AB, Yaksh TL. Efficacy of spinal NMDA receptor
antagonism in formalin hyperalgesia and nerve injury evoked allodynia in
the rat. The Journal of Pharmacology and Experimental Theraputics
1997;280:829-38.
(137) Laurido C, Pelissier T, Perez H, Flores F, Hernandez A. Effect of ketamine
on spinal cord nociceptive transmission in normal and monoarthritic rats.
NeuroReport 2001;12:1551-4.
(138) Davar G, Hama A, Deykin A, Vos B, Maciewicz R. MK-801 blocks the
development of thermal hyperalgesia in a rat model of experimental painful
neuropathy. Brain Research 1991;553:327-30.
(139) Mao J, Price DD, Mayer DJ, Lu J, Hayes RL. Intrathecal MK-801 and local
nerve anaesthesia synergistically reduce nociceptive behaviour in rats with
experimental peripheral mononeuropathy. Brain Research 1992;576:254-
62.
(140) Mao J, Price DD, Hayes RL, Lu J, Mayer DJ, Frenk H. Intrathecal
treatment with dextrorphan or ketamine potently reduces pain-related
behaviors in a rat model ofperipheral mononeuropathy. Brain Research
1993;605:164-8.
(141) Eisenberg E, LaCross S, Strassman AM. The clinically tested N-methyl-D
aspartate receptor antagonist memantine blocks and reverses thermal
hyperalgesia in a rat model of painful mononeuropathy. Neurosci Lett
1995;187:17-20.
(142) Smith GD, Wiseman J, Harrison SM, Elliott PJ, Birch PJ. Pre treatment
with MK-801, a non-competitive NMDA antagonist, prevents development
ofmechanical hyperalgesia in a rat model of chronic neuropathy, but not in
a model of chronic inflammation. Neurosci Lett 1994;165:79-83.
(143) Carlton SM, Hargett GL. Teatment with the NMDA antagonist memantine
attenuates nociceptive responses to mechanical stimulation in neuropathic
rats. Neurosci Lett 1995;198:115-8.
178
(144) Burton AW, Lee DH, Saab S, Chung JN. Preemptive Intrathecal ketamine
injection produces a long-lasting decrease in neuropathic pain behaviours in
a rat model. Regional Anesthesia and Pain Medicine 1999;24:208-13.
(145) Hartrick CT, Wise JJ, Patterson JS. Preemptive Intrathecal ketamine delays
mechanical hyperalgesia in the neuropathic rat. Anaesthesia and Analgesia
1997;86:557-60.
(146) Wei H, Pertovaara A. Influence ofpreemptive treatment with MK-801, an
N-methyl-D-aspartate receptor antagonist, on the development of
neuropathic symptoms induced by spinal nerve ligation in the rat.
Anesthesiology 1999;91:313-6.
(147) Domino EF, Chodoff P, Corssen G. Pharmaclogical effects ofCI-581, A
new dissociative anesthetic, in man. Clin Pharmacol Ther 1965;40:279-91.
(148) Hirota K, Lambert DG. Ketamine: its mechanism(s) of action and unusual
clinical uses. Br J Anaesth 1996;77:441-4.
(149) Kohrs R, Durieux ME. Ketamine: teaching an old drug new tricks. Anesth
Analg 1998;87:1186-93.
(150) Dowdy EG, Kaya K, Gocho Y. Some pharmacologic similarities of
ketamine, lidocaine, and procaine. Anesth Analg 1973;52:839-42.
(151) Passie T, Karst M, Wiese B, Emrich HM, Schneider U. Effects of different
subanesthetic doses of (S)-ketamine on neuropsychology, psychopathology,
and state of consciousness in man. Neuropsychobiology 2005;51:226-33.
(152) De Kock M, Lavand'homme P, Waterloos H. 'Balanced analgesia' in the
perioperative period: is there a place for ketamine? Pain 2001;92:373-80.
(
(153) Hocking G, Cousins MJ. Ketamine in chronic pain management: an
evidence-based review. Anesth Analg 2003;97:1730-9.
(154) Bell RF, Dahl JB, Moore RA, Kalso E. Perioperative ketamine for acute
postoperative pain. Cochrane Database Syst Rev 2006 Jan
25;(1):CD004603.
(155) Elia N, TramerMR. Ketamine and postoperative pain—a quantitative
systematic review of randomised trials. Pain 2005;113:61-70.
(156) Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated
N-methyl-D-aspartate (NMDA) receptor antagonist—a review of preclinical
data. Neuropharmacology 1999;38:735-67.
(157) Eisenberg E, Kleiser A, Dortort A, Haim T, Yarnitsky D. The NMDA (N-
methyl-D-aspartate) receptor antagonist memantine in the treatment of
postherpetic neuralgia: a double blind, placebo controlled study. Eur J Pain
1998;2:321-327.
179
(158) Nikolajsen L, Gottrup H, Kristensen AG, Jensen TS. Memantine (a N-
methyl-D-aspartate receptor antagonist) in the treatment of neuropathic pain
after amputation or surgery: a randomized, double-blinded, cross-over
study. Anesth Analg 2000;91:960-6.
(159) Sang CN, Booher S, Gilron I, Parada S, Max MB. Dextromethorphan and
memantine in painful diabetic neuropathy and postherpetic neuralgia:
efficacy and dose-response trials. Anesthesiology 2002;96:1053-61.
(160) Maier C, Dertwinkel R, Mansourian N, Hosbach I, Schwenkreis P, Senne I,
et al. Efficacy of the NMDA-receptor antagonist memantine in patients
with chronic phantom limb pain—results of a randomized double-blinded,
placebo-controlled trial. Pain 2003;103:277-83.
(161) Schwenkreis P, Maier C, Pleger B, Mansourian N, Dertwinkel R, Malin JP,
et al. NMDA-mediated mechanisms in cortical excitability changes after
limb amputation. Acta Neurol Scand 2003;108:179-84.
(162) Wiech K, Kiefer RT, Topfner S, Preissl H, Braun C, Unertl K, et al. A
placebo-controlled randomized crossover trial of the N-methyl-D-aspartic
acid receptor antagonist, memantine, in patients with chronic phantom limb
pain. Anesth Analg 2004;98:408-13.
(163) Mogil JS, Crager SE. What should we be measuring in behavioral studies of
chronic pain in animals? Pain 2004;112:12-5.
(164) Blackburn-Munro G. Pain-like behaviours in animals - how human are
they? Trends Pharmacol Sci 2004;25:299-305.
(165) Church J, Sawyer D, McLarnon JG. Interactions of dextromethorphan with
the N-methyl-D-aspartate receptor-channel complex: single channel
recordings. Brain Res 1994;666:189-94.
(166) Su TP. Sigma receptors. Putative links between nervous, endocrine and
immune systems. Eur J Biochem 1991;200:633-42.
(167) Dematteis M, Lallement G, Mallaret M. Dextromethorphan and
dextrorphan in rats: common antitussives—different behavioural profiles.
Fundam Clin Pharmacol 1998;12:526-37.
(168) Carlsson KC, Hoem NO, Moberg ER, Mathisen LC. Analgesic effect of
dextromethorphan in neuropathic pain. Acta Anaesthesiol Scand
2004;48:328-36.
(169) Ben Abraham R, Marouani N, Weinbroum AA. Dextromethorphan
mitigates phantom pain in cancer amputees. Ann Surg Oncol 2003;10:268-
74.
180
(170) Heiskanen T, Hartel B, Dahl ML, Seppala T, Kalso E. Analgesic effects of
dextromethorphan and morphine in patients with chronic pain. Pain
2002;96:261-7.
(171) Gilron I, Booher SL, Rowan MS, Smoller MS, Max MB. A randomized,
controlled trial of high-dose dextromethorphan in facial neuralgias.
Neurology 2000;55:964-71.
(172) Nelson KA, Park KM, Robinovitz E, Tsigos C, Max MB. High-dose oral
dextromethorphan versus placebo in painful diabetic neuropathy and
postherpetic neuralgia. Neurology 1997;48:1212-8.
(173) McQuay HJ, Carroll D, Jadad AR, Glynn CJ, Jack T, Moore RA, et al.
Dextromethorphan for the treatment ofneuropathic pain: a double-blind
randomised controlled crossover trial with integral n-of-1 design. Pain
1994;59:127-33.
(174) Komhuber J, Schoppmeyer K, Riederer P. Affinity of 1-aminoadamantanes
for the sigma binding site in post-mortem human frontal cortex. Neurosci
Lett 1993;163:129-31.
(175) Kornhuber J, Weller M, Schoppmeyer K, Riederer P. Amantadine and
memantine are NMDA receptor antagonists with neuroprotective
properties. J Neural Transm Suppl 1994;43:91-104.
(176) Pud D, Eisenberg E, Spitzer A, Adler R, Fried G, Yamitsky D. The NMDA
receptor antagonist amantadine reduces surgical neuropathic pain in cancer
patients: a double blind, randomized, placebo controlled trial. Pain
1998;75:349-54.
(177) Amin P, Sturrock ND. A pilot study of the beneficial effects of amantadine
in the treatment of painful diabetic peripheral neuropathy. Diabet Med
2003;20:114-8.
(178) Mitchell SW. Phantom Limbs. The Lippincott Magazine 8, 563-569. 1871.
Philadelphia.
(179) Nikolajsen L, Jensen TS. Phantom limb pain. Br J Anaesth 2001;87:107-16.
(180) Kehlet H, Jensen TS, Woolf CJ. Persistent postsurgical pain: risk factors
and prevention. Lancet 2006;367:1618-25.
(181) Jensen TS, Krebs B, Nielsen J, Rasmussen P. Phantom limb, phantom pain
and stump pain in amputees during the first 6 months following amputation.
Pain 1983;17:243-56.
(182) Krane EJ, Heller LB. The prevalence of phantom sensation and pain in
pediatric amputees. Journal of Pain & Symptom Management 1995; 10:21-
9.
181
(183) Montoya P, Larbig W, Grulke N, Flor H, Taub E, Birbaumer N. The
relationship ofphantom limb pain to other phantom limb phenomena in
upper extremity amputees. Pain 1997;72:87-93.
(184) Kooijman CM, Dijkstra PU, Geertzen JB, Elzinga A, Van der Schans CP.
Phantom pain and phantom sensations in upper limb amputees: An
epidemiological study. Pain 2000;87:33-41.
(185) Dijkstra PU, Geertzen JH, Stewart R, Van der Schans CP. Phantom pain
and risk factors: a multivariate analysis. J Pain Symptom Manage
2002;24:578-85.
(186) Wilkins KL, McGrath PJ, Finley GA, Katz J. Phantom limb sensations and
phantom limb pain in child and adolescent amputees. Pain 1998;78:7-12.
(187) Flor H. Phantom-limb pain: characteristics, causes, and treatment. Lancet
Neurol 2002;1:182-9.
(188) Davies RW. Phantom Sensation, Phantom Pain and Stump Pain. Arch Phys
Med Rehabil 1993;74:79-91.
(189) Carlen PL, Wall PD, Nadvorna H, Steinbach T. Phantom limbs and related
phenomena in recent traumatic amputations. Neurology 1978;28:211-7.
(190) Jensen TS, Krebs B, Nielsen J, Rasmussen P. Non-painful phantom limb
phenomena in amputees: Incidence, clinical characteristics and temporal
course. Acta Neurologica Scandinavica 1984;70:407-14.
(191) Shukla GD, Sahu SC, Tripathi RP, Gupta DK. Phantom limb: A
phenomenological study. British Journal of Psychiatry 1982;141:54-8.
(192) Nikolajsen L, Ilkjaer S, Kroner K, Christensen JH, Jensen TS. The
influence of preamputation pain on postamputation stump and phantom
pain. Pain 1997;72:393-405.
(193) Schott GD. Delayed onset and resolution of pain: some observations and
implications. Brain 2001;124:1067-76.
(194) Jensen TS, Krebs B, Nielsen J, Rasmussen P. Immediate and long-term
phantom limb pain in amputees: Incidence, clinical characteristics and
relationship to pre-amputation limb pain. Pain 1985;21:267-78.
(195) Parkes CM. Factors determining the persistence of phantom pain in the
amputee. J Psychosom Res 1973;17:97-108.
(196) Houghton AD, Nicholls G, Houghton AL, Saadah E, McColl L. Phantom
pain: natural history and association with rehabilitation. Ann R Coll Surg
Engl 1994;76:22-5.
182
(197) Wartan SW, Hamann W, Wedley JR, McColl I. Phantom pain and
sensation among British veteran amputees. British Journal ofAnaesthesia
1997;78:652-9.
(198) Bailey AA, Moersch FP. Phantom Limb. Canandian Medical Association
Journal 1941;45:37-42.
(199) Hermann LG, Gibbs EW. Phantom limb pain. American Journal of Surgery
1945;67:168-80.
(200) Henderson WR, Smyth GE. Phantom limbs. Journal of neurology,
neurosurgery and psychiatry 1948;11:88-112.
(201) Finch DR, Macdougal M, Tibbs DJ, Morris PJ. Amputation for vascular
disease: the experience of a peripheral vascular unit. Br J Surg
1980;67:233-7.
(202) Steinbach TV, Nadvorna H, Arazi D. A five year follow-up study of
phantom limb pain in post traumatic amputees. Scand J Rehabil Med
1982;14:203-7.
(203) Sherman RA, Sherman CJ, Parker L. Chronic phantom and stump pain
among American veterans:Results of a survey. Pain 1984;18:83-95.
(204) Buchanan DC, Mandell AR. The prevalence of phantom limb experience in
amputees. Rehabilitation Psychology 1986;31:183-8.
(205) Pohjolainen T. A clinical evaluation of stumps in lower limb amputees.
Prosthet Orthot Int 1991;15:178-84.
(206) Smith DG, Ehde DM, Legro MW, Reiber GE, del Aguila M, Boone DA.
Phantom limb, residual limb, and back pain after lower extremity
amputations. Clin Orthop 1999;:29-38.
(207) Weiss SA, Lindell B. Phantom limb pain and etiology of amputation in
unilateral lower extremity amputees. Journal of Pain & Symptom
Management 1996;11:3-17.
(208) Katz J, Melzack R. Pain 'memories' in phantom limbs: review and clinical
observations. Pain 1990;43:319-36.
(209) Sherman RA, Sherman CJ, Bruno GM. Psychological factors influencing
chronic phantom limb pain: an analysis of the literature. Pain 1987;28:285-
95.
(210) Ephraim PL, Wegener ST, MacKenzie EJ, Dillingham TR, Pezzin LE.
Phantom pain, residual limb pain, and back pain in amputees: results of a
national survey. Arch Phys Med Rehabil 2005;86:1910-9.
183
(211) Hanley MA, Jensen MP, Smith DG, Ehde DM, Edwards WT, Robinson
LR. Preamputation pain and acute pain predict chronic pain after lower
extremity amputation. J Pain 2007;8:102-9.
(212) Sherman RA, Sherman CJ, Gall N. A survey of current phantom limb
treatments in the United States. Pain 1980;8:85-99.
(213) Dworkin RH, O'Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen
TS, et al. Pharmacologic management of neuropathic pain: evidence-based
recommendations. Pain 2007;132:237-51.
(214) Moulin DE, Clark AJ, Gilron I, Ware MA, Watson CP, Sessle BJ, et al.
Pharmacological management of chronic neuropathic pain - consensus
statement and guidelines from the Canadian Pain Society. Pain Res Manag
2007;12:13-21.
(215) Attal N, Cruccu G, HaanpaaM, Hansson P, Jensen TS, Nurmikko T, et al.
EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J
Neurol 2006;13:1153-69.
(216) Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for
neuropathic pain treatment: an evidence based proposal. Pain
2005;118:289-305.
(217) Cook RJ, Sackett DL. The number needed to treat: a clinically useful
measure of treatment effect. British Medical Journal 1995;310:452-454.
(218) Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of
neuropathic pain: an update and effect related to mechanism of drug action.
Pain 1999 Dec;83(3):389-400.
(219) Backonja M. Anticonvulsants and antiarrhythmics in the treatment of
neuropathic pain. In: Hansson PT, Fields HL, Hill RG, Marchettini P,
editors. Neuropathic pain: Pathophysiology and Treatment.Seattle: IASP
Press; 2001. p. 185-202.
(220) Urban BJ, France RD, Steinberger EK, Scott DL, Maltbie AA. Long-term
use of narcotic/antidepressant medication in the management of phantom
limb pain. Pain 1986;24:191-6.
(221) Jacobson L, Chabal C, Brody MC. Relief ofpersistent postamputation
stump and phantom limb pain with intrathecal fentanyl. Pain 1989;37:317-
22.
(222) Jacobson L, Chabal C. Prolonged relief of acute postamputation phantom
limb pain with intrathecal fentanyl and epidural morphine. Anesthesiology
1989;71:984-5.
(223) Stannard CF, Porter GE. Ketamine hydrochloride in the treatment of
phantom limb pain. Pain 1993;54:227-30.
184
(224) Knox DJ, Mcleod BJ, Goucke CR. Acute phantom limb pain controlled by
ketamine. Anaesth Intens Care 1995;23:620-2.
(225) Omote K, Ohmori H, Kawamata M, Matsumoto M, Namiki A. Intrathecal
buprenorphine in the treatment ofphantom limb pain. Anesth Analg
1995;80:1030-2.
(226) Nikolajsen L, Hansen PO, Jensen TS. Oral ketamine therapy in the
treatment of postamputation stump pain. Acta Anaesthesiol Scand
1997;41:427-9.
(227) Robinson LR, Czerniecki JM, Ehde DM, Edwards WT, Judish DA,
Goldberg ML, et al. Trial of amitriptyline for relief of pain in amputees:
results of a randomized controlled study. Arch Phys Med Rehabil
2004;85:1-6.
(228) Bone M, Critchley P, Buggy DJ. Gabapentin in postamputation phantom
limb pain: a randomized, double-blind, placebo-controlled, cross-over
study. Reg Anesth Pain Med 2002;27:481-6.
(229) Kissin I. Preemptive analgesia. Anesthesiology 2000;93:1138-43.
(230) MacRae WA. Chronic post-surgical pain: 10 years on. Br J Anaesth
2008;101:77-86.
(231) Nikolajsen L, Finnerup NB, Kramp S, Vimtrup AS, Keller J, Jensen TS. A
randomized study of the effects of gabapentin on postamputation pain.
Anesthesiology 2006;105:1008-15.
(232) Pinzur MS, Garla PGN, Pluth T, Vrbos L. Continuous postperative infusion
of a regional anesthetic after amputation of the lower extremity. The
Journal ofBone and Joint Surgery 1996;78:1501-5. i
(233) Lambert A, Dashfield A, Cosgrove C, Wilkins D, Walker A, Ashley S.
Randomized prospective study comparing preoperative epidural and
intraoperative perineural analgesia for the prevention of postoperative
stump and phantom limb pain following major amputation. Reg Anesth
Pain Med 2001;26:316-21.
(234) Schley M, Topfner S, Wiech K, Schaller HE, Konrad CJ, Schmelz M, et al.
Continuous brachial plexus blockade in combination with the NMDA
receptor antagonist memantine prevents phantom pain in acute traumatic
upper limb amputees. Eur J Pain 2007; 11:299-308.
(235) Bach S, Noreng MF, Tjellden NU. Phantom limb pain in amputees during
the first 12 months followinglimb amputation, after preoperative lumbar
epidural blockade. Pain 1988;33:297-301.
185
(236) Nikolajsen L, Ilkjaer S, Christensen JH, Kroner K, Jensen TS. Randomised
trial of epidural bupivacaine and morphine in prevention of stump and
phantom pain in lower-limb amputation. Lancet 1997;350:1353-7.
(237) Fischer A, Meller Y. Continuous postoperative regional analgesia by nerve
sheath block for amputation surgery- A pilot study. Anaesthesia and
Analgesia 1991;72:300-3.
(238) Elizaga AM, Smith DG, Sharar SR, EdwardsWT, Hansen ST. Continuous
regional analgesia by intraneural block: Effect on postoperative opioid
requirements and phantom limb pain following amputation. Journal of
Rehabilitation Research and Development 1994;31:179-87.
(239) Jahangiri M, Jayatunga AP, Bradley JW, Dark CH. Prevention ofphantom
pain after major lower limb amputation by epidural infusion of
diamorphine, clonidine and bupivacaine. Ann R Coll Surg Engl
1994;76:324-6.
(240) Katsuly-Liapis I, Georgakis P, Tierry C. Pre-emptive extradural analgesia
reduces the incidence ofphantom pain in lower limb amputees. British
Journal ofAnaesthesia 1996;76, Supplement 2:125.
(241) Hayes C, Armstrong-Brown A, Burstal R. Perioperative intravenous
ketamine infusion for the prevention of persistent post-amputation pain: a
randomized, controlled trial. Anaesth Intensive Care 2004;32:330-8.
(242) Randall LO, Selitto JJ. A method for measurement of analgesic activity on
inflamed tissue. Arch Int Pharmacodyn Ther 1957; 111:409-19.
(243) Porro CA, Carli G. Immobilization and restraint effects on pain reactions in
animals. Pain 1988;32:289-307.
(244) Rolke R, Magerl W, Campbell KA, Schalber C, Caspari S, Birklein F, et al.
Quantitative sensory testing: a comprehensive protocol for clinical trials.
Eur J Pain 2006;10:77-88.
(245) Hargreaves K, Dubner R, Brown F, Flores C, Joris J. A new and sensitive
method for measuring thermal nociception in cutaneous hyperalgesia. Pain
1988;32:77-88.
(246) Proudfoot CJ, Garry EM, Cottrell DF, Rosie R, Anderson H, Robertson
DC, et al. Analgesia mediated by the TRPM8 cold receptor in chronic
neuropathic pain. Curr Biol 2006;16:1591-605.
(247) Xing H, Chen M, Ling J, Tan W, Gu JG. TRPM8 mechanism of cold
allodynia after chronic nerve injury. J Neurosci 2007 ;27:13680-90.
(248) Dray A. Neuropathic pain: emerging treatments. Br J Anaesth 2008; 101:48-
58.
186
(249) Allchorne AJ, Broom DC, Woolf CJ. Detection of cold pain, cold allodynia
and cold hyperalgesia in freely behaving rats. Mol Pain 2005; 1:36.
(250) Moss A, Blackburn-Munro G, Garry EM, Blakemore JA, Dickinson T,
Rosie R, et al. A role of the ubiquitin-proteasome system in neuropathic
pain. JNeurosci 2002 ;22:1363-72.
(251) Ramos-Vara JA. Technical aspects of immunohistochemistry. Vet Pathol
2005;42:405-26.
(252) Lequin RM. Enzyme immunoassay (EIA)/enzyme-linked immunosorbent
assay (ELISA). Clin Chem 2005;51:2415-8.
(253) Turk DC, Dworkin RH, Allen RR, Bellamy N, Brandenburg N, Carr DB, et
al. Core outcome domains for chronic pain clinical trials: IMMPACT
recommendations. Pain 2003;106:337-45.
(254) McQuay H. Consensus on outcome measures for chronic pain trials. Pain
2005;113:1-2.
(255) Gagliese L, Weizblit N, Ellis W, Chan VW. The measurement of
postoperative pain: a comparison of intensity scales in younger and older
surgical patients. Pain 2005;117:412-20.
(256) Breivik EK, Bjornsson GA, Skovlund E. A comparison of pain rating scales
by sampling from clinical trial data. Clin J Pain 2000;16:22-8.
(257) Campbell WI. Practical methods for pain intensity measurements. In:
Breivik H, Campbell WI, Eccleston C, editors. Practical Applications and
Procedures. First ed. London: Arnold; 2003. p. 15-26.
(258) Breivik H, Borchgrevink PC, Allen SM, Rosseland LA, Romundstad L,
Hals EK, et al. Assessment ofpain. Br J Anaesth 2008;101:17-24.
(259) Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz
NP, et al. Core outcome measures for chronic pain clinical trials:
IMMPACT recommendations. Pain 2005; 113:9-19.
(260) Melzack R. The short-form McGill Pain Questionnaire. Pain 1987;30:191-
7.
(261) Melzack R. The McGill Pain Questionnaire: major properties and scoring
methods. Pain 1975;1:277-99.
(262) Turk DC. Clinical effectiveness and cost-effectiveness of treatments for
patients with chronic pain. Clin J Pain 2002;18:355-65.
(263) Kerns RD, Turk DC, Rudy TE. The West Haven-Yale Multidimensional
Pain Inventory (WHYMPI). Pain 1985;23:345-56.
187
(264) Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain
Inventory. Ann Acad Med Singapore 1994;23:129-38.
(265) Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for
measuring depression. Arch Gen Psychiatry 1961;4:561-71.
(266) McNair DM, Lorr D, Droppleman LF. Profile of Mood States. 1971. San
Diego, CA, Educational and Industrial Testing Service.
(267) Bennett M. The LANSS Pain Scale: the Leeds assessment of neuropathic
symptoms and signs. Pain 2001;92:147-57.
(268) Bouhassira D, Attal N, Alchaar H, Boureau F, Brochet B, Bruxelle J, et al.
Comparison ofpain syndromes associated with nervous or somatic lesions
and development of a new neuropathic pain diagnostic questionnaire
(DN4). Pain 2005;114:29-36.
(269) Bennett MI, Attal N, BackonjaMM, Baron R, Bouhassira D, Freynhagen
R, et al. Using screening tools to identify neuropathic pain. Pain
2007;127:199-203.
(270) Galer BS, Jensen MP. Development and preliminary validation of a pain
measure specific to neuropathic pain: The neuropathic pain scale.
Neurology 1997;48:332-338.
(271) Bouhassira D, Attal N, Fermanian J, Alchaar H, Gautron M, Masquelier E,
et al. Development and validation of the Neuropathic Pain Symptom
Inventory. Pain 2004;108:248-57.
(272) Turk DC, Rudy TE, Salovey P. The McGill Pain Questionnaire
reconsidered: confirming the factor structure and examining appropriate
uses. Pain 1985;21:385-97.
(273) Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta
Psychiatr Scand 1983;67:361-70.
(274) Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital
Anxiety and Depression Scale. An updated literature review. J Psychosom
Res 2002;52:69-77.
(275) Keeley P, Creed F, Tomenson B, Todd C, Borglin G, Dickens C.
Psychosocial predictors of health-related quality of life and health service
utilisation in people with chronic low back pain. Pain 2008;135:142-50.
(276) Pallant JF, Bailey CM. Assessment of the structure of the Hospital Anxiety
and Depression Scale in musculoskeletal patients. Health Qual Life
Outcomes 2005;3:82.
188
(277) Desmond DM, MacLachlan M. Affective distress and amputation-related
pain among older men with long-term, traumatic limb amputations. J Pain
Symptom Manage 2006;31:362-8.
(278) Fishbain DA, Lewis JE, Cutler R, Cole B, RosomoffHL, Rosomoff RS.
Can the neuropathic pain scale discriminate between non-neuropathic and
neuropathic pain? Pain Med 2008;9:149-60.
(279) WoolfCJ, Bennett GJ, Doherty M, Dubner R, Kidd B, Koltzenburg M, et
al. Towards a mechanism-based classification ofpain? Pain 1998;77:227-9.
(280) Gracely RH. Quantitative Sensory Testing. In: Dostrovsky JO, Carr DB,
Koltzenburg M, editors. Proceedings of the 10th World Congress on
Pain.Seattle: IASP Press; 2003. p. 589-600.
(281) Rolke R, Baron R, Maier C, Tolle TR, Treede RD, Beyer A, et al.
Quantitative sensory testing in the German Research Network on
Neuropathic Pain (DFNS): standardized protocol and reference values. Pain
2006;123:231-43.
(282) Park KM, Max MB, Robinovitz E, Gracely RH, Bennett GJ. Effects of
intravenous ketamine, alfentanil, or placebo on pain, pinprick hyperalgesia,
and allodynia produced by intradermal capsaicin in human subjects. Pain
1995;63:163-72.
(283) Stubhaug A, Breivik H, Eide PK, Kreunen M, Foss A. Mapping of punctate
hyperalgesia around surgical incision demonstrates that ketamine is a
powerful suppressor of central sensitization to pain following surgery. Acta
Anaesthesiol Scand 1997;41:1132.
(284) Lang PM, Schober GM, Rolke R, Wagner S, Hilge R, Offenbacher M, et al.
Sensory neuropathy and signs of central sensitization in patients with
peripheral arterial disease. Pain 2006;124:190-200.
(285) Nikolajsen L, Ilkjaer S, Jensen TS. Effect of preoperative extradural
bupivacaine and morphine on stump sensation in lower limb amputees.
British Journal of Anaesthesia 1998;81:348-54.
(286) Hunter JP, Katz J, Davis KD. Dissociation ofphantom limb phenomena
from stump tactile spatial acuity and sensory thresholds. Brain
2005;128:308-20.
(287) Kvamstrom A, Karlsten R, Quiding H, Emanuelsson BM, Gordh T. The
effectiveness of intravenous ketamine and lidocaine on peripheral
neuropathic pain. Acta Anaesthesiol Scand 2003;47:868-77.
(288) Herrmann DN, Pannoni V, Barbano RL, Pennella-Vaughan J, Dworkin RH.
Skin biopsy and quantitative sensory testing do not predict response to
lidocaine patch in painful neuropathies. Muscle Nerve 2006;33:42-8.
189
(289) Holdcroft A, Power I. Recent developments: management ofpain. BMJ
2003;326:635-9.
(290) Kohr G. NMDA receptor function: subunit composition versus spatial
distribution. Cell Tissue Res 2006;326:439-46.
(291) Daoudal G, Debanne D. Long-term plasticity of intrinsic excitability:
learning rules and mechanisms. Learn Mem 2003;10:456-65.
(292) Coderre TJ, Katz J, Vaccarino AL, Melzack R. Contribution of central
neuroplasticity to pathological pain: review of clinical and experimental
evidence. Pain 1993;52:259-85.
(293) Dickenson AH, Sullivan AF. Evidence for a role of the NMDA receptor in
the frequency dependent potentiation of deep rat dorsal horn nociceptive
neurones following C fibre stimulation. Neuropharmacology 1987;26:1235-
8.
(294) Bleakman D, Alt A, Nisenbaum ES. Glutamate receptors and pain. Semin
Cell Dev Biol 2006;17:592-604.
(295) Landmark CJ. Targets for antiepileptic drugs in the synapse. Med Sci Monit
2007 ;13:RA1-RA7.
(296) Hynd MR, Scott HL, Dodd PR. Glutamate-mediated excitotoxicity and
neurodegeneration in Alzheimer's disease. Neurochem Int 2004;45:583-95.
(297) Spedding M, Neau I, Harsing L. Brain plasticity and pathology in
psychiatric disease: sites of action for potential therapy. Curr Opin
Pharmacol 2003;3:33-40.
(298) Sang CN. NMDA-receptor antagonists in neuropathic pain: experimental
methods to clinical trials. J Pain Symptom Manage 2000;19(1 Suppl):S21-
S25.
(299) Chen HS, Lipton SA. The chemical biology of clinically tolerated NMDA
receptor antagonists. J Neurochem 2006;97:1611-26.
(300) Tzschentke TM. Glutamatergic mechanisms in different disease states:
overview and therapeutical implications - an introduction. Amino Acids
2002;23:147-52.
(301) Hewitt DJ. The use ofNMDA-receptor antagonists in the treatment of
chronic pain. Clin J Pain 2000; 16(2 Suppl):S73-S79.
(302) Wang CX, Shuaib A. NMDA/NR2B selective antagonists in the treatment
of ischemic brain injury. Curr Drug Targets CNS Neurol Disord
2005;4:143-51.
190
(303) Furukawa H, Singh SK, Mancusso R, Gouaux E. Subunit arrangement and
function in NMDA receptors. Nature 2005;438:185-92.
(304) Yao Y, Mayer ML. Characterization of a soluble ligand binding domain of
the NMDA receptor regulatory subunit NR3A. J Neurosci 2006;26:4559-
66.
(305) Nagy GG, Watanabe M, Fukaya M, Todd AJ. Synaptic distribution of the
NR1, NR2A and NR2B subunits of the N-methyl-d-aspartate receptor in the
rat lumbar spinal cord revealed with an antigen-unmasking technique. Eur J
Neurosci 2004;20:3301-12.
(306) Monyer H, Bumashev N, Laurie DJ, Sakmann B, Seeburg PH.
Developmental and regional expression in the rat brain and functional
properties of four NMDA receptors. Neuron 1994;12:529-40.
(307) Laurie DJ, Bartke I, Schoepfer R, Naujoks K, Seeburg PH. Regional,
developmental and interspecies expression of the four NMDAR2 subunits,
examined using monoclonal antibodies. Brain Res Mol Brain Res
1997;51:23-32.
(308) Marvizon JC, McRoberts JA, Ennes HS, Song B, Wang X, Jinton L, et al.
Two N-methyl-D-aspartate receptors in rat dorsal root ganglia with
different subunit composition and localization. J Comp Neurol
2002;446:325-41.
(309) Li J, McRoberts JA, Nie J, Ennes HS, Mayer EA. Electrophysiological
characterization ofN-methyl-D-aspartate receptors in rat dorsal root ganglia
neurons. Pain 2004;109:443-52.
(310) Hizue M, Pang CH, Yokoyama M. Involvement ofN-methyl-D-aspartate-
type glutamate receptor epsilonl and epsilon4 subunits in tonic <
inflammatory pain and neuropathic pain. Neuroreport 2005;16:1667-70.
(311) Inoue M, Mishina M, Ueda H. Locus-specific rescue of GluRepsilonl
NMDA receptors in mutant mice identifies the brain regions important for
morphine tolerance and dependence. J Neurosci 2003;23:6529-36.
(312) Mallon AP, Auberson YP, Stone TW. Selective subunit antagonists suggest
an inhibitory relationship between NR2B and NR2A-subunit containing N-
methyl-D: -aspartate receptors in hippocampal slices. Exp Brain Res
2005;162:374-83.
(313) Tolle TR, Berthele A, Zieglgansberger W, Seeburg PH, Wisden W. The
differential expression of 16 NMDA and non-NMDA receptor subunits in
the rat spinal cord and in the periaqueductal gray. The Journal of
Neuroscience 1993;13:5009-28.
191
(314) Luque JM, Bleuel Z, Malherbe P, Richards JG. Alternatively spliced
isoforms of the N-methyl-D-aspartate receptor subunit 1 are differentially
distributed within the rat spinal cord. Neuroscience 1994;63:629-35.
(315) Petralia RS, Wang YX, Wenthold RJ. The NMDA receptor subunits NR2A
and NR2B show histological and ultrastructural localization patterns similar
to those ofNR1. J Neurosci 1994;14:6102-20.
(316) O'Donnell R, Molon-Noblot S, Laroque P, Rigby M, Smith D. The
ultrastructural localisation of the N-methyl-D-aspartate NR2B receptor
subunit in rat lumbar spinal cord. Neurosci Lett 2004;371:24-9.
(317) Christie JM, Jane DE, Monaghan DT. Native N-methyl-D-aspartate
receptors containing NR2A and NR2B subunits have pharmacologically
distinct competitive antagonist binding sites. J Pharmacol Exp Ther
2000;292:1169-74.
(318) Erreger K, Traynelis SF. Zinc inhibition of rat NR1/NR2A N-methyl-D-
aspartate receptors. J Physiol 2008;586:763-78.
(319) Wu LJ, Xu H, Ren M, Cao X, Zhuo M. Pharmacological isolation of
postsynaptic currents mediated by NR2A- and NR2B-containing NMDA
receptors in the anterior cingulate cortex. Mol Pain 2007;3:11
(320) Paoletti P, Neyton J. NMDA receptor subunits: function and pharmacology.
Curr Opin Pharmacol 2007;7:39-47.
(321) Merchant RE, Bullock MR, Carmack CA, Shah AK, Wilner KD, Ko G, et
al. A double-blind, placebo-controlled study of the safety, tolerability and
pharmacokinetics ofCP-101,606 in patients with a mild or moderate
traumatic brain injury. Ann N Y Acad Sci 1999;890:42-50.
(322) Bullock MR, Merchant RE, Carmack CA, Doppenberg E, Shah AK, Wilner
KD, et al. An open-label study ofCP-101,606 in subjects with a severe
traumatic head injury or spontaneous intracerebral hemorrhage. Ann N Y
Acad Sci 1999;890:51-8.
(323) Yurkewicz L, Weaver J, Bullock MR, Marshall LF. The effect of the
selective NMDA receptor antagonist traxoprodil in the treatment of
traumatic brain injury. J Neurotrauma 2005;22:1428-43.
(324) Gallagher MJ, Huang H, Lynch DR. Modulation of the N-methyl-D-
aspartate receptor by haloperidol: NR2B-specific interactions. J Neurochem
1998;70:2120-8.
(325) Olverman HJ, Jones AW, Watkins JC. L-glutamate has higher affinity than
other amino acids for [3HJ-D-AP5 binding sites in rat brain membranes.
Nature 1984;307:460-2.
192
(326) Davies J, Evans RH, Herrling PL, Jones AW, Olverman HJ, Pook P, et al.
CPP, a new potent and selective NMDA antagonist. Depression of central
neuron responses, affinity for [3HJD-AP5 binding sites on brain membranes
and anticonvulsant activity. Brain Res 1986;382:169-73.
(327) Wong EH, Kemp JA, Priestley T, Knight AR, Woodruff GN, Iversen LL.
The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist.
Proc Natl Acad Sci U S A 1986;83:7104-8.
(328) Williams K. Ifenprodil discriminates subtypes of the N-methyl-D-aspartate
receptor: selectivity and mechanisms at recombinant heteromeric receptors.
Mol Pharmacol 1993;44:851-9.
(329) Grimwood S, Richards P, Murray F, Harrison N, Wingrove PB, Hutson PH.
Characterisation ofN-methyl-D-aspartate receptor-specific [(3)H]Ifenprodil
binding to recombinant human NRla/NR2B receptors compared with
native receptors in rodent brain membranes. J Neurochem 2000;75:2455-
63.
(330) Brimecombe JC, Boeckman FA, Aizenman E. Functional consequences of
NR2 subunit composition in single recombinant N-methyl-D-aspartate
receptors. Proc Natl Acad Sci USA 1997;94:11019-24.
(331) Miyamoto H, Saito Y, Kirihara Y, Hara K, Sakura S, Kosaka Y. Spinal
coadministration of ketamine reduces the development of tolerance to
visceral as well as somatic antinociception during spinal morphine infusion.
Anesth Analg 2000;90:136-41.
(332) Laird JM, Bennett GJ. An electrophysiological study of dorsal horn neurons
in the spinal cord of rats with an experimental peripheral neuropathy. J
Neurophysiol 1993;69:2072-85.
(333) Takaishi K, Eisele JH, Jr., Carstens E. Behavioral and electrophysiological
assessment of hyperalgesia and changes in dorsal horn responses following
partial sciatic nerve ligation in rats. Pain 1996;66:297-306.
(334) Chapman V, Suzuki R, Dickenson AH. Electrophysiological
characterization of spinal neuronal response properties in anaesthetized rats
after ligation of spinal nerves L5-L6. J Physiol 1998;507:881-94.
(335) Mao J, Price DD, Hayes RL, Lu J, Mayer DJ. Differential roles ofNMDA
and non-NMDA activation in induction and maintenance of thermal
hyperalgesia in rats with painful peripheral mononeuropathy. Brain
Research 1992;598:271-8.
(336) Wagner R, Deleo JA. Pre-emptive dynorphin and N-methyl-D-aspartate
glutamate receptor antagonism alters spinal immunocytochemistry but not
allodynia following complete peripheral nerve injury. Neuroscience
1996;72:527-34.
193
(337) Tal M, Bennett GJ. Extra-territorial pain in rats with a peripheral
mononeuropathy: mechano-hyperalgesia and mechano-allodynia in the
territory of an uninjured nerve. Pain 1994;57:375-82.
(338) Wegert S, Ossipov MH, Nichols ML, Bian D, Vanderah TW, Malan TP, Jr.,
et al. Differential activities of intrathecal MK-801 or morphine to alter
responses to thermal and mechanical stimuli in normal or nerve-injured
rats. Pain 1997;71:57-64.
(339) Coggeshall RE, Dougherty PM, Pover CM, Carlton SM. Is large myelinated
fiber loss associated with hyperalgesia in a model of experimental
peripheral neuropathy in the rat? Pain 1993;52:233-42.
(340) Shim B, Kim DW, Kim BH, Nam TS, Leem JW, Chung JM. Mechanical
and heat sensitization of cutaneous nociceptors in rats with experimental
peripheral neuropathy. Neuroscience 2005;132:193-201.
(341) Caterina MJ, SchumacherMA, Tominaga M, Rosen TA, Levine JD, Julius
D. The capsaicin receptor: a heat-activated ion channel in the pain pathway.
Nature 1997;389:816-24.
(342) Hwang SJ, Burette A, Rustioni A, Valtschanoff JG. Vanilloid receptor
VR1-positive primary afferents are glutamatergic and contact spinal
neurons that co-express neurokinin receptor NK1 and glutamate receptors. J
Neurocytol 2004;33:321-9.
(343) Hudson LJ, Bevan S, Wotherspoon G, Gentry C, Fox A, Winter J. VR1
protein expression increases in undamaged DRG neurons after partial nerve
injury. Eur J Neurosci 200113:2105-14.
(344) Roh DH, Kim HW, Yoon SY, Seo HS, Kwon YB, Han HJ, et al. Depletion
of capsaicin sensitive afferents prevents lamina-dependent increases in
spinal N-methyl-D-aspartate receptor subunit 1 expression and
phosphorylation associated with thermal hyperalgesia in neuropathic rats.
Eur J Pain 2008;12:552-63.
(345) McCartney CJ, Sinha A, Katz J. A qualitative systematic review of the role
ofN-methyl-D-aspartate receptor antagonists in preventive analgesia.
Anesth Analg 2004;98:1385-400.
(346) Siegan JB, Sagen J. Attenuation of NMDA-induced spinal hypersensitivity
by adrenal medullary transplants. Brain Res 1995;680:88-98.
(347) Petrenko AB, Yamakura T, Baba H, Sakimura K. Unaltered pain-related
behavior in mice lacking NMDA receptor GluRepsilon 1 subunit. Neurosci
Res 2003;46:199-204.
(348) Portera-Cailliau C, Price DL, Martin LJ. N-methyl-D-aspartate receptor
proteins NR2A and NR2B are differentially distributed in the developing
194
rat central nervous system as revealed by subunit-speciflc antibodies. J
Neurochem 1996;66:692-700.
(349) Ma QP, Hargreaves RJ. Localization ofN-methyl-D-aspartate NR2B
subunits on primary sensory neurons that give rise to small-caliber sciatic
nerve fibers in rats. Neuroscience 2000;101:699-707.
(350) Momiyama A. Distinct synaptic and extrasynaptic NMDA receptors
identified in dorsal horn neurones of the adult rat spinal cord. Journal of
Physiology 2000;523:621-8.
(351) Taniguchi K, Shinjo K, Mizutani M, Shimada K, Ishikawa T, Menniti FS,
et al. Antinociceptive activity ofCP-101,606, an NMDA receptor NR2B
subunit antagonist. Br J Pharmacol 1997;122:809-12.
(352) Joy CB, Adams CE, Lawrie SM. Haloperidol versus placebo for
schizophrenia. Cochrane Database Syst Rev 2006 Oct 18;(4):CD003082.
(353) Halbert J, Crotty M, Cameron ID. Evidence for the optimal management of
acute and chronic phantom pain: a systematic review. Clin J Pain
2002;18:84-92.
(354) WoolfCJ, Mannion RJ. Neuropathic pain: aetiology, symptoms,
mechanisms, and management. Lancet 1999;353:1959-64.
(355) WoolfCJ. Somatic pain—pathogenesis and prevention. Br J Anaesth
1995;75:169-76.
(356) Melzack R, Coderre TJ, Katz J, Vaccarino AL. Central neuroplasticity and
pathological pain. Ann N Y Acad Sci 2001;933:157-74.
(357) Boswell MV, Iacono RP, Guthkelch AN. Sites of action of subarachnoid
lidocaine and tetracaine: observations with evoked potential monitoring
during spinal cord stimulator implantation. Reg Anesth 1992;17:37-42.
(358) Loughman BA, Fennelly ME, Henley M, Hall GM. The effects of differing
concentrations ofbupivacaine on the epidural somatosensory evoked
potential after posterior tibial nerve stimulation. Anesth Analg
1995;81:147-51.
(359) Munglani R, Hudspith MJ, Fleming B, Harrison S, Smith G, Bountra C, et
al. Effect of pre-emptive NMDA antagonist treatmant on long-term Fos
expression and hyperalgesia in a model of chronic neuropathic pain. Brain
Research 1999;822:210-9.
(360) Subramaniam K, Subramaniam B, Steinbrook RA. Ketamine as adjuvant
analgesic to opioids: a quantitative and qualitative systematic review.
Anesth Analg 2004;99:482-95.
195
(361) Nikolajsen L, Hansen CL, Nielsen J, Keller J, Arendt-Nielsen L, Jensen TS.
The effect of ketamine on phantom pain: a central neuropathic disorder
maintained by peripheral input. Pain 1996;67:69-77.
(362) Aulivola B, Hile CN, Hamdan AD, Sheahan MG, Veraldi JR, Skillman JJ,
et al. Major lower extremity amputation: outcome of a modem series. Arch
Surg 2004;139:395-9.
(363) Mao J, Mayer DJ. Spinal cord neuroplasticity following repeated opioid
exposure and its relation to pathological pain. Ann N Y Acad Sci
2001;933:175-84.
(364) Nikolajsen L, Ilkjaer S, Jensen TS. Relationship between mechanical
sensitivity and postamputation pain: a prospective study. European Journal
of Pain 2000;4:327-4.
(365) Bromage PR. A comparison of the hydrochloride and carbon dioxide salts
of lidocaine and prilocaine in epidural analgesia. Acta Anaesthesiol Scand
Suppl 1965;16:55-69.
(366) Wilkins KL, McGrath PJ, Finley GA, Katz J. Prospective diary study of
nonpainful and painful phantom sensations in a preselected sample of child
and adolescent amputees reporting phantom limbs. Clin J Pain
2004;20:293-301.
(367) Davies SN, Lodge D. Evidence for involvement ofN-methylaspartate
receptors in 'wind-up' of class 2 neurones in the dorsal hom of the rat. Brain
Research 1987;424:402-6.
(368) Torsney C, MacDermott AB. Disinhibition opens the gate to pathological
pain signaling in superficial neurokinin 1 receptor-expressing neurons in rat
spinal cord. J Neurosci 2006;26:1833-43.
(369) Li S, Stys PK. Mechanisms of ionotropic glutamate receptor-mediated
excitotoxicity in isolated spinal cord white matter. J Neurosci
2000;20:1190-8.
(370) Larbig W, Montoya P, Flor H, Bilow H, Weller S, Birbaumer N. Evidence
for a change in neural processing in phantom limb pain patients. Pain
1996;67:275-83.
(371) Brock-Utne JG, Kallichurum S, Mankowitz E, Maharaj RJ, Downing JW.
Intrathecal ketamine with preservative - histological effects on spinal nerve
roots of baboons. S Afr Med J 1982;61:440-1.
(372) Borgbjerg FM, Svensson BA, Frigast C, Gordh T, Jr. Histopathology after
repeated intrathecal injections of preservative-free ketamine in the rabbit: a
light and electron microscopic examination. Anesth Analg 1994;79:105-11.
196
(373) Malinovsky JM, Lepage JY, Cozian A, Mussini JM, PinaudtM, Souron R.
Is ketamine or its preservative responsible for neurotoxicity in the rabbit?
Anesthesiology 1993;78:109-15.
(374) Olney JW, Labruyere J, Price MT. Pathological changes induced in
cerebrocortical neurons by phencyclidine and related drugs. Science
1989;244:1360-2.
(375) Ikonomidou C, Bosch F, Miksa M, Bittigau P, Vockler J, Dikranian K, et
al. Blockade ofNMDA receptors and apoptotic neurodegeneration in the
developing brain. Science 1999;283:70-4.
(376) de LJ, Beggs S, Howard R. Neural toxicity of ketamine and othe NMDA
antagonists. Pain 2000;88:311-2.
(377) Dalens B. Some current controversies in paediatric regional anaesthesia.
Curr Opin Anaesthesiol 2006;19:301-8.
(378) Acosta A, Gomar C, Bombi JA, Graca DL, Garrido M, Krauspenhar C.
Ultrastructure of canine meninges after repeated epidural injection of S(+)-
ketamine. Reg Anesth Pain Med 2006;31:438-44.
(379) Lilja J, Endo T, Hofstetter C, Westman E, Young J, Olson L, et al. Blood
oxygenation level-dependent visualization of synaptic relay stations of
sensory pathways along the neuroaxis in response to graded sensory
stimulation of a limb. J Neurosci 2006;26:6330-6.
(380) Christoph T, Schiene K, EnglbergerW, Parsons CG, Chizh BA. The
antiallodynic effect ofNMDA antagonists in neuropathic pain outlasts the
duration of the in vivo NMDA antagonism. Neuropharmacology
2006;51:12-7.
I
(381) Clements JA, Nimmo WS, Grant IS. Bioavailability, pharmacokinetics, and
analgesic activity of ketamine in humans. J Pharm Sci 1982;71:539-42.
(382) Eichenberger U, Neff F, Sveticic G, Bjorgo S, Petersen-Felix S, rendt-
Nielsen L, et al. Chronic phantom limb pain: the effects of calcitonin,
ketamine, and their combination on pain and sensory thresholds. Anesth
Analg 2008;106:1265-73.
(383) Wilson JA, Garry EM, Anderson HA, Rosie R, Colvin LA, Mitchell R, et
al. NMDA receptor antagonist treatment at the time of nerve injury prevents
injury-induced changes in spinal NR1 and NR2B subunit expression and
increases the sensitivity of residual pain behaviours to subsequently
administered NMDA receptor antagonists. Pain 2005 Oct;l 17:421-32.
(384) Garry EM, Fleetwood-Walker SM. Organizing pains. Trends Neurosci
2004;27:292-4.
197
(385) Duedahl TH, Romsing J, Moiniche S, Dahl JB. A qualitative systematic
review of peri-operative dextromethorphan in post-operative pain. Acta
Anaesthesiol Scand 2006;50:1-13.
(386) Ozyalcin NS, Yucel A, Camlica H, Dereli N, Andersen OK, Arendt-Nielsen
L. Effect of pre-emptive ketamine on sensory changes and postoperative
pain after thoracotomy: comparison of epidural and intramuscular routes.
Br J Anaesth 2004;93:356-61.
(387) Machin P, de CWA. Stiff upper lip: coping strategies ofWorld War II
veterans with phantom limb pain. Clin J Pain 1998;14:290-4.
(388) Bacon NM, Bacon SF, Atkinson JH, SlaterMA, Patterson TL, Grant I, et
al. Somatization symptoms in chronic low back pain patients. Psychosom
Med 1994;56:118-27.
(389) Kudoh A, Takahira Y, Katagai H, Takazawa T. Small-dose ketamine
improves the postoperative state of depressed patients. Anesth Analg
2002;95:114-8.
(390) Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS,
et al. Antidepressant effects of ketamine in depressed patients. Biol
Psychiatry 2000;47:351-4.
(391) Zarate CA, Jr., Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh
DA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in
treatment-resistant major depression. Arch Gen Psychiatry 2006;63:856-64.
(392) Sprenger T, Valet M, Woltmann R, Zimmer C, Freynhagen R, Kochs EF, et
al. Imaging pain modulation by subanesthetic S-(+)-ketamine. Anesth
Analg 2006;103:729-37.
(393) Goodman WK. Selecting pharmacotherapy for generalized anxiety
disorder. J Clin Psychiatry 2004;65 Suppl 13:8-13.
(394) Zarate CA, Jr., Du J, Quiroz J, Gray NA, DenicoffKD, Singh J, et al.
Regulation of cellular plasticity cascades in the pathophysiology and
treatment ofmood disorders: role of the glutamatergic system. Ann N Y
Acad Sci 2003;1003:273-91.
(395) Kronenberg RH. Ketamine as an analgesic: parenteral, oral, rectal,
subcutaneous, transdermal and intranasal administration. J Pain Palliat Care
Pharmacother 2002;16:27-35.
(396) Swanson LW. Mapping the human brain: past, present, and future. Trends
Neurosci 1995;18:471-4.
(397) Backonja MM, Stacey B. Neuropathic pain symptoms relative to overall
pain rating. J Pain 2004;5:491-7.
198
(398) Colpaert FC, Tarayre JP, Alliaga M, Bruins Slot LA, Attal N, Koek W.
Opiate self-administration as a measure of chronic nociceptive pain in
arthritic rats. Pain 2001;91:33-45.
(399) Kontinen VK, Kauppila T, Paananen S, Pertovaara A, Kalso E. Behavioural
measures of depression and anxiety in rats with spinal nerve ligation-
induced neuropathy. Pain 1999;80:341-6.
(400) Max MB. Is mechanism-based pain treatment attainable? Clinical trial
issues. J Pain 2000 Sep; 1(3 Suppl):2-9.
(401) Taylor TJ, Diringer K, Russell T, Venkatakrishnan K, Wilner K,
Crownover PH, et al. Absolute oral bioavailability of traxoprodil in
cytochrome P450 2D6 extensive and poor metabolisers. Clin
Pharmacokinet 2006;45:989-l 001.









Height: cm Weight: Kg
Leg to be amputated: L / R
Do you have pain in the limb? Y / N
Where is the pain in the limb?
Verbal description of the pain
VAS score:
a) How long have you had pain in the limb?





Do you get pain in the stump? Y / N
If so, how often does it occur?
i. Few times per hour
ii. Few times per day
iii. Few times per week
iv. Few times per month
v. Few times per year







VAS score for stump pain
Treatments or medicines for pain in your stump? Y / N
If so, give details
Do you have sensations from the part of the limb that has been amputated, i.e.
phantom sensations (not pain)
If these sensations were painful, how strong would you say that these were on a
scale of 0-10?
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Do you have pain in the any pain in the part of the limb that has been removed?
If so, how often does it occur?
i. Few times per hour
ii. Few times per day
iii. Few times per week
iv. Few times per month
v. Few times per year






















From which part of the phantom do these pains seem to come from?
What do they feel like?
VAS score worst pain :
VAS score least pain :
Vas score usual pain :
Have you seen a doctor regarding your pain? Y / N
What treatment did you receive
Was it successful Y / N
202
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Abstract
Spinal NMDA receptors (NMDA R) are important in neuropathic sensitisation and acute administration of antagonists can provide
temporary attenuation of sensitisation. If establishment of the chronic pain state could be prevented by brief administration of such agents at
or around the time of nerve injury (pre-emptive analgesia) it might be possible to avoid many of the unacceptable side effects associated with
repeated administration of these or other antagonists. Several reports describe aspects of effective pre-emptive analgesia from NMDA R
antagonists in animal models of neuropathic pain. The first aim of the present study was to make a direct comparison of changes in
mechanical allodynia, cold allodynia and thermal hyperalgesia following nerve injury, demonstrating their increasing degree of. susceptibility
to pre-emptive NMDA R antagonist treatment. Secondly, we used immunoblotting and immunohistochemistry to investigate the effects of
nerve injury on NMDA receptor subunit expression, revealing increased expression of NR2B, but not NR2A and reduced NR1 in the
superficial dorsal horn. These changes were attenuated following NMDA receptor antagonist pre-treatment. Thirdly, we investigated the
pharmacological properties of residual mechanical allodynia and cold allodynia that remained after pre-emptive treatment and revealed a
greater sensitivity to NMDA R antagonists. These findings indicate that in addition to a marked suppression of thermal hyperalgesia and cold
allodynia, pre-emptive treatment with NMDA R antagonist causes a lasting change in spinal NMDA R complexes such that remaining
mechanical allodynia should be more effectively targeted by NMDA R antagonists.
© 2005 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.
Keywords: NMDA receptor; Pre-emptive analgesia; NR1 and NR2B subunits; Neuropathic pain; Spinal
1. Introduction
Peripheral nerve injury often results in neuropathic pain,
characterised by hyperalgesia (increased pain elicited by
noxious stimuli), allodynia (pain from normally innocuous
* Corresponding author. Tel.: +44 131 650 6091; fax: +44 131 650
6576.
E-mail address: s.m.fleetwood-walker@ed.ac.uk (S.M. Fleetwood-
Walker).
stimuli) and spontaneous pain, which are difficult to treat
(Arner and Meyerson, 1988; Galer, 1995; Kingery, 1997).
The mechanisms underlying neuropathic pain are unclear,
involving changes in afferent and central spinal sensory
relays, leading to neuronal hyperexcitability (Kohama et al.,
2000; Laird and Bennett, 1993; Takaishi et al., 1996; Woolf,
1983). Central sensitisation crucially involves spinal
A-methyl D-aspartate receptors (NMDA R) (Coderre and
Melzack, 1992; Davies and Lodge, 1987; Dickenson and
Sullivan, 1987; Leem et al., 1996; Sotgiu and Biella, 2000;
0304-3959/S20.00 © 2005 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.
doi:10.1016/j.pain.2005.07.005
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Woolf and Thompson, 1991). NMDA R antagonists reverse
neuropathic pain behaviours (Chaplan et al., 1997; Davar
et al., 1991; Garry et al., 2003; Mao et al., 1992a,b, 1993;
Tal and Bennett, 1993; Yamamoto and Yaksh, 1992), dorsal
horn neuronal hyper-responsiveness (Carlton et al., 1998;
Dougherty and Willis, 1991; Laurido et al., 2001; Leem et
al., 1996; Suzuki et al., 2001) and human neuropathic pain
(Kingery, 1997). Side effects can limit the use of NMDA R
antagonists, although ketamine is effective (De Kock et al.,
2001; Felsby et al., 1996).
In animal neuropathic pain models, spinally administered
NMDA R antagonists are effective in reducing mechanical
allodynia (Chaplan et al., 1997; Yamamoto and Yaksh,
1992) and reducing spinal neuron sensitisation (Laurido
etal., 2001).
Evaluation of the effectiveness of pre-emptive NMDA R
antagonists in preventing sensitisation following nerve
injury has been hampered since different sensory tests
were assessed in different animal models. Administration of
NMDA R antagonists (memantine, MK801 or ketamine) for
3-8 days from chronic constriction injury (CCI), reduced
development of thermal hyperalgesia (Davar et al., 1991;
Eisenberg et al., 1995; Mao et al., 1992a; 1993). Similar
observations have been made for mechanical hyperalgesia
in the spinal nerve ligation (SNL) model (Carlton and
Hargett, 1995; Smith et al., 1994). Single bolus adminis¬
tration of intrathecal or systemic ketamine or memantine
prior to SNL nerve injury attenuates mechanical allodynia
from 6 h to 2 weeks (Burton et al., 1999; Carlton and
Hargett, 1995), or delays its development for 3 days in the
CCI model (Hartrick et al., 1998). The timing of
administration is important, attenuation of mechanical
allodynia only being observed with pre-, not post-operative
MK-801 (Wei and Pertovaara, 1999).
The two principal NMDA R subunits, NR1 and NR2,
show differential expression in sensory pathways in spinal
dorsal horn (Boyce et al., 1999; Luque et al., 1994; Petralia
et al., 1994; Tolle et al., 1993; Yung, 1998). Single dorsal
horn neurons may express multiple NMDA R subunit
combinations (Karlsson et al., 2002), although the contri¬
bution made by specific subunits to neuropathic sensitis¬
ation remain unclear, despite selective NR2B antagonists
reversing neuropathic pain behaviour (Boyce et al., 1999).
We compare the effects of pre-emptive NMDA R
antagonists on different sensory reflex responses, on
expression of spinal NMDA R subunits and explore whether
there is altered sensitivity of residual pain behaviours to acute,
spinal NMDA R antagonists in a neuropathic pain model.
2. Materials and methods
2.1. Partial chronic constriction injury (pCCI) to the sciatic nerve
Experiments were carried out in accordance with the UK
Animals (Scientific Procedures) Act 1986 and follow IASP
guidelines. Adult male Wistar rats (200-350 g, Charles River,
UK) were anaesthetised with intraperitoneal (i.p.) sodium
pentobarbital (0.06 ml/100 g, Rhone Merieux, UK), supplemented
with halothane/02 (Astra-Zeneca, UK). Under aseptic conditions,
the right sciatic nerve was exposed in the region of the trifurcation
and four 4/0 chromic gut ligatures (Ethicon, Edinburgh, UK) were
tied to loosely constrict the tibial and peroneal nerves, but leaving
the smallest, sural nerve intact (ie partial chronic constriction
injury (pCCI), a variation of the chronic constriction injury, (CCI)
(Bennett and Xie, 1988), as adapted previously for partial neve
injury (Garry et al., 2003). Sham-operated animals underwent the
same surgical procedure, but no ligatures were placed around the
nerve.
2.2. Assessment of behavioural reflex responses to mechanical,
thermal and cold stimuli
Behavioural testing began prior to surgery, recommenced on
day 5 following surgery and continued every 2 or 3 days until
evidence of recovery was seen. In the experiments involving
intrathecal injections, only nerve-injured animals that showed
clear signs of thermal hyperalgesia, mechanical and cold
allodynia were used for further study. Behavioural tests were
carried out as previously described (Moss et al., 2002), using
quantified, sensory stimuli delivered to the mid-plantar glabrous
surface of the hind paw. Mechanical allodynia was assessed
using calibrated von Frey filaments (Stoelting, Wood Dale, 1L),
measuring the threshold for paw withdrawal (PWT, mN/mm2) in
response to graded mechanical stimuli. Thermal hyperalgesia
was monitored as paw withdrawal latency (PWL, s) from
noxious radiant heat (48 °C; Hargreaves' thermal device, Linton
Instruments, Diss, UK). Cold allodynia was assessed as the
suspended paw elevation time (SPET, s) in a shallow (4 °C) iced
water bath (Moss et al., 2002). The behavioural responses
obtained at each time point were calculated as the mean + SEM
for each test and data were analysed by SigmaStat software
(version 2.03). In tests of thermal hyperalgesia and cold
allodynia, the ipsilateral value was compared to the contralateral
value at each time point using a paired Student's /-test, then each
compared to pre-surgery or pre-drug baseline using a One-Way
repeated measures ANOVA, with post hoc analysis using
Dunnett's test. In tests of mechanical allodynia, the ipsilateral
value was compared to the contralateral value at each time point
using a Wilcoxon test and each compared to pre-surgery or pre-
drug baseline using a repeated measures ANOVA on ranks
(Friedman's test) with Dunn's post hoc analysis.
2.3. Pre-treatment protocol for NMDA receptor antagonists
NMDA R antagonists, memantine (15 mg/kg in 0.5 ml saline,
n= 10; Sigma-RBl, Poole, Dorset, UK), Ro 25-6891 (10 mg/kg in
0.5 ml saline with 45% hydroxypropyl-beta-cyclodextrin, n= 8;
Sigma-RBl and Tocris, Bristol, UK), or vehicle (0.9% saline,
0.5 ml, n= 10; Sigma-RBl, Poole, Dorset, UK) were administered
by intraperitoneal (i.p.) injection immediately prior to exposure of
the nerve and repeated at the end of the first day and then twice a
day for a further two days following surgery. Previous experiments
showed no discernible effect of the vehicle used with Ro 25-6891
on nociceptive reflex responses.
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Continuous lumbar intrathecal infusion of ketamine (Sigma-
RBI), was provided by an implanted osmotic minipump (Alzet,
0.25 pi per hour, total capacity 28 days, Alza Corporation, Palo
Alto, CA, USA). Ketamine was dissolved in sterile 0.9% saline, pH
7.4, to give an infusion rate of 150 pg/kg/h over 3 days. The day 3
volume of ketamine solution in the cannula was separated by a
small volume of paraffin from saline filling the remainder of the
cannula connected to the minipump. In this way, the infusion was
switched from ketamine to saline after 3 days. Under sterile
conditions, the minipump was placed between the interscapular
muscles. The silicone cannula (12 cm) tip (Degania, Merck, UK)
was passed through a small dural incision into the subarachnoid
space to lie in the lumbar L3-L6 region, as previously described
(Young et al., 1998). Only data from animals with L3-6 cannula
placement (ascertained at the end of the experiment) and showing
normal gait were used in analysis.
2.4. Acute intrathecal administration ofNMDA receptor
antagonists
All intrathecal injection experiments were carried out on
pCCI animals, 16 days following surgery, at peak behavioural
change. These animals had received pre-treatments of either
vehicle (n= 8), memantine (n= 10) or the NMDA NR2B subunit
selective antagonist, Ro 25-6981 (n= 8) just prior to nerve injury
and for the next 3 days. Baseline reflex withdrawal responses
were recorded both ipsilateral and contralateral to nerve injury
over 2 h prior to injection and mean values calculated. The
effects of intrathecal administration of the highly selective
NMDA R antagonist, 3-(2-carboxypiperazin-4-yl) propyl-1-
phosphonic acid, ((R)-CPP), memantine, the NMDA NR2B
subunit selective antagonists, Ro 25-6981 and ifenprodil, or
vehicle (saline) were examined on behavioural reflex responses.
Rats were briefly anaesthetised with halothane/02 and injected
intrathecally at the L4-5 spinal segments with either (R)-CPP
(1, 3 or lOnmol, where 10 nmol was used as the standard dose
in all figures; Tocris), memantine (150 nmol; Sigma-RBl), Ro
25-6981, (50 nmol; Tocris), or ifenprodil (25 nmol; Sigma-RBI),
all in 50 pi saline, using a 25 guage needle microsyringe. The
vehicle for ifenprodil was 0.3% dimethylformamide in saline
(previous experiments have shown this has no effect on
ipsilateral or contralateral nociceptive reflexes, following nerve
injury). Behavioural reflex testing began 15-20min post-
injection (following recovery from anaesthetic) and was carried
out until recovery to pre-injection values was observed. In the
extensive tests comparing the acute sensitivity of mechanical
allodynia to NMDA R antagonists in control or pre-treated rats,
the percentage reversal of the pre-drug ipsilaterahcontralateral
difference in responses was calculated for each time point
following drug injection. Statistical significance of differences in
these values between control and pre-treated rats was assessed
by Wilcoxon test.
2.5. Assessment ofNMDA receptor subunit expression levels
by Western immunoblotting
Immunoblotting was carried out using methodology described
previously on tissue taken from animals under deep anaesthesia
(halothane/02) at peak behavioural change (16 days later; Garry
et al., 2003) or from sham operated or naive animals (n= 6 in
each case). Blots were probed with rabbit or goat polyclonal
primary antibodies to NR1 (Cat No: SC-1467, Santa Cruz
Biotech, CA, USA), NR2A (Cat No: 06-313, Upstate Biotech,
Milton Keynes, UK) or NR2B (Cat No: AB1557P, Chemicon)
and detected by peroxidase-linked secondary antibody enhanced
chemiluminescence. The ubiquitous housekeeping enzyme,
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was mon¬
itored as a control for protein level normalisation, using mouse
monoclonal antibody (Cat No: MAB374, 1:750, Chemicon).
Following quantitative densitometry, arbitary grey scale values
for receptor subunits were calculated as a percentage of that for
GAPDH in each case and the statistical significance of injury-
induced changes between the ipsilateral and the contralateral
side, sham or naive controls was assessed by Wilcoxon test.
2.6. Immunohistochemical studies on NMDA receptor
subunit expression
Immunohistochemistry was carried out using a protocol
similar to that described previously (Young et al., 1998), to
assess the expression and localisation of NR1 and NR2B NMDA
R subunits in the lumbar spinal cord. Rats with either vehicle
(n= 3) or memantine (n= 3) pre-treatment (at the time of surgery
for the pCCI injury) were studied at peak behavioural change
(16 days later). Under deep anaesthesia (halothane/02), rats were
perfused transcardially with saline containing 100 units heparin/
ml, followed by 4% paraformaldehyde in 0.1 M phosphate
buffer, pH 7.4. Lumbar spinal segments (L3-6) were post-fixed
in 4% paraformaldehyde/0.1 M phosphate buffer for 4-5 h at
4 °C, before being stored in 0.1 M phosphate buffer at 4 °C.
Transverse sections (70 pm) were initially incubated in normal
serum from the species which donated the secondary antibody,
to block non-specific binding. They were then incubated
overnight at 4°C with either rabbit anti-NMDARl polyclonal
antibody (Chemicon, 1:500) or rabbit anti-NMDAR2B poly¬
clonal antibody (Chemicon, 1:750). Control sections were
processed without the addition of primary antibody and
incubated overnight at 4 °C in 0.1 M phosphate buffer.
Simultaneous staining was carried out for all treatments. All
sections were then incubated in biotinylated donkey-anti-rabbit
IgG (1:200, 60min; Chemicon), followed by incubation for a
further 60 min with an avidin-biotin complex solution (ABC
Elite, Vector Laboratories, UK, 1:50). Following wash, sections
were exposed to 3,3' diaminobenzidine tetrachloride (DAB;
0.2 mg/ml; Sigma, UK) in the presence of 3% hydrogen peroxide
(1 pl/ml) to enable visualisation of the precipitate, washed and
mounted onto poly-L-lysine-coated microscope slides (BDH,
UK), air-dried dehydrated through ascending concentrations of
alcohol, cleared in xylene (Sigma) and mounted in DePeX
(BDH, UK).
For relative quantification of immunoreactivity, an Improvision
1.44 Image Analysis Package (NIH) was used at a magnification of
X40. Each image field was captured, using a CCD video camera
(Sony, Japan), mounted on a Zeiss Axioscope microscope. The
images were blank field-adjusted to compensate for any artefacts in
the camera apparatus. A standardised region of interest (ROl;
80 (m diameter circle) cursor was aligned and consecutively
centred on the mediolateral region of laminae I—11 or III. Arbitrary
grey scale units (in the range of 1-200) were assigned to make
optimal use of the range for the given sample. Non-specific
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background levels were recorded from the dorsal column region
for each section, and the net density was calculated by subtraction.
ROIs were taken in lamina I/II and lamina III from contralateral
and ipsilateral sides and ventral horn motoneurons from 45
sections, for each experimental condition. Immunohistochemical
data for NR1 and NR2B subunits were pooled for each animal and
presented as the mean+SEM. Ipsilateral values were compared
with the contralateral side in pCCI animals that had been pre-
treated with either NMDA R antagonist or vehicle and statistical
significance assessed by matched pair Student's r-test. Between
treatment significance, was assessed by One-Way ANOVA with
Dunnett's post hoc test.
3. Results
3.1. Neuropathic behavioural hyperalgesia and allodynia
Neuropathic sensitisation of behavioural reflexes,
characteristic of the pCCI model (Garry et al., 2003),
began to appear at 7-9 days following surgery, with peak
changes in thermal hyperalgesia, cold allodynia and
mechanical allodynia being observed by 16 days in all
cases in vehicle-treated animals (Figs. 1 and 2 a, c, e). No
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Fig. 1. The effect of memantine pre-treatment on the development of sensitised reflex withdrawal responses to sensory stimuli after nerve injury. Data show
mean +SEM responses before (time zero) and following the induction of pCCI for both ipsilateral (•) and contralateral (□) hindlimbs (n=10). (a) In
vehicle-pre-treated rats (i—i), paw withdrawal latency (PWL, s) from a noxious thermal stimulus (Hargreaves' thermal stimulator) ipsilateral to pCCI showed
significant differences between pre- and post-operative values (fp<0.05, Repeated measures ANOVA with Dunnett's post hoc analysis) and from post¬
operative, contralateral values (*p<0.05 by Student's paired t-test). Memantine pre-treatment (■"), however, prevented the development of thermal
hyperalgesia ipsilateral to nerve ligation (b). Memantine pre-treatment also significantly attenuated the development of responses to a noxious cold (4 °C water)
stimulus. The Suspended Paw Elevation Time (SPET, numberof paw lifts) in response to the cold stimulus is shown for the ipsilateral and contralateral paws in
(c) vehicle-pre-treated and (d) memantine-pre-treated rats. Following nerve ligation, SPET scores for the contralateral paw was always zero for both vehicle
and memantine pre-treated rats. Statistically significant differences are shown between pre- and post-surgery ipsilateral values (tp<0.05, Repeated measures
ANOVA with Dunnett's post hoc analysis) and between post-surgery ipsilateral and contralateral responses, (*p<0.05 by Student's paired (-test). However,
some attenuation of SPET scores can be seen following memantine pre-treatment (c) compared to vehicle pre-treatment (d). In (e) paw withdrawal thresholds
(PWT, mN/mm2) from calibrated von Frey filaments in vehicle-pre-treated rats showed significant differences between post-operative and pre-operative values
on the side ipsilateral to pCCI (+/? <0.05; Repeated measures ANOVA on ranks, Friedman's test with Dunn's post hoc analysis) and between post-operative
ipsilateral and contralateral values (*p<0.05 by Wilcoxon test). No significant differences were seen on the contralateral side following nerve ligation in either
vehicle- or in memantine pre-treated rats, (f) Pre-treatment with memantine, caused no discernible change in the development of mechanical allodynia
ipsilateral to nerve ligation compared to vehicle pre-treatment.
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Fig. 2. The effect of ketamine pre-treatment on the development of sensitised reflex withdrawal responses to sensory stimuli after nerve injury. Data show
mean +SEM values for PWL responses to a noxious thermal (Hargreaves' thermal stimulator) in (a, b), SPET to noxious cold 4 °C water in (c, d) and PWT to
calibrated mechanical von Frey (e, f) stimuli before and following the induction of pCCI for intrathecal vehicle (a, c, e) or ketamine (b, d, f) administration over
3 days from the time of pCCI surgery. Statistical analyses were carried out as in Fig. 1.
injury. In each case the changes recovered to baseline
levels by 43 days post-treatment. Rats that had undergone
sham surgery showed no change from baseline.
3.2. Neuropathic thermal hyperalgesia and cold allodynia,
hut not mechanical allodynia, are substantially attenuated
by NMDA receptor antagonist pre-treatment
Pre-treatment with non-competitive NMDA receptor
ion channel blockers memantine or ketamine or a NR2B-
selective antagonist, Ro 25-6891, gave similar results.
Memantine (15 mg/kg, i.p.) given systemically twice
daily over 3 days, beginning immediately prior to
exposure of the sciatic nerve, completely prevented the
reduction in paw withdrawal latency to noxious heat that
occurs ipsilateral to nerve injury in saline-treated pCCI
rats (Fig. lb). Cold allodynia responses which are
observed only in neuropathic animals, ipsilateral to
nerve injury, were significantly reduced after memantine
treatment to approximately half the magnitude of those in
vehicle-treated animals through the first 30 days
following pCCI (Fig. Id). In contrast, memantine pre-
treatment caused little alteration in the reduced paw
withdrawal threshold to von Frey filaments that occurs
ipsilateral to nerve injury (Fig. If).
Fig. 2 shows similar studies in which another NMDA
R antagonist, ketamine was administered locally, by
intrathecal infusion over a 3-day period encompassing
the time of nerve injury. Results were very similar to
those with systemic memantine, with behavioural reflexes
at 16 days after surgery showing abolition of thermal
hyperalgesia (Fig. 2b), significant attenuation of cold
allodynia (Fig. 2d) and no discernible effect on
mechanical allodynia (Fig. 2f).
Interestingly, pre-treatment with the NR2B-se!ective
antagonist, Ro 25-6891, given systemically over 3 days,
beginning immediately prior to exposure of the sciatic
nerve, also showed similar effects to memantine and
ketamine, with the main residual sensitisation being
mechanical allodynia (data not shown).
—CL n—□—ci n—□
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3.3. NMDA receptor antagonist pre-treatment selectively
enhances the reversal of nerve injury-induced mechanical
allodynia and cold allodynia caused by acute spinal
administration ofNMDA receptor antagonists, (R)-CPP,
memantine or the NR2B subunit-selective antagonists, Ro
25-6891 or ifenprodil
Although pre-treatment with NMDA R antagonists
blocks the development of thermal hyperalgesia, it is
unknown whether any residual sensitisation, such as some
cold allodynia and mechanical allodynia, displays altered
susceptibility to pharmacological intervention using acute,
spinally administered NMDA R antagonists. Here we
assessed whether there were any alterations in the
subsequent sensitivity to NMDA R antagonists with
particular interest in the NR2B subunit, since selective
antagonists exert marked analgesic effects on sensitised
behaviours following CCI (Boyce et al., 1999). The effects
of memantine pre-treatment on subsequent sensitivity of
mechanical allodynia to acute challenge with different types
of NMDA R antagonist (either the general NMDA R
antagonists, (R)-CPP, memantine, or the NR2B subunit-
selective antagonists, Ro 25-6891 or ifenprodil) can be seen
on Figs. 3a, b and 4a, b.
Although the degree of mechanical allodynia was
essentially unaffected by memantine pre-treatment, there
was a significantly greater extent and/or duration of reversal
of mechanical allodynia by acute intrathecal administration
of (R)-CPP, memantine, ifenprodil or Ro 25-6891. In
vehicle pre-treated rats acutely administered (R)-CPP,
memantine and ifenprodil each caused significant attenu¬
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Fig. 3. The effect of memantine pre-treatment on subsequent sensitivity of allodynia to different types of NMDA receptor antagonist. Data in (a) and (b) reveal
differences in the acute, spinally administered drug-induced reversal of mechanical allodynia (expressed as mean percentage reversal of the
ipsilateral/contralateral difference in paw withdrawal threshold (PWT+ SEM, n= 8) in vehicle or memantine pre-treated animals, (a) shows enhanced
reversal by (R)-CPP of mechanical allodynia ipsilateral to injury following memantine pre-treatment compared to vehicle pre-treatment in nerve injured
animals, ""indicates statistically significant differences between control and memantine pre-treated animals in the extent of allodynia reversal by (R)-CPP,
p< 0.05 by Wilcoxon test. There were no detectable effects of (R)-CPP on the contralateral hindlimb mechanical PWT. (b) Compares the effects of NMDA R
antagonists, (R)-CPP, memantine and NR2B subunit-selective antagonists, Ro 25-6891 or ifenprodil on residual mechanical allodynia (either 15-30 min
(striped bars) or 35-50 min (white bars) following intrathecal injection of drug), following either vehicle (veh) or memantine (mem) pre-treatment. The
residual mechanical allodynia was more sensitive to acute injection of NMDA R antagonists or NR2B-selective antagonists in memantine pre-treated animals.
Following memantine pre-treatment all drugs showed significantly enhanced extent or duration of reversal of mechanical allodynia (expressed as mean
percentage reversal of the control ipsilateral/contralateral difference in paw withdrawal threshold (PWT)+SEM) compared to vehicle pre-treatment (n= 8 in
each case), ""represents a significant ipsilateral to contralateral difference at each time point, p<0.05 by Wilcoxon test.
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Fig. 4. A highly selective NR2B antagonist elicits inhibition of both mechanical and cold allodynia after memantine pre-treatment and can effectively substitute
for memantine in the pre-treatment paradigm. Data in (a) are presented as mean paw withdrawal threshold (PWT) responses to graded mechanical stimuli (von
Frey filaments). In (a), memantine pre-treated animals showed a marked prolongation of the Ro 25-6891-induced reversal of ipsilateral mechanical allodynia
(•) compared to vehicle-treated animals (O). Statistically significant differences between memantine pre-treated and vehicle pre-treated animals in the extent
of reversal of allodynia are shown as *p<0.05 (by Wilcoxon test). In (b), memantine pre-treated animals (•) showed a clear prolongation (up to 30 min
longer) of the Ro 25-6891-induced reversal of cold allodynia, compared to vehicle-treated animals (O; n= 8). Statistically significant differences between
ipsilateral pre-drug and post-drug values are shown, t/?<0.05, Repeated measures ANOVA with Dunnett's post-hoc analysis, (c) When Ro 25-6891 (Ro) was
substituted as a pre-treatment instead of memantine, acute intrathecal administration of (R)-CPP or ifenprodil caused enhanced reversal of mechanical
allodynia, ipsilateral to nerve injury (expressed as mean percentage reversal of the control ipsilateral/contralateral difference in paw withdrawal threshold
((PWT)±SEM, n = 8) compared to vehicle (veh) pre-treated animals. The striped and white bars show mean data from 15-30 min and 35-50 min periods
following drug injection respectively. *represents a significant ipsilateral to contralateral difference at each time point, p<0.05 by Wilcoxon test.
was significantly greater in memantine-pre-treated rats
(Fig. 3a, b). Facilitation of the acute reversal of allodynia
following memantine pre-treatment was seen with (R)-CPP
doses of 10 nmol (Fig. 3) and also 3 nmol, but not 1 nmol
(data not shown). Ro 25-6891 did not cause significant
attenuation of ipsilateral allodynia in vehicle pre-treated
rats, but did in memantine pre-treated animals. This reversal
was sustained for up to 65 min following injection (Fig. 4a)
such that the Ro 25-6891-induced reversal of allodynia in
the 35-50 min period of memantine pre-treated rats was
significantly greater than in controls. None of the acutely
administered drugs had any significant effect on contral¬
ateral responses. Acute intrathecal injection of saline
vehicle, in both groups of rats, had no discernible effect
on behavioural reflexes. It was not possible to test thermal
hyperalgesia as this was effectively absent following
memantine pre-treatment.
Ro 25-6891 also inhibited cold allodynia with the
partially reduced responses (SPET scores) after memantine
pre-treatment being significantly inhibited for 80 min by
acute Ro 25-6891 injection, whereas in vehicle pre-treated
controls there was no significant effect of Ro 25-6891
beyond 50 min (Fig. 4b). Contralateral SPET scores for cold
allodynia were zero in every case. It is notable that the
2B-selective agent can substitute effectively for memantine
in the pre-treatment paradigm with subsequent reversal of
pCCI-induced mechanical allodynia by acute (R)-CPP or
ifenprodil, both being significantly facilitated following the
pre-emptive treatment (Fig. 4c).
3.4. NMDA receptor antagonist pre-treatment reverses
nerve injury-induced changes in NR1 and NR2B NMDA
receptor subunit expression in superficial spinal dorsal horn
In animals 16 days after nerve injury, at peak
behavioural sensitisation, or in sham operated or naive
animals, the levels of NR1 and NR2 subunit expression
were examined by Western immunoblotting (Fig. 5) and
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NR1 30.7+1.9* 41.811.5 44.3 + 2.0 40.9 + 4.0
NR2A 48.612.7 51.3 + 3.1 47.2 ± 1.6 50.0 + 2.6
NR2B 72.815.3* 47.31 4.2 48.513.9 53.816.0
Fig. 5. Assessment of injury-induced changes in spinal cord expression of NMDA receptor subunits by immunobloting. Immunoblots for the levels of NR1,
NR2A and NR2B NMDA receptor subunit expression in L3-6 spinal cord from ipsilateral and contralateral pCCI, as well as sham-operated or naive rats
showed that NR1 subunit expression was reduced and NR2B subunit expression was increased ipsilateral to pCCI. NR2A expression appeared to be
unchanged. The table shows mean + SEM values (n= 6-8) derived from quantitative densitometry of co-processed immunoblots for NR1, NR2A and NR2B in
the spinal cord following pCCI. Differences in the levels of protein expression (arbitary grey scale values) given as a percentage of GAPDH levels, were
assessed between ipsilateral and contralateral pCCI, sham operated or naive spinal cord (as shown in blots above the table) and statistically significant changes
are shown as *p< 0.05 by Wilcoxon test.
their localisation was examined by immunohistochemistry
(Fig. 6). In Fig. 5 the levels of NR1, NR2A and NR2B
immunoreactivity in L3-6 spinal cord were compared
between animals ipsilateral/contralateral to pCCI, sham
surgery or naive controls. Expression levels were
compared (on the same blots) with those of the
ubiquitous housekeeping enzyme GAPDH, which under¬
goes no discernible change in expression following a
wide range of afferent manipulations. Fig. 5 shows
examples of immunoblots showing a reduction in NR1
subunit expression ipsilateral to pCCI, no change in
NR2A, and an increase in NR2B subunit expression.
These results were typical of at least six separate
experiments. Quantitative densitometry and image anal¬
ysis relative to GAPDH expression were used to
calculate values for the relative changes in NR1 and
NR2B expression levels (Fig. 5). Immunohistochemistry
and subsequent image analysis of grey scale densities
compared to GAPDH confirmed that NR1 expression was
decreased in spinal dorsal horn and further that this
change took place selectively in ipsilateral laminae I—II
(but not laminae III or ventral horn) in pCCI animals
pre-treated with vehicle (Fig. 6a, c, d, e). This reduction
in NR1 expression represented a change of -7.3+0.96
grey scale units ipsilateral to pCCI compared to the
contralateral side, which had a grey scale score of 28.2 +
1.54; mean + SEM; one ROI per side; n = 45 sections
(Fig. 6a, c). In laminae I—II of naive animals, the mean
ipsilateral:contralateral difference was 0.0 + 0.52 grey
scale units. In contrast, in memantine pre-treated animals
there was a relative increase in laminae I—II NR1
immunoreactivity ipsilateral to pCCI (+7.1+2.2 grey
scale units ipsilateral to pCCI compared to the
contralateral side of 23.6+1.61; mean + SEM). Both
of these ipsilateral/contralateral differences in NR1
immunoreactivity in dorsal hom laminae I/II were
statistically significant (p<0.05; Student's t-test). There
was no change in laminae III or ventral horn NR1
immunoreactivity (Fig. 6d, e). Equivalent analysis of
NR2B immunoreactivity (Fig. 6b-e) showed a relative
increase in NR2B immunoreactivity on the ipsilateral
side relative to the contralateral side in vehicle-pre-
treated pCCI rats. In laminae I—II the increment in NR2B
immunoreactivity represented +9.6 + 1.3 grey scale units
ipsilateral to pCCI compared to the contralateral side,
which had a grey scale score of 16.5 + 1.25; mean +
SEM; Fig. 6b, c, p<0.05, Student's /-test. Corresponding
values for ipsilateral/contralateral differences from naive
rats were 0.61+0.85 (not significant). In pCCI animals
that had been pre-treated with memantine, NR2B
expression appeared similar in laminae I—II of both
dorsal horns (with an excess grey scale score of only
0.6+1.2 units ipsilaterally compared to a contralateral
score of 17.1 + 1.45; mean + SEM; Fig. 6c).
NR2B immunoreactivity was also increased in laminae
III ipsilateral compared to the contralateral side in vehicle-
pre-treated pCCI rats (Fig. 6d). The increment was +8.3 +
1.4 grey scale units above the contralateral side, which had a
grey scale score of 19.4+1.3, mean + SEM, (p<0.05,
Student's t-test). However, in contrast to the results in more
superficial laminae, memantine-pre-treatment appeared to
have little effect (Fig. 6d). Ipsilateral NR2B expression in
lamina III of memantine pre-treated pCCI rats was 24.1 +
2.1 grey scale units greater than that on the contralateral
side, which had a score of 17.9 + 1.9 units, mean + SEM,
(p>0.05, Student's /-test). Ventral horn values for NR2B
immunoreactivity were not discernibly different ipsilateral/
contralateral to pCCI, nor were they detectably altered by
memantine pre-treatment (Fig. 6e).
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Fig. 6. Immunohistochemical localisation and image analysis of NR1 and NR2B NMDA receptor subunit expression in the superficial dorsal horn, following
nerve injury and the effects of pre-treatment with memantine. Typical examples are shown of the expression of NR1 (a) or NR2B (b) subunits of the NMDA
receptor in the ipsilateral and contralateral dorsal horn of pCCl animals pre-treated with either vehicle (upper panels; n = 3) ormemantine (lower panels; n= 3).
In vehicle pre-treated animals (a) shows relatively lower levels of NR1 subunit, ipsilateral topCCI compared to the contralateral side. Memantine pre-treatment
however, results in relatively higher levels of NR1 expression ipsilateral to pCCI, compared to the contralateral side, (b) Shows that in contrast to NR1, higher
levels of the NR2B subunit are expressed ipsilateral to pCCI compared to the contralateral (white bar) side. Following memantine pre-treatment, this
ipsilateralxontralateral difference in the NR2B subunit expression is no longer apparent. Scale bar represents 100 pm in each panel. In (c-e) data from the
immunohistochemisty experiments were analysed by quantitative densitometry and expressed as arbitrary grey scale values (mean +SEM) in vehicle- (veh;
n = 3) and memantine-pre-treated animals (mem; n—3). Relative expression of NR1 subunit (on left hand side) or NR2B subunit (on right hand side) is shown
for ipsilateral (black bar) or contralateral (white bar). Statistically significant differences between ipsilateral (black bar) and contralateral (white bar) within a
treatment group are represented by *p <0.05, Student's matched pair (-test; fp <0.05 represents statistically significant differences between vehicle and
memantine pre-treated animals (One-Way ANOVA with Dunnett's post hoc analysis).
4. Discussion
Peripheral nerve injury leads to central sensitisation,
where increased excitability of neurons in the spinal dorsal
horn is thought to underlie chronic hyperalgesia and
allodynia (Chapman et al., 1998; Laird and Bennett, 1993;
Takaishi et al., 1996; Woolf, 1983). Pre-emptive analgesia
attempts to reduce or prevent the spinal plasticity associated
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with the development of chronic pain and would be of clear
clinical value. The spinal NMDA R plays a crucial role in
sensitisation, however previous studies investigating the
potential of pre-emptive NMDA R antagonist treatment
show little direct comparison of relative effectiveness on
different sensory modalities of neuropathic pain.
Our results show clearly that pre-emptive NMDA R
antagonist treatment over 3 days from nerve injury caused
differential effects on the development of neuropathic pain
behaviours to different sensory stimuli. We found a virtual
abolition of thermal hyperalgesia and marked attenuation of
cold-related pain behaviours, contrasting with minimal
effects on mechanical allodynia in the same animals.
Similar results were obtained with pre-emptive use of
several different NMDA R antagonists, including meman-
tine, ketamine and the NR2B-selective antagonist, Ro 25-
6891, and several routes of administration (systemic
memantine, Ro 25-6891 or intrathecal ketamine). The
marked preventative effect on thermal hyperalgesia is
consistent with previous pre-emptive NMDA R antagonist
studies in rodents, using chronic administration, where only
noxious thermal heat responses were measured following
CCI, using either memantine (i.p. for 7 days; Eisenberg
et al., 1995) or MK801 (i.p. 7-15 days; Davar et al., 1991;
Mao et al., 1992b). Shorter duration NMDA R antagonist
administration (MK801, HA966, ketamine or dextrorphan,
either i.p. or i.t. for 4 days), yielded only partial attenuation
of thermal hyperalgesia (Mao et al., 1992a,b, 1993).
The effects of pre-emptive NMDA R antagonists on the
degree and duration of development of neuropathic
mechanical allodynia in previous studies have been more
variable. Single dose intrathecal ketamine pre-treatment at
CCI surgery delayed mechanical allodynia until post-
surgery day 3 (Hartrick et al., 1998), although prolonged
intrathecal ketamine (Burton et al., 1999) or intravenous
MK-801 treatment (Wei and Pertovaara, 1999) gave
attenuation up to 14 days after surgery in the SNL model.
MK-801 administration for 8 days (subcutaneously)
following CCI was reported to attenuate mechanical
allodynia at 27 days (Smith et al., 1994), although 8 days
of memantine treatment (i.p.) following SNL attenuated
mechanical allodynia for only 3 days (Carlton and Hargett,
1995). Our results establish that the sensitisation of different
sensory modalities is differentially affected by early
administration of NMDA R antagonists following nerve
injury.
The present study shows directly that pre-emptive
systemic or intrathecal administration of NMDA R
antagonists attenuates the development of thermal hyper¬
algesia more than that of mechanical allodynia, indicating
that there may be different molecular mechanisms under¬
lying thermal and mechanical sensitisation following
nerve injury. A similar profile of allodynia resistant to
pre-treatment with NMDA receptor antagonists has
been reported in a neuropathic pain model that involves
transient cryoneurolysis injury to the peripheral nerve
(Wagner and Deleo, 1996). In agreement, acutely adminis¬
tered NMDA R antagonists reversed thermal hyperalgesia,
but not mechanical allodynia following CCI (Tal and
Bennett, 1994) or nerve root ligation (Wegert et al., 1997).
However, other animal studies describe robust reversal of
thermal hyperalgesia and mechanical allodynia by NMDA
R antagonists (Chaplan et al., 1997; Garry et al., 2003;
Yamamoto and Yaksh, 1992).
The mechanisms responsible for sensitisation of sensory
responsiveness are complex, with changes occurring in the
peripheral and central nervous system. Centrally, the
NMDA R plays a pivotal role in injury-induced sensitisation
in the spinal cord (Coderre and Melzack, 1992; Davies and
Lodge, 1987; Dickenson and Sullivan, 1987; Woolf and
Thompson, 1991).
This study shows for the first time that the expression of
glutamate NR1 and NR2 R subtypes in the spinal dorsal
horn changes radically and differentially over the time of
development of neuropathic pain behaviours following
pCCI and that this is prevented by NMDA R antagonist
pre-treatment. We also provide novel evidence that the
sensitivity of pCCI-induced mechanical allodynia to acute,
intrathecal administration of NMDA R antagonists or
NR2B-selective antagonists was greater or longer lasting
in animals that had been pre-treated with an NMDA R
antagonist at the time of injury. The substantial time after
injury (16 days) ensures there is no significant concentration
of the original drug still present, suggesting that the pre-
treatment regime may enable more effective analgesic
treatment for any residual pain development in human pain
patients.
The NMDA R subunits, NR1 and NR2 are important
candidates in the cellular mechanisms underlying neuro¬
pathic sensitisation after nerve injury. Immunoblotting and
immunohistochemical studies show an alteration in
expression levels of NR1 and NR2B, but not NR2A, in
animals with established pCCI sensitisation. NR1
expression appeared to be reduced ipsilateral to pCCI,
consistent with previous reports (Garry et al., 2003; Siegan
and Sagen, 1995). Although we found no change in NR2A
expression in dorsal horn tissue following pCCI, a single
cell RT-PCR study on acutely dissociated dorsal horn
neurons reported a relative decrease following L5 spinal
nerve transection (Karlsson et al., 2002). The neuronal
population sampled from dissociated dorsal horn neurons
and that assayed here by immunoblot and immunohisto-
chemistry are unlikely to be equivalent. Moreover, no overt
changes in pain-related behaviours were observed in NR2A
subunit knockout mice (Petrenko et al., 2003). Nevertheless,
our data do not address directly a role for NR2A, which may
still be functionally important, either alone in complexes
with NR1 or in mixed complexes with NR1 and other NR2
subunits such as NR2B.
In contrast, the expression of NR2B was elevated
ipsilateral to pCCI. It might therefore be expected that
nerve-injury-induced pain states would show a relatively
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greater sensitivity to selective NR2B antagonists than other
forms of pain. Although some previous reports have
described only scarce expression ofNR2B mRNA in dorsal
horn (Luque et al., 1994; Portera-Cailliau et al., 1996; Tolle
et al., 1993), single cell RT-PCR found NR2B to be the most
commonly expressed variant in dissociated dorsal horn
neurons (Karlsson et al., 2002). Recent immunohistochem-
ical evidence suggests that NR2B protein shows a
distribution associated both with small diameter fibres in
laminae I and II, which are postulated to be of primary
afferent origin (Boyce et al., 1999; Ma and Hargreaves,
2000) and post-synaptically on dorsal horn neurons
(Momiyama, 2000; Yung, 1998). Several NR2B-selective
antagonists show good efficacy and a particularly low
incidence of side effects upon acute administration in
animal models of inflammatory and neuropathic hyperalge¬
sia (Boyce et al., 1999; Taniguchi et al., 1997). In these
studies mechanical allodynia and mechanical hyperalgesia
were both shown to be sensitive to NR2B-selective
antagonists.
Following NMDA R antagonist pre-treatment, we found
that pCCI-induced thermal hyperalgesia was essentially
prevented, while cold allodynia was reduced and mechan¬
ical allodynia was apparently unaffected. This would be
consistent with the idea that NMDA R complexes are
involved to different degrees in these different types of
sensitised sensory reflexes. In view of these findings, we
further assessed the analgesic effectiveness of NMDA R
antagonists (including NR2B-selective agents) on the pCCI-
induced mechanical allodynia that remained following pre-
treatment with NMDA R antagonist around the time of
injury. Sensitivity to all acutely administered antagonists
(including agents selective to a greater or lesser degree for
NR2B subunit-containing complexes) was increased in
nerve-injured animals following NMDA R antagonist pre-
treatment. This suggests an important role of NMDA Rs,
especially the NR2B subunit, not only in the untreated
neuropathic pain state but notably in the case of residual
pain following pre-emptive NMDA R antagonist treatment.
When injury-induced changes in NMDA R subunit
expression were investigated, the increased expression of
NR2B in lamina II was prevented following memantine pre-
treatment, whereas the similar increment in lamina III was
unaffected.
In summary these studies provide further evidence for a
role for the NMDA R in the development of neuropathic
pain and suggest that the NMDA R may normally play a
greater role in the development and expression of thermal
hyperalgesia than of mechanical allodynia. Correspond¬
ingly, the lasting attenuation of neuropathic behavioural
sensitisation caused by NMDA R antagonist pre-treatment
is more marked for thermal hyperalgesia than mechanical
allodynia. The timing of pre-emptive drug administration
may also be relevant, with prolonged delivery being more
effective. The increased expression of NR2B relative to
NR1 that we observed in spinal dorsal horn laminae II and
III may contribute to the sensitisation of behavioural
reflexes following pCCI. Since pre-treatment with the
NMDA R antagonist, memantine blocks both NR2B
expression in lamina II and thermal hyperalgesia, these
may be linked events. In contrast, pCCI-induced NR2B
expression in lamina III was undiminished by memantine
pre-treatment, although the residual pCCI-induced mech¬
anical allodynia showed increased sensitivity to NMDA R
or NR2B-selective antagonists. These findings suggest that
NMDA R antagonist pre-treatment is an effective analgesic
therapy for thermal aspects of neuropathic pain and that it
increases the subsequent sensitivity of residual mechanical
allodynia to treatment with NMDA R and NR2B-selective
antagonists.
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Abstract
Persistent pain has been reported in up to 80% of patients after limb amputation. The mechanisms are not fully understood,
but nerve injury during amputation is important, with evidence for the crucial involvement of the spinal A'-methyl D-aspartate
(NMDA) receptor in central changes. The study objective was to assess the effect of pre-emptively modulating sensory input
with epidural ketamine (an NMDA antagonist) on post-amputation pain and sensory processing. The study recruited 53
patients undergoing lower limb amputation who received a combined intrathecal/epidural anaesthetic for surgery followed
by a randomised epidural infusion (Group K received racemic ketamine and bupivacaine; Group S received saline and bupiv-
acaine). Neither general anaesthesia nor opioids were used during the peri-operative period. Pain characteristics were assessed
for 12 months. The primary endpoint was incidence and severity of post-amputation pain. Persistent pain at one year was much
less in both groups than in comparable studies, with no significant difference between groups (Group K = 21% (3/14) and 50%
(7/14); and Group S = 33% (5/15) and 40% (6/15) for stump and phantom pain, respectively). Post-operative analgesia was
significantly better in Group K, with reduced stump sensitivity. The intra thecal/epidural technique used, with peri-operative sen¬
sory attenuation, may have reduced ongoing sensitisation, reducing the overall incidence of persistent pain. The improved short-
term analgesia and reduced mechanical sensitivity in Group K may reflect acute effects of ketamine on central sensitisation.
Longer term effects on mood were detected in Group K that requires further study.
© 2007 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.
Keywords: Phantom limb; Epidural analgesia; Ketamine; NMDA receptors; RCT
1. Introduction
Persistent pain after amputation is an important clin¬
ical problem with no reliably effective treatment (Hal-
bert et al., 2002). Up to 80% of patients may
Corresponding author. Tel.: 444 0131 537 1646; fax: +44 0131 537
2179.
E-mail address: Iesley.colvin@ed.ac.uk (L.A. Colvin).
experience persistent pain after lower limb amputation
(Nikolajsen and Jensen, 2001; Ephraim et al., 2005).
This may either be stump pain (pain at the site of ampu¬
tation that may have neuropathic elements) or phantom
pain, which is a form of neuropathic pain, perceived
where the limb was previously.
The underlying mechanisms are not understood,
but it is clear that major changes occur in the periph¬
eral and central nervous system in response to
0304-3959/S32.00 © 2007 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.
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peripheral nerve injury and subsequent alterations in
peripheral sensory input (Woolf and Mannion, 1999;
Flor, 2002). Central sensitisation, occurring at the
level of the spinal cord, is likely to play a key role
in ongoing pain (Woolf, 1995). Animal models of
peripheral nerve injury have shown that activation
of the ionotropic glutamate receptor, the TV-methyl
D-aspartate (NMDA) receptor, is integral to the pro¬
cess of central sensitisation, particularly in nerve
injury models (Woolf and Thompson, 1991). Labora¬
tory studies implicate sensory input at the time of
nerve injury with acute central neural plasticity lead¬
ing to persistent neuropathic pain. In animals,
NMDA antagonists given before nerve injury can
reduce behavioural signs of neuropathic pain and
associated neurochemical changes (Burton et al.,
1999; Munglani et al., 1999).
Clinical studies of pre-emptive treatment interfering
with spinal sensory input are inconsistent. One non-
blinded, non-randomised study found a reduction in
long-term phantom limb pain by using epidural analge¬
sia with bupivacaine and morphine prior to surgery
(Bach et al., 1988). A larger randomised controlled trial
found an incidence of ~70% for phantom pain at one
year regardless of whether epidural bupivacaine and
morphine were commenced 18 h before surgery or
immediately after surgery (Nikolajsen et al., 1997).
Neither of those studies aimed to specifically modulate
spinal NMDA receptors, activated at the time of
nerve injury and likely to be important in central
sensitisation. Additionally, the route of administration
of NMDA receptor antagonists may be clinically
relevant in terms of efficacy. Superior analgesia after
thoracotomy was achieved with epidural administration
of ketamine, an NMDA antagonist, compared to
intramuscular administration (Ozyalcin et al., 2004).
Intravenous ketamine used around the time of amputa¬
tion in combination with general anaesthetic and
morphine had no significant effect on the incidence of
phantom limb pain (Hayes et al., 2004). Modulation
of sensory input to the spinal cord around the time
of nerve injury may play a key role in altering neuronal
plasticity. While there may be some NMDA receptor
activation as a result of pre-operative pain, the aim of
this study was to focus on NMDA receptor blockade
at the time of nerve injury. At this time a massive
excitotoxic injury discharge may occur, with excessive
glutamate release.
In this study we assessed the effect of pre-emptive
treatment with an epidurally administered NMDA
receptor antagonist, ketamine, in combination with
local anaesthetic, on reducing spinal sensory transmis¬
sion, acute central sensitisation and the development
of persistent post-amputation pain.
2. Methods
2.1. Overview
The study was approved by the local Research Ethics Com¬
mittee and was in accordance with the Helsinki Declaration of
1975 (revised 1983). International Standard Randomised Con¬
trolled Trial Number (ISRCTN) 48374927 was assigned to this
trial.
2.2. Subjects
Patients scheduled to undergo lower limb amputation in the
Vascular Surgery Unit, Royal Infirmary of Edinburgh, Scot¬
land, were approached regarding participation in the trial.
After written informed consent was obtained they were then
entered into the trial. Trial recruitment took place over a 20-
month period. Patients had to be able to participate in the
questionnaire-based pain assessment and lower limb examina¬
tion before they were invited to take part in the study. Exclu¬
sion criteria included: contraindication to spinal or epidural
blockade; contraindication to the use of ketamine or bupiva¬
caine; previous lower limb amputation. Patients who under¬
went further amputation during the follow-up period were
excluded from further analysis. Written informed consent
was obtained for each patient.
2.3. Study design
Patients who met entry criteria were randomly assigned to
one of two treatment groups: Group K to receive epidural
bupivacaine and racemic ketamine and Group S (control
group) to receive epidural bupivacaine and saline around the
time of amputation.
Both patients and staff were blinded as to treatment group,
but for safety reasons, one of the researchers (AN) held sealed
records as to the group allocation. The researchers involved in
assessments were blind to patient allocation until all subjects
had completed their 1-year assessment.
Recruiting and post-operative analgesic adjustments were
carried out by a single researcher (J.W.).
Randomisation was by GraphPad StatMate version 1.0
(GraphPad software Inc., San Diego) which allocated subjects
to either group using computer generated pseudo-random
numbers.
All patients underwent a detailed pain assessment, includ¬
ing bedside quantitative sensory testing (QST), of both lower
limbs before surgery, and at 8 days, 6 weeks, 3 months, 6
months and 12 months after surgery. If the stump was infected
or not healed, no QST was performed at that visit.
2.3.1. Pain assessment
This consisted of four structured questionnaires:
1. A modification of Sherman et al.'s phantom limb question¬
naire (Sherman et al., 1984) (Appendix 1; Supplementary
information on the web). The characteristics of any phan¬
tom and stump pain were recorded, including frequency
110 J. A. Wilson et at. I Pain 135 (2008) 108-118
and severity of attacks. Current analgesic medications were
also recorded, and classified in terms of the WHO analgesic
ladder, i.e., simple analgesics, weak opioids, strong opioids
and adjuvant drugs for neuropathic pain.
2. The McGill pain questionnaire (MPQ) (Melzack, 1975).
Results were expressed as total Pain rating index (PRI)
scores (Turk et al., 1985).
3. The Neuropathic pain scale (NPS) (Galer and Jensen,
1997). Results were expressed as a total NPS score out of
100.
4. The Hospital anxiety and depression scale (HADS)
(Zigmond and Snaith, 1983). HAD scores were divided
into HADS-anxiety (HADS-A) and HADS-depression
(HADS-D).
The examination used bedside QST carried out on the base
of the stump, or where it was anticipated to be (for pre-oper-
ative testing), using the ventral aspect of the contralateral limb
as a control. Testing on each limb was carried out equidistant
from the corresponding iliac crest. Initially any area of altered
mechanical sensation was mapped out using a soft artist's
paintbrush. The brush was drawn over the skin from an area
of normal sensation towards the stump and the patient asked
to note any change (increase or decrease) in the stimulus per¬
ception. Further assessment was carried out in any area of
altered sensation or, if none detected, on the base of the stump.
Tactile and pain thresholds were assessed using von Frey (VF)
filaments (North Coast Medical, Inc., San Jose, CA). These
were applied in ascending and descending force magnitude
until the subject was able to perceive four out of six stimuli.
VAS scores to pain and to unpleasantness were recorded fol¬
lowing brush stimuli, vibration (using a standard electric
toothbrush), pinprick, using neurological examination pins
(Neurotips ™; Owen Mumford) and cold (acetone drops).
For a review of QST methodology, see Jorum and Arendt-
Nielsen (2003).
2.3.2. Peri-operative management
The peri-operative period was from the time of consent for
surgery up until 72 h afterwards. No premedication was given.
Any prescribed analgesics were continued up until the time of
surgery. No patient received general anaesthesia or supplemen¬
tary opioids over the period of epidural use. Both groups
received combined spinal and epidural anaesthesia and intra¬
venous sedation. Epidural catheters (16G Portex) were placed
just before surgery through either the L2-L3 or L3-L4 inter¬
space. A test-dose of 4 ml of 2% lidocaine was given to exclude
intravascular or intrathecal placement. Immediately after the
epidural test-dose, a spinal (intrathecal) anaesthetic was
administered at an interspace below the epidural catheter
(24G Sprotte needle; 2 x 5-3 x 0 ml of bupivacaine 0.5%;
AstraZeneca). Before starting surgery, an epidural bolus dose
of bupivacaine 0.5% (1 mg/kg) with either 0.5 mg/kg preserva¬
tive free racemic ketamine (Curamed Pharma, Germany) (Gp
K) or an equivalent volume of NaCl 0 x 9% (Gp S) was given.
The epidural infusion mixture was prepared in theatre by an
anaesthetist not involved in the study and labelled "study med¬
ication". Additional study medication was prepared at this
time to be available if required during the infusion period in
order to maintain blinding. Neither ward staff nor the
researcher carrying out the assessments was aware of the con¬
tents of the mixture.
Sedation was given as required using a target-controlled
infusion of propofol. Intraoperatively all patients had stan¬
dard monitoring, supplemental oxygen and intravenous fluids.
During surgery the epidural infusion was commenced at
15ml/h. Group K received an infusion of bupivacaine
0.125% with ketamine 3.3 mg/kg/1. Group S had bupivacaine
0.125% with an equivalent volume of NaCl 0.9%. Following
surgery the epidural infusion was adjusted by a blinded
observer within the range of 10-20 ml/h to ensure adequate
pain relief (VAS ^ 30). If analgesia was inadequate, top-up
boluses (10-15 ml) were given from the infusion mixture.
Epidural ketamine is used in routine clinical practice in our
centre. The doses chosen for this study were based on previous
experience that had found that bolus doses of greater than
500 meg/kg were likely to be associated with increased seda¬
tion after surgery. We have found previously that epidural ket¬
amine by infusion at between 2 and 4 mg/h rarely resulted in
side effects such as sedation and dysphoria.
Post-operative analgesia was supplemented with paraceta¬
mol 1 g 6 h orally. No other analgesic medication was permitted
during the period of epidural use. All epidurals ran for between
48 and 72 h. Failure of the epidural to provide adequate analge¬
sia required the removal of the patient from the study.
During the period of epidural analgesia, block height (blunt
pin prick) and motor block using a modified Bromage scale
(Bromage, 1965), number of epidural bolus doses, average
pain VAS scores, sedation score, respiratory rate and presence
of nausea or vomiting (self-report) were recorded twice-daily.
2.4. Statistics - design and analysis
The primary outcome measure was the incidence and sever¬
ity of both phantom limb and stump pain. The incidence of
phantom pain was chosen to calculate sample size. Secondary
outcome measures were the effectiveness of post-operative
analgesia and changes in sensory processing as measured by
QST.
The incidence of phantom pain in most comparable studies
is around 80% (Nikolajsen and Jensen, 2001; Ephraim et al.,
2005). We considered that a decrease to 40% would be clini¬
cally significant. For a power of 80%, an estimated sample size
of 23 per group was needed (SigmaStat 2.03; Power = 0.8;
a = 0.05). A 30% 1-year death rate would increase the sample
size to 30 per group. This drop-out rate is comparable to that
found in other studies in this patient population (Aulivola
et al., 2004). Interim analysis by an observer not connected
with the study was carried out at the midpoint of the study per¬
iod, using Fisher's exact test, with the primary endpoint being
rate of phantom pain occurrence. This was done to further
refine the sample size and ensure that recruiting did not con¬
tinue inappropriately.
Statistics were carried out using SigmaStat for Window ver¬
sion 2.03. Proportions were compared using Chi-squared anal¬
ysis or Fisher's exact test as appropriate. Other measures were
compared using one way Analysis of Variance (ANOVA) or
Kruskal Wallis ANOVA on Ranks if non-parametric data.
J. A. Wilson et al. / Pain 135 (2008) 108-118 111
3. Results
3.1. Recruitment and baseline characteristics
Of 186 patients undergoing lower limb amputation
over the 20-month period studied, 53 patients were
suitable and consented to participate in the study.
They were randomised such that 24 subjects were allo¬
cated to Group K and 29 to Group S. Six were with¬
drawn post-randomisation. Fourty-seven patients were
included in the analysis, with 21 subjects in group K
and 26 subjects in group S. Four subjects subse¬
quently had a below knee amputation revised to an
above knee and were removed from further analysis
(Fig. 1).
The subjects were comparable in age, weight, height,
incidence of diabetes mellitus and type of amputation.
Group K consisted of 19 males and 2 females. Males
had a mean (SD) age, weight and height of 69 (9.4),
74.8 kg (20.0) and 173.5 cm (9.0), respectively. Females
had a mean (SD) age, weight and height of 73 (0.7),
67.0 kg (1.4) and 161.5 cm (2.1), respectively. Group S
consisted of 16 males and 10 females. Males had a
mean (SD) age, weight and height of 73 (5.3), 68.3 kg
(13.1) and 172.3 cm (6.1), respectively. Females had a
mean (SD) age, weight and height of 78 (5.5), 51.6 kg
(10.0) and 163.9 cm (9.1), respectively. Sixteen subjects
(5 Group K; 11 Group S) underwent an above knee
amputation and 31 (16 Group K; 15 Group S) a below
knee amputation. There was no difference in median
(quartiles) pre-operative VAS pain scores (Group K
50 (40-50), Group S 70 (50-83)). The incidence of
diabetes in Group K and Group S was 7 and 6,
respectively. Similar numbers in both groups used
pre-operative opioids (K11/21 :S21/26; ns; Chi-squared,
p — 0.078). No problems with withdrawal were seen
when opioids were stopped from the time of surgery
onwards.
3.2. Interim analysis
After the first 35 patients had been assessed at 3
months, interim analysis (using Fisher's exact test) was
carried out for the primary end-point (presence or
absence of phantom pain) by an independent assessor
not involved in the study. The rate of phantom pain at
8 days, 6 weeks and 3 months in Group K was 3/11
(27%), 7/11 (64%) and 4/10 (40%), respectively, com¬
pared with Group S where 9/18 (50%), 8/17 (47%) and
6/15 (40%) patients had phantom limb pain. There
was no significant difference between groups at 8 days,
6 weeks and 3 months (with p-values of 0.273, 0.460
and 1.000, respectively). The study authors were blinded
to the result details, but were advised that recruitment
should cease.
3.3. Outcomes
3.3.1. Assessment during epidural infusion period
There was no difference in median (Quartiles) epidu¬
ral infusion rates between the groups (Group K 15 ml/h
(15-18) and Group S 15 ml/h (14-16)), Mann-Whitney
rank sum test; p = 0.397. Both groups had good post¬
operative analgesia with median total VAS scores of less
than 30 mm. Group K had significantly lower pain
scores than Group S. Median mean VAS (quartiles)
Group K 0 mm (0-17), Group S 17 mm (0-35)
(Mann-Whitney rank sum test; p = Ox031). Group K
required a significantly lower number of epidural top-
ups. Group K 1.8 (2.2), mean (SD) and Group S 3.5
(3.2), mean (SD) (Student's /-test; p = 0.044). Following
establishment of epidural blockade, no subject was with¬
drawn due to inadequate analgesia. Mean epidural infu¬
sion rate and duration was the same for both groups.
There was no significant difference in motor block
between the groups during the duration of epidural infu¬
sion. Median (IQ range) Bromage scores on day one
were 1 (0-2) for Group K and 0 (0-1) for Group S.
On day two median (IQ range) Bromage scores were 0
(0-1) in both groups. The incidence of nausea and vom¬
iting (Group K: 4/21; Group S: 3/26; p — 0.684), seda¬
tion (Group K: 2/21; Group S: 1/26; p = 0.579) and
confusion (Group K: 2/21; Group S: 0/26; p = 0.194)
were low and did not differ between groups (Fisher's
exact test).
No patients suffered from hallucinations. There were
no complications that required revealing the composi¬
tion of the infusion.
3.3.2. Post-amputation pain
The rates of phantom and stump pain did not differ
between the two groups at any of the assessments up
to and including one year, when the rate of phantom
pain was no more than 50% and stump pain was no
more than 33% in either group (Table 1). Neither
stump pain nor phantom pain intensity, as measured
using VAS, differed between groups at any time point
(Figs. 2 and 3). There was no detectable difference in
the frequency of attacks between the two groups
(Table 2).
3.3.3. Questionnaire data
Total MPQ scores were highest before surgery,
Group K: 23 (15-33), Group S: 28.5 (15.25-35.75); med¬
ian (IQ range). These fell to 3 (0-8) in Group K and 3
(1 11) in Group S at 12 months. Scores in both groups
were significantly less than pre-operative values by 6
weeks (Kruskal-Wallis one way Analysis of Variance
on Ranks with Dunn's post-hoc analysis, p< 0.001),
but groups did not differ from each other at any time
point.
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12 months 1 death 15 15 0
Fig. 1. Consort diagram.
Median NPS scores started high and dropped with
time, pre-operatively scores were: Group K; 49 (40-59)
vs Group S; 50 (37-66); median (IQ range). This fell to
a median score of 4 (1-22) in Group K and 5 (0-16) in
Group S at 12 months. There was a significant reduction
from pre-operative values in both groups at all time
points post-operatively, but with no difference between
groups (Kruskal-Wallis ANOVA on Ranks with Dunn's
post-hoc analysis, p < 0.001).
Levels of anxiety, as assessed by HADS scoring
(expressed as mean (SD)), were: Group K: 8.4 (4.5)
pre-operatively, decreasing to 5.4 (2.8) at 6 weeks
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Table 1
Incidence of stump and phantom pain at each time point
Time Stump pain P Phantom pain P
Group K Group S Group K Group S
n (%) n (%) n (%) n (%)
8 days 11/17 (65) 15/26(58) 0.888 6/17 (35) 13/26 (50) 0.525
6 weeks 9/17(53) 9/20 (45) 0.879 10/17 (59) 9/20 (45) 0.611
3 months 5/15 (33) 9/19 (43) 0.635 6/15 (40) 7/19 (37) 0.867
6 months 7/15 (47) 5/16 (32) 0.609 6/15 (40) 3/16 (19) 0.252*
12 months 3/14(21) 5/15 (33) 0.682* 7/14 (50) 6/15 (40) 0.867
Proportions compared using Chi-squared analysis except as indicated by f.
tFisher's exact test.
Data are shown as numbers experiencing pain over total number in the group at each time point for both Group K and Group S (percentages in
brackets) for up to 12 months following surgery.
post-amputation, and remained significantly lower at all
time points up to and including one year (4.3(2.9)) (one
way ANOVA with Dunnett's post-hoc analysis;
p< 0.001) and Group S: 8.2 (3.7) pre-operatively with
no significant reduction any time point up to and includ¬
ing one year (4.7 (4.0)) (one way ANOVA with Dun¬
nett's post-hoc analysis; p — 0.071).
Levels of depression for Group K were 8.1 (4.3) pre-
operatively, reducing significantly at 3 months to 5.4
(3.8) and remaining significantly reduced up to and
including one year (one way ANOVA with Dunnett's
post-hoc analysis; p — 0.003). Pre-operative scores for
depression in Group S were 6.0 (3.4), with no significant
reduction at any time point up to and including one year
(4.5 (4.6)) (one way ANOVA p = 0.829).
3.3.4. Sensory processing as measured by QST
Pre-operatively there was a slightly higher tactile
threshold in the ischaemic limb (206 mN mm"2 (191))
than the contralateral limb: (139 mN mm-2 (82)), /-test
p = 0.036. Ketamine did modify some aspects of sen¬
sory transmission, with an alteration in the tactile
threshold of the stump on day 8 after surgery. In
Group K, the tactile threshold was found to be
significantly higher on the stump (589 mN mm""2
(782); mean (SD)) compared to the contralateral limb
(180mNmm~2 (160); mean (SD)) and to both limbs
in Group S (stump; 250 mN mm"2 (97); mean (SD)),
contralateral, 208 mN mm"2 (140); mean (SD)); (one
way ANOVA with Tukey test; p = 0.005). This differ¬
ence was not found at 6 weeks (see Table 3). There
was no significant difference between sides at any other
time point.
There was no difference between the groups in the
evoked response to pin prick at any time point (Table 4).
VAS scores for cold and vibration were 0 in the
majority of patients (88-100%) at all time points. Fur¬
ther detailed analysis was not carried out.
Stump Pain
VAS scores
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Fig. 2. Intensity of stump pain at each time point following ampu¬
tation. Data are shown as box plots with medians represented by
horizontal lines with the 75th percentile at the top and the 25th
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Fig. 3. Intensity of phantom pain at each time point following
amputation. Data are shown as box plots with medians represented by
horizontal lines with the 75th percentile at the top and the 25th
percentile at the bottom. The 10th and 90th percentiles are shown as
whiskers.
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Table 2
Frequency of phantom pain attacks in each group
Group K Group S





















Data are shown at 8 days, 6 months and 12 months. The data show the
number of patients experiencing pain at each time point. The fre¬
quency of the pain attacks is shown at each time point. Due to the
small numbers involved meaningful analysis is not possible.
3.3.5. Analgesic medications
The overall number of analgesic drugs prescribed did
not vary between groups. The number of analgesic drugs
prescribed pre-operatively was Group K; 2 (2-3) vs
Group S 3 (2-3); median IQ range. The number of anal¬
gesic drugs prescribed was less in both groups after sur¬
gery. At 12 months the number prescribed was the same
in both groups: 1 (1-2); median (IQ range). There was
no difference between the two groups in the median
numbers of drugs at any time point after surgery (Krus-
kal Wallis ANOVA on ranks).
4. Discussion
This study has found that modulation of sensory
input at the time of amputation may have both short
and longer term effects on pain perception.
The anaesthetic/analgesic technique used in our study
has resulted in a lower incidence of persistent pain than
other randomised controlled trials of lower limb ampu¬
tation where around 70% of patients have persistent
pain (Nikolajsen et al., 1997; Hayes et al., 2004). A wide
range of incidences for post-amputation pain has been
found (Nikolajsen and Jensen, 2001; Ephraim et al.,
2005), with lower incidences in particular types of study
(retrospective or postal survey) and patient groups (pae-
diatric or upper limb amputation) compared to lower
limb amputation (Montoya et al., 1997; Wartan et al.,
1997; Kooijman et al., 2000; Wilkins et al., 2004).
A key difference in our study is the anaesthetic tech¬
nique used compared to previous studies. This combined
spinal/epidural technique, without use of general anaes¬
thesia or opioids, produces a very dense block of sensory
input that may provide a novel strategy for reducing
persistent pain after amputation.
The initial hypothesis was that specific blockade of the
NMDA receptor would be required to reduce persistent
pain. This was based on evidence from basic science stud¬
ies of the key role that the NMDA receptor plays in cen¬
tral sensitisation and subsequent spinal events in
pathological pain states (Davies and Lodge, 1987; Tors-
ney and MacDermott, 2006). Failure of previous studies
to reduce persistent pain may have been related to inad¬
equate block of the effects of massive glutamate release
and excitotoxic discharge at the time of nerve injury
(Li and Stys, 2000; Moore et al., 2002). Clinically, there
is also some evidence for involvement of the NMDA
receptor in central processing in patients with established
phantom pain (Larbig et al., 1996; Schwenkreis et al.,
2003). Intravenous ketamine has been used peri-opera-
tively at the time of lower limb amputation, but no acute
effect on central processing was found, nor a statistically
significant reduction in phantom limb pain at 6 months,
although phantom pain was 47% in the ketamine group
and 71% in the control group (Hayes et al., 2004).
One reason for our study not detecting an additional
effect of ketamine, over and above local anaesthetic
alone, may be that, due to the much lower overall inci¬
dence of persistent pain, the power of the study to
answer the original hypothesis was reduced. It may be,
however, that the key element to reducing persistent
Table 3
Tactile threshold for the stump and the contralateral limb as measured by von Frey filaments
Time Group K stump Group K con Group S stump Group S con P
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
8 days 589 (782) 180 (160) 250 (97) 208 (140) 0.005*
6 weeks 314 (412) 180 (156) 255 (173) 145 (68) 0.224
3 months 216(225) 199 (224) 154 (106) 127 (77) 0.442
6 months 180 (145) 138 (61) 143 (72) 134(70) 0.472
12 months 147 (103) 150 (102) 215 (123) 155 (90) 0.236
*One way Analysis of Variance.
Data are shown as mean tactile threshold (force/unit area; g/mm2) with SD for both Group S and Group K, for up to 12 months following surgery.
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Table 4
Mean VAS score to pinprick for the stump and the contralateral limb
Time Group K stump Group K con Group S stump Group S con P
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
8 days 29 (29) 22 (25) 46 (29) 36 (32) 0.051
6 weeks 46 (37) 29 (31) 47 (33) 33 (23) 0.208
3 months 35 (34) 33 (37) 30 (23) 28 (25) 0.935
6 months 35 (31) 32 (34) 33 (34) 41 (25) 0.761
12 months 45 (30) 40 (32) 42 (31) 42 (26) 0.972
Data are shown as mean VAS score (0-100 mm) with SD for both Group S and Group K, for up to 12 months following surgery.
pain is the blockade of spinal sensory transmission
(either NMDA receptor-specific or non-specific block¬
ade). Previous studies have found that neither general
anaesthesia, acute opioid use, nor prolonged sensory
block, with epidural analgesia before or after surgery,
was sufficient to reduce persistent pain (Nikolajsen
et al., 1997; Hayes et ah, 2004). In order to adequately
reduce the massively increased peripheral input at the
time of nerve injury, it would be necessary to reduce sen¬
sory input to such an extent that spinal responses were
prevented. It has been shown previously that local
anaesthetic administered via the epidural route does
not completely suppress neuronal input to the spinal
cord (Loughman et ah, 1995). There is also recent evi¬
dence from animal models that electrical stimuli well
below that required to elicit spinal cord activity may
evoke neuronal activity within the brainstem, as assessed
by functional Magnetic resonance imaging (Lilja et ah,
2006).
While electrophysiological recordings of spinal input
were not made during our study, the combined spinal/
epidural technique did provide a significant block of sen¬
sory input such that amputation was performed without
general anaesthesia or other analgesia such as strong
opioids. This blockade of sensory input was associated
with an incidence of persistent pain of 50% or less in
both groups in our study.
Despite no additional reduction in persistent pain in
the ketamine group, there were alterations in pain
processing, with significant improvements in acute
post-operative analgesia. Specific effects on sensory pro¬
cessing were also detected, with a selective decrease in
mechanical sensitivity on the stump that outlasted the
expected pharmacological action of ketamine (Clements
et ah, 1982), similar to that seen in established phantom
and stump pain (Nikolajsen et ah, 1996). The timing of
NMDA receptor blockade may be important in its effect
on the neurobiological response, as some studies have
found that NMDA receptor antagonists did not affect
phantom or stump pain, or responses to mechanical
and thermal stimuli, and cortical changes, in established
post-amputation pain (Nikolajsen et ah, 2000; Wiech
et ah, 2004), with one small study of traumatic upper
limb amputates finding that acute administration of
memantine (in addition to brachial plexus blockade)
reduced prevalence and severity of phantom limb pain
up to 6 months but not one year afterwards (Schley
et ah, 2007).
Other studies in animal models have also found an
anti-allodynic effect of NMDA receptor antagonists that
outlast their expected pharmacological duration of
action (Christoph et ah, 2006), with selective effects on
different aspects of pain behaviours (Burton et ah,
1999; Munglani et ah, 1999). Additionally we have
found that treatment with NMDA antagonists prior to
nerve injury in a rodent model resulted in an enhance¬
ment of subsequent responses to NMDA antagonists,
particularly responses to mechanical stimuli (Wilson
et ah, 2005). There is also evidence of inhibitory path¬
ways mediated by metabotropic glutamate receptors
type II/III in neuropathy models, with a complex rela¬
tionship between the ionotropic NMDA receptors and
metabotropic (Garry and Fleetwood-Walker, 2004;
Proudfoot et ah, 2006). This may partly explain the
reduced mechanical sensitivity, although the precise
mechanism requires further study.
These results would support a role for the NMDA
receptor in acute central sensitisation as well as provid¬
ing clinical evidence supporting the role of epidural ket¬
amine in modifying pain processing acutely.
There is still debate as to the role of ketamine as
part of multimodal post-operative analgesia. System¬
atic reviews of ketamine found that ketamine could
reduce pain scores and opioid consumption, with min¬
imal adverse effects (Elia and Tramer, 2005; Bell et ah,
2006). A systematic review of another clinically avail¬
able NMDA antagonist, dextromethorphan, also found
a reduction in opioid consumption, but no effect on
post-operative pain scores (Duedahl et ah, 2006). The
route of administration may be important, with epidu¬
ral being superior to systemic ketamine after thoracot¬
omy, while another study found no effect of
intravenous ketamine acutely or at 6 months post
lower limb amputation (Hayes et ah, 2004; Ozyalcin
et ah, 2004). By giving ketamine, close to its putative
site of action on nociceptive pathways in the spinal
cord, an adequate dose may be given without signifi¬
cant adverse effects. Our study provides evidence of
the efficacy of epidural ketamine as part of an acute
analgesic strategy with some detectable effects on acute
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sensory responses. An additional benefit, particularly in
an elderly population, is the lack of sedation or respi¬
ratory depression produced by using a technique with¬
out a requirement for opioid in the peri-operative
analgesic regimen.
The potential neurotoxicity of spinal ketamine (either
epidural or intrathecal) must be considered. First, there
is concern that preservatives in commercially available
compound may be neurotoxic, as has been demon¬
strated in sub-human primates and rabbits (Brock-Utne
et al., 1982; Malinovsky et al., 1993; Borgbjerg et al.,
1994). Second, although preservative free ketamine
widely used in some European countries, there have
been concerns both about a direct toxic effect specifically
related to the action of NMDA antagonists and an
increased rate of apoptosis during neuronal develop¬
ment. The direct toxic effect has only been found selec¬
tively, certain cortical neurons in rodents (cingulate
and retrosplenial cortices), with both toxicity and apop¬
tosis only seen with high doses, unlikely to be used in
clinical practice (Olney et al., 1989; Ikonomidou et al.,
1999; de Lima et al., 2000). Additionally, repeated intra¬
thecal injections of up to 1% of preservative free keta¬
mine (Dalens, 2006) or repeat epidural boluses of
ketamine in dogs (Acosta et al., 2006) had no neurotoxic
effect.
Recent systematic reviews of ketamine have found no
clinical evidence of neurotoxicity from epidural use,
with some benefits in analgesia (Subramaniam et al.,
2004).
Further study of the unexpected finding of ketamine
in reducing anxiety and depression is warranted. The
acute, and often dose-limiting, effects of ketamine on
mood, such as dysphoria and increased anxiety, were
not found in our study, which may relate to the route
of administration.
Improvement in mood has been found with ketamine
after peri-operative use in depressed patients (Kudoh
et al., 2002), and acutely in the treatment of major
depression (Berman et al., 2000; Sprenger et al., 2006;
Zarate et al., 2006). No previous study has found a posi¬
tive long-term effect of short-term ketamine administra¬
tion on levels of anxiety and depression (Zarate et al.,
2003; Goodman, 2004).
It has been suggested that a combination of general
and regional techniques is needed to reduce central sen-
sitisation (Melzack et al., 2001). However, this may not
be the case, with the key element being modulation of
sensory transmission around the time of nerve injury.
A combination of specific (ketamine) and non-specific
agents (local anaesthetic) administered close to the
spinal cord can alter acute and chronic pain processing.
The NMDA receptor has a defined role in the develop¬
ment of pain, but further study is needed to clarify the
role of the NMDA receptor in persistent phantom limb
pain.
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